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ABSTRACT 
Organ, tissue, and cellular transplants annually save or enhance the lives of tens of 
thousands to millions of patients with severe diseases or debilitating injuries. However, grafts 
are vulnerable to immune-mediated rejection. An ideal alternative to treating recipients with 
toxic, life-long immunosuppressive therapies would be to administer transient regimens that 
achieve durable immune tolerance. Unfortunately, clinically relevant factors can block 
transplant tolerance induction, including peri-transplant inflammation and preexisting anti-
donor immunity. In order to develop effective immunotherapies for patients, we must 
understand the pathways that either promote or disrupt transplant tolerance. 
Using an animal model of pancreatic islet cell transplantation, I demonstrate that T 
lymphocytes target islet cell allografts through at least three different antigen-specific 
recognition pathways that are individually sufficient for rejection. This suggests that 
combination therapies may be necessary to control all pertinent alloreactive effector T cell 
pathways. I additionally tested a long-held paradigm that costimulatory blockade therapies 
promote tolerance by converting naïve T cells to regulatory phenotypes. I did not find 
evidence for rapid fate deviation and instead suggest that transplant tolerance evolves 
gradually through biphasic requirements: Effectors must be restrained from initially attacking 
the donor graft, and subsequent regulation must be generated through host-dependent 
mechanisms of peripheral tolerance. 
Finally, I describe a novel pathway through which preexisting host immunity 
attenuates tolerance induction. The prevailing view for immune memory as a tolerance 
barrier is that the host harbors memory cells that cross-react to donor major 
histocompatibility complex (MHC) antigens. Such “heterologous” memory cells react to 
donor MHC and resist most tolerance regimens. I determined whether an alternative form of 
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immune memory could block tolerance when host memory T cells respond to donor-derived 
non-MHC antigens to which the host is immune. Results show that immunity to a model 
nonself antigen, ovalbumin (OVA), can dramatically disrupt tolerance despite undetectable 
initial reactivity to donor MHC antigens. This blockade of tolerance was CD8+ T cell-
dependent and required linked antigen presentation of alloantigens with the test OVA antigen. 
Thus this pathway represents an unapparent, or “incognito,” form of immunity that is 
sufficient to prevent tolerance and that can be an unforeseen additional immune barrier to 
clinical transplant tolerance. 
The form and content of this abstract are approved. I recommend its publication. 
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• Chronic illness leads to a remarkable need for transplanted organs, tissues, and cells. 
• Severely diabetic patients could greatly benefit from islet cell transplantation but 
many clinical barriers block long-term graft survival. 
• We need to clarify the roles of T lymphocytes in immune-mediated rejection and 
define the mechanism(s) that promote transplant tolerance. 
Transplants Save and Enhance Lives 
 For patients with end-stage organ failure, replacement of their non-functioning 
diseased organs with healthier donated organs through solid organ transplantation is often the 
only treatment that can save their lives. Other types of transplants include cellular grafts, 
such as bone marrow and pancreatic islet cells, and tissue grafts, such as skin, corneas, and 
bones. These grafts can restore sight or enhance and heal lives debilitated by disease or injury. 
Donors are usually genetically disparate from recipients, so these transplants are termed 
allografts (from Greek allos, meaning “other”). As summarized in Table 1-1, reports from 
national registries show that tens of thousands to millions of allografts are transplanted 
nationally every year. Unfortunately, with >118,500 total candidates awaiting organ 
transplants and 22 people dying each day while waiting, the need for organ replacement far 
exceeds the available supply for transplantation, which has remained steady at approximately 
30,000 total organs transplanted each year (Organ Procurement and Transplantation Network, 
https://optn.transplant.hrsa.gov, accessed March 5, 2017). This gap between available supply 
and demand is expected to dramatically increase as more Americans develop chronic 
illnesses (Wu and Green, 2000). Clearly, this urgent challenge in medicine should be met 
with effective strategies. 
Projected increase for allograft transplantation in diabetic patients 
 For my dissertation, I studied allografts of pancreatic islets of Langerhans, which 
contain insulin producing beta cells that regulate cellular utilization of glucose. In people 
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with type 1 diabetes (T1D) mellitus, autoimmune responses destroy most of the beta cells. 
T1D patients thus require daily insulin injections or insulin pump delivery systems to control 
their blood glucose levels. Beta cell replacement therapy via whole pancreas transplantation 
or the much less invasive procedure of pancreatic islet cell infusions can give better glycemic 
control to patients who experience severe “brittle” (or labile) diabetes with dangerous 
episodes of hypoglycemic unawareness (Ryan et al., 2001). 
 Although first pioneered 45 years ago in animal models and soon thereafter in 
humans (Ballinger and Lacy, 1972; Najarian et al., 1980), islet cell transplantation is 
currently an experimental procedure in the United States. Clinical trials data are being 
evaluated by the Food and Drug Administration and the procedure could be approved within 
the next few years (Ahearn et al., 2015). If approved, then from among the 1.5 million people 
with T1D, an estimated 4500 candidates with labile diabetes who have failed intensive 
insulin therapy, roughly 3 in 1000 T1D patients (Vantyghem and Press, 2006), might benefit 
from islet cell transplantation becoming more widely available. 
 The need for kidney transplantation is even greater than for islet transplantation in the 
diabetic population. Uncontrolled diabetes (both type 1 and type 2) is the leading cause of 
chronic kidney disease and kidney failure in the United States. Complications from diabetes 
resulting in end-stage renal disease were responsible for 44% of new cases in 2011 (Center 
for Disease Control and Prevention, 2014). With total diabetes prevalence in the United 
States already at 29.1 million people and projected to increase by 54% to more than 54.9 
million diabetic Americans by the year 2030, we can expect tremendous future demand for 
kidney, whole pancreas, and islet cell transplants (Center for Disease Control and Prevention, 
2014; Rowley et al., 2017). 
Clinical dilemmas in transplantation 
 The growing national shortage of available organs for transplantation is only one 
problem among many rate limiting clinical dilemmas. Other major barriers can affect both 
donors and recipients before and after transplantation, and together impact graft outcomes. 
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These factors include the state of the donor before graft recovery. Physiological changes in 
the donor, such as cardiovascular instability and altered cytokine milieu, vary depending on 
whether donation occurred after brain death or after circulatory (cardiac) death. On the other 
hand, living donation obviates many of the issues associated with deceased donation 
(Pratschke et al., 1999; Wood et al., 2004; Quintini et al., 2013). Organ preservation 
techniques impact the pre-transplant quality of the organ. Techniques range from cold static 
storage to hypothermic and normothermic machine perfusion, which can mitigate apoptosis 
and improve immediate and long-term organ function (Cypel et al., 2011; Moers et al., 2012). 
Moreover, after implantation, ischemia reperfusion injury significantly injures grafts, 
especially vulnerable “marginal” allografts that are increasingly recovered from expanded 
criteria sub-optimal donors (Foley and Chari, 2007). Ongoing metabolic disease in the 
recipient can also harm the transplant. For example, uncontrolled blood glucose in a diabetic 
recipient after kidney transplant can lead to nephropathy, allograft failure, advancement to 
dialysis, and progression to recurrent end-stage renal disease (Peev et al., 2014). 
Immunological barriers present another challenging crux of transplantation because 
most allografts are subject to immune-mediated rejection. Some transplant recipients have 
prior autoimmunity to their grafted organs or tissues, so they experience simultaneous 
alloimmune attack and autoimmune disease recurrence in the graft. Toxic side effects from 
antirejection regimens further threaten recipient health and transplant survival (Table 1-2). 
Fortunately, we are making medical advances. Both graft and recipient short-term survival 
have improved over the last few decades due to improved immunosuppression and optimized 
medical care of nonimmune-related issues. However, long-term graft survival rates and 
knowledge about chronic rejection mechanisms have not changed much in the last two 
decades. While one-year survival rates approach 90% for most vascularized organs, survival 
rates drop to approximately 50% for five- to ten-year survival and then to 10-20% for 
twenty-year survival (depending on the type of allograft) (Lodhi et al., 2011; Gruessner R et 
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al., 2013; Organ Procurement and Transplantation Network (OPTN) and Scientific Registry 
of Transplant Recipients (SRTR), 2014). 
 While not exhaustive, this summary of ongoing clinical dilemmas in transplantation 
highlights the main point that a transplant does not necessarily end disease for the recipient. 
For patients with end-stage organ failure who receive an allograft, a transplant marks the 
beginning of trading one disease for another. In clinical transplantation, seemingly unlimited 
combinations of injurious factors can manifest in new complications that influence graft 
survival and contribute to graft loss through dysfunction and rejection. 
To narrow this broad scope of possible areas for investigation and research in 
transplantation, my dissertation focused on identifying the specific roles of T lymphocytes in 
a few clinically relevant barriers to transplantation. Since T lymphocyte activities are the 
main subject of this dissertation, it is important to understand how T cells become activated 
in the setting of transplantation. 
T Cell Activation During Transplantation 
Donor-reactive T cells are sufficient for rejection of transplanted allografts. The acute 
allograft response was first described as cellular infiltrate in rejecting genetically disparate 
tissues, and then from the transfer of second-set rejection by lymphoid cells but not serum 
(Medawar, 1944; Billingham et al., 1954). The requirement for T cells in rejection was 
subsequently established when neonatally thymectomized mice and congenitally athymic 
nude mice failed to reject allogeneic skin grafts, unless the latter group received cells primed 
to donor antigens from a mixed lymphocyte response (Miller, 1962; Corley and Kindred, 
1977). Reconstitution experiments next showed that small recirculating T lymphocytes 
adoptively transferred to lethally irradiated hosts were sufficient to restore skin and cardiac 
allograft rejection without production of alloantibody (Dorsch and Roser, 1974; Hall et al., 
1978). Furthermore, T lymphocytes depleted of cells reactive to one set of alloantigens were 
unable to restore rejection of grafts from that strain, while they retained the capacity to effect 
third-party rejection (Hall et al., 1977). Finally, animals sensitized to alloantigens were found 
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to harbor T cells with 10- to 200-fold greater potency that, upon adoptive transfer, restored 
allograft rejection in new recipients (Wilson et al., 1978). Together these experiments 
demonstrated that alloantigen-reactive T cells could directly mediate graft rejection. 
Major histocompatibility complex molecules are key targets of rejection 
Major histocompatibility complexes (MHC) are the major targets in transplantation. 
MHC molecules bind peptides and present them to adaptive immune cells that discriminate 
between self and non-self antigens (Burnet and Fenner, 1949). In humans, MHC molecules 
are called human leukocyte antigens (HLA) because they were first discovered through 
antigenic differences between white blood cells from different individuals. Allogeneic MHC 
provokes strong immune responses among T cells, B cells, and natural killer (NK) cells. As 
such, the genetic mismatches between donor and recipient MHC alleles can lead to vigorous 
immune-mediated rejection of MHC-expressing grafts. 
All mature host T cells are slightly reactive to self-MHC as a result of positive 
selection during thymic development. Allogeneic MHC molecules presenting donor-derived 
antigens may be similar enough to self-MHC to allow T cell receptor (TCR) binding. 
However, the small differences between allogeneic peptide:MHC complexes (pMHC) and 
self pMHC can be misinterpreted by the host T cell as being self-MHC bearing foreign 
peptide [i.e. altered self (Zinkernagel and Doherty, 1974)], which initiates T cell priming. 
The TCR’s “obsession” with the MHC regardless of the presented peptides (McDuffie et al., 
1987) means that a relatively high percentage of polyclonal T cells are spontaneously 
reactive to allo-MHC. Typically, 1-10% of an individual’s naïve T cell repertoire can 
recognize donor MHC molecules (Brondz and Snegirova, 1971; Lindahl and Wilson, 1977; 
Suchin et al., 2001).  
The bias in the germline TCR repertoire toward recognition of MHC proteins can 
give rise to even greater frequencies of alloreactive T cells in the antigen-experienced 
memory pool. Through a process called “heterologous immunity,” virally induced memory T 
cells with TCR that happen to cross-react to alloantigens are intrinsically also alloreactive 
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memory T cells without actual prior sensitization to donor antigens (Burrows et al., 1994; 
Burrows et al., 1995; Adams et al., 2003b). Among a large panel of human virus-specific 
memory T cells, 45% could cross-react to at least one allo-HLA haplotype (Amir et al., 2010). 
Several mouse strains of different MHC haplotypes help us investigate alloreactivity. 
The mouse MHC is also called H-2 antigen, and its genes are located on chromosome 17. 
Mouse MHC can be divided into class I and class II, and further divided into 11 subclasses. 
The “classical MHC class I” (also called MHC-Ia) comprises H-2D, H-2K and H-2L 
subclasses; the “non-classical MHC class I” (MHC-Ib) comprises H-2Q, H-2M, and H-2T 
subclasses; the “classical MHC class II” (MHC-IIa) includes H-2A(I-A) and H-2E(I-E) 
subclasses; and the “non-classical MHC class II” (MHC-IIb) comprises H-2M and H-2O. 
MHC class I and MHC class II are discussed throughout this dissertation. MHC class 
I molecules are expressed on most nucleated cells and bind short peptides of 8-10 amino 
acids. These peptides are derived from intracellular proteins and are presented as a means of 
immune surveillance for intracellular pathogens, such as viral infections. MHC class II 
molecules are normally expressed by antigen-presenting cells (APCs) -- dendritic cells (DCs), 
B lymphocytes, and macrophages -- and bind peptides of at least 13 amino acids. These 
peptides are derived from exogenous proteins that were acquired, processed, and presented 
by the APC as a means of activating effector cells. 
In large outbred populations, MHC molecules are highly polymorphic; that is, 
multiple variants of each gene are expressed within the entire population. However, due to 
intentional selection and extensive inbreeding, each laboratory mouse strain is homozygous 
and has a unique MHC haplotype designated by a small letter (a, b, d, k, q, s, etc.). For 
example, the MHC haplotype of the BALB/cByJ mouse strain is H-2d and its MHC antigens 
are H-2Kd, H-2Dd, H-2Ld, I-Ad, and I-Ed. The MHC haplotypes and alleles of the mouse 
strains used in this dissertation are listed in Table 1-3. 
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T cell receptor engagement (signal 1) 
 A T cell can become an effector cell only after it is activated through a multiple step 
process. Myeloid DCs are essential for initiating naïve T cell responses by presenting pMHC 
to T cells. The engagement of TCR molecules with cognate pMHC complexes [together with 
the TCR associated signaling subunits (the CD3 complex and ζ chain)], provides the 
necessary intracellular “signal 1” that initiates antigen-specific responsiveness. Antigen 
recognition involves TCR binding to features of both the peptide and the MHC, also known 
as MHC restriction. Transplantation creates a unique added dimension to antigen recognition 
because host TCRs can be self- or donor-MHC restricted, since donor antigens can be 
presented to the TCR bound by self-MHC or allo-MHC. 
 TCR-mediated recognition of allografts involves at least three pathways through 
which donor antigens are presented to donor-reactive TCRs. These pathways are defined by 
whether donor MHC or host MHC is on the surface of donor APCs or host APCs (Figure 1-
1). In “direct” allorecognition (Figure 1-1A), donor-reactive T cells recognize donor peptides 
bound by intact donor MHC presented by donor APCs (Lombardi et al., 1989). Thus, the 
direct pathway is heavily dependent on allogeneic DCs and graft parenchymal cells that 
express donor MHC. In “indirect” allorecognition (Figure 1-1B), donor-reactive T cells 
recognize processed donor-derived antigens bound by host MHC presented by host APCs 
(Benichou et al., 1992; Fangmann et al., 1992; Liu et al., 1992). The indirect pathway is 
similar to conventional T-cell recognition of most foreign antigens where peptides are bound 
to self-MHC. In “semi-direct” allorecognition (Figure 1-1C), donor-reactive T cells 
recognize donor peptides bound by intact donor MHC presented by host APCs (Harper et al., 
2015; Liu et al., 2016). As recently shown by Liu et al. (2016), donor MHC for the semi-
direct pathway can be acquired on host APCs through the natural transfer of donor-derived 
exosomes. Note that direct allorecognition (from the TCR’s perspective) could actually be 
antigen presentation through the direct or semi-direct pathways because both involve donor 
MHC-restriction. For my studies, we focused primarily on T-cell dependent graft rejection 
 8 
that occurs through donor MHC-restricted (direct) recognition or self MHC-restricted 
(indirect) recognition of donor antigens. 
Costimulation receptors (signal 2) 
Graft antigen by itself is not sufficient to activate naïve host T cells. In conjunction 
with the expression of pMHC complexes, a second signal must be delivered to the T cell by 
costimulatory molecules expressed by APCs (Lafferty and Cunningham, 1975; Lafferty and 
Woolnough, 1977). These additional signals fine-tune the antigen-specific response and 
influence its strength, nature, and duration. TCR triggering of a naïve T cell results in its up-
regulation of a costimulatory receptor, the TNF II superfamily member CD154 (CD40 
ligand). CD154 interacts with CD40 on APCs and induces them to up-regulate the 
costimulatory molecules, B7-1 (CD80) and B7-2 (CD86). These B7 molecules interact with 
their counter-receptors on the T cell (e.g. CD28) to augment CD154 expression and induce T 
cell proliferation. Lack of costimulation after pMHC-TCR engagement leads to impaired T 
cell responsiveness or T cell anergy (Linsley and Ledbetter, 1993). Thus, the removal of 
donor APCs from the graft reduces the immunogenicity of a transplant (though not the 
antigenicity) (Lafferty et al., 1986). 
Cytokines (signal 3) 
 In addition to presenting antigen to T cells and ligating costimulation receptors, DCs 
also regulate the nature and extent of the immune response by producing cytokines and 
chemokines (Andrus and Lafferty, 1980; Hart, 1997). Interleukin 2 (IL-2) is produced early 
after TCR ligation and costimulation as an autocrine and paracrine factor that stimulates T 
cells to proliferate. Type I IFN (IFNα and IFNβ) and IL-12, for example, can promote the 
development of differentiated T cells and are powerful inducers of IFN-γ by T cells. 
Roles for CD4+ and CD8+ T cell subsets during transplantation 
The binding of T cell surface coreceptors, CD4 and CD8, to invariant sites on the 
MHC is an additional requirement for an effective T cell response. These coreceptors are 
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expressed by CD4+ and CD8+ T cell subsets, which were distinguished by their ability to 
recognize MHC class II or MHC class I, respectively (Sprent et al., 1986). 
When a naïve CD4+ T cell is activated by an APC, it differentiates into one of various 
T helper (Th) cell subsets that are classified based on the dominant cytokines produced upon 
activation. The Th1 cytokines (IFN-γ, IL-2, and TNF-α) are particularly effective at 
activating macrophage microbicidal mechanisms, such as iNOS, against intracellular bacteria, 
protozoa, and viruses. The Th2 cytokines (IL-4, IL-5, IL-13, and IL-10) promote humoral 
responses. Peripherally derived regulatory T (Treg) cells prevent inflammation-mediated 
tissue injury through the local secretion of suppressive cytokines such as IL-10, IL-35, and 
transforming growth factor-β (TGF-β), or through the cell-cell contact-mediated inhibition of 
CD4+ effector cell proliferation. 
CD8+ T cells can polarize in much the same way as CD4+ T cells to become 
cytotoxic T (Tc) cell subsets that produce specific cytokines such as IFN-γ (Tc1), or IL-4 and 
IL-5 (Tc2). In some models, the optimal generation of cytotoxic CD8+ T cells and memory 
cells requires that CD8+ T cells receive help from CD4+ T cells through a single APC that 
simultaneously presents both cognate antigens. Antigen presentation to the CD4+ T cell 
permits activation of the DC through CD154-CD40 interactions. This “licensing” induces the 
expression of costimulatory molecules such as B7, CD40, and 4-1BB ligand on the DC that 
allows full activation of cognate cytotoxic CD8+ T cells (Ridge et al., 1998). However, CD4+ 
T cell help is not a universal feature of CD8+ T cell activation; it is typically required when 
the antigen recognized by the CD8+ T cells is derived from an agent that does not cause 
inflammation, so CD4+ T cell help is therefore required to license the APC. However, when 
adjuvants or proinflammatory infectious agents are present, the DC can become fully 
conditioned to directly activate CD8+ T cells without CD4+ T cell help (Ridge et al., 1998; 
Lindell et al., 2005; Edwards et al., 2013). T cells with high avidity (that is, multiple 
interactions of TCR and CD8 molecules on the T cell with pMHC complexes on the APC) 
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may also receive a strong signal that induces both IL-2 receptor and IL-2 synthesis resulting 
in helper-independent responses. 
As summarized in Table 1-4, the specific CD8+ or CD4+ T cell subsets that are 
necessary and/or sufficient for allograft rejection vary depending on the tissue transplanted. 
For example, either CD8+ or CD4+ T cells are sufficient to reject skin allografts. CD4+ T 
cells are necessary and sufficient to reject cardiac allografts (Pietra et al., 2000). Islet 
allografts are more susceptible to CD8-mediated rejection, but CD8+ T cells still usually 
require CD4+ T cell help (Prowse et al., 1983; Warren et al., 1984; Diamond and Gill, 2000). 
The relatively greater dependency of CD8+ T cells on CD4+ T cell help during islet allograft 
rejection suggests that reducing the activity of helper CD4+ T cells might reduce direct CD8+ 
effector T cell responses against the transplant. 
Controlling Alloreactive T Cells 
Given that donor-reactive T cells are required for transplant rejection, the field has 
focused much effort on developing agents that inhibit effector T (Teff) cells, often via 
strategies that prevent T cell activation or that divert T cell fates toward more favorable or 
protective phenotypes. 
Immunosuppression 
The advent of immunosuppressive agents in the 1950s largely prevented acute graft 
rejection and represented a major advancement that made clinical transplantation possible. 
Ironically, in islet cell transplantation, the drugs used for inhibiting immune responses also 
had inhibitory effects on beta-cell function. This led to replacement of the calcineurin 
inhibitors (e.g. cyclosporine A) and glucocorticoids with a glucocorticoid-free 
immunosuppressive regimen called the “Edmonton protocol” that could establish 
normoglycemia in diabetic recipients with an average of two sequential islet transplants 
(Shapiro et al., 2000). However, even with newer advances in immunosuppression, post-one-
year graft survival rates for all solid organ and islet cell transplantation have not improved in 
the last 20 years (Gruessner R et al., 2013). Additionally, the tradeoff between end-stage 
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organ failure and chronic immunosuppression for transplant recipients is essentially 
exchanging one disease for another, as they experience increased risk of cancer, infection, 
and toxicities from off-target effects of immunosuppression (Table 1-2). Medical 
management challenges can include patient non-compliance with medications, frequent 
manipulation of drug dosing and biochemical monitoring, and social support issues that may 
increase risk of graft loss. Toward avoiding many of these issues associated with long-term 
immunosuppression, the field has endeavored to develop immune modulating therapies that 
can promote immune tolerance instead. 
Transplant tolerance 
The induction of immune tolerance to a graft has long been sought as an alternative to 
immunosuppression. Medawar originally described acquired tolerance in the 1950s as “a 
specific failure of the host’s immunological response,” or essentially nonresponsiveness to 
non-self antigens (Billingham et al., 1953). Prior to that, seminal studies of dizygotic cattle 
twins found that they harbored the same distinct groups of red blood cell antigens that must 
have been derived from the other twin’s sire, indicating that the non-self cells were acquired 
in utero but were not rejected even into adulthood (Owen, 1945). Thereafter, a series of skin 
allografts between newly hatched chicks further demonstrated that tolerance could be 
induced in neonatal animals, provided that the transplants occurred within 1 day after 
hatching (Cannon and Longmire, 1952). It was subsequently shown that tolerance to skin 
allografts could be induced experimentally in adult mice following fetal exposure to donor-
derived cells (Billingham et al., 1953). All of these landmark experiments demonstrated that 
the inoculation of non-self antigens during the fetal or neonatal period -- prior to the 
development of mature immunity -- conferred antigen-specific tolerance in mature 
immunologically competent recipients. 
Modern descriptions of transplant tolerance are often reflective of Medawar’s 
definition, as in “a state in which donor specific immune unresponsiveness permits the 
unimpeded survival of allogeneic transplants” (Shinoda et al., 2014). Another definition 
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describes transplant tolerance as “the state in which transplant recipients fail to mount a 
pathologic injurious response to donor antigens, while responses to other antigens including 
microbial pathogens are not altered in the absence of continued immunosuppression” (Li and 
Jevnikar, 2016). We have chosen to define transplant tolerance as an antigen (donor)-specific 
change in an immune competent recipient that permits indefinite allograft survival. Our 
definition implies that nonresponsiveness to donor antigens is not sufficient for tolerance. For 
example, the survival of a skin graft transplanted onto an immune-deficient animal is not 
tolerance when the animal does not have the capacity to reject the graft in the first place. We 
want to be clear with our definition that the absence of rejection is not equivalent to tolerance. 
Since testing for true tolerance in humans is more challenging than with animal 
models, clinical “operational tolerance” in human transplantation is defined as the absence of 
rejection without immune suppression. Operational tolerance has been observed in liver and 
kidney allograft recipients whose immunosuppressive dugs were discontinued for medical or 
non-compliant reasons (Roussey-Kesler et al., 2006). Pediatric liver recipients seem 
especially amenable to spontaneously developing tolerance, as 20-50% of selected pediatric 
liver recipients can develop operational tolerance (Schulz-Juergensen et al., 2013). 
Spontaneous tolerance is much less rare in conventional renal transplant recipients, with 
frequencies estimated at less than 5% (Roussey-Kesler et al., 2006). Although certainly more 
difficult to achieve in humans than small animal models, these reports of spontaneous 
operational tolerance, together with results from experimental models of transplantation, 
provide the proof-of-principle that achieving tolerance in transplantation is fundamentally 
possible. 
Exploiting Mechanisms of Self-Tolerance to Induce Transplantation Tolerance 
 The immune system evolved to protect the host from potentially harmful pathogens 
and malignant cells. Unfortunately, its acute ability to recognize and reject foreign entities 
can be unleashed on transplanted allografts. Fortunately, however, the immune system also 
co-evolved critical checkpoints that keep this powerful weapon from attacking healthy 
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tissues and inflicting consequential injury to self. We aim to exploit these same mechanisms 
of self-tolerance to intentionally induce donor-specific tolerance during transplantation. 
Central and peripheral self-tolerance 
 A fundamental feature of the immune system is the discrimination between self and 
non-self. Central tolerance is the active elimination of autoreactive T cells and B cells. For T 
cells, central tolerance to self antigens is established in the thymus through selective clonal 
deletion during development (Kappler et al., 1987). T cells that express TCRs with high 
affinity for self-pMHC are deleted by negative selection, which largely prevents the escape 
of autoreactive T cells into the periphery. 
In addition to central tolerance, mechanisms of peripheral tolerance suppress the 
activation and population expansion of self-reactive T cells (Sakaguchi, 2005). The 
mechanisms for polyclonal T cell checkpoints in peripheral self-tolerance include clonal 
deletion, hyporesponsiveness (or anergy), ignorance, and the conversion to regulatory or 
suppressive phenotypes. Importantly, it was shown that the same epitope-specific CD4+ T 
cell can make use of all of these distinct mechanisms for self-tolerance, with the specific 
mechanism that is used being determined in large part by the patterns of self-peptide 
expression throughout the body (Malhotra et al., 2016). In contrast to these cell intrinsic 
mechanisms, regulatory T cells influence other immune responses to ensure the continuity of 
peripheral self-tolerance and to control the primary immune response to foreign antigens 
(Haribhai et al., 2007; Kim et al., 2007; Lahl et al., 2007; Lin et al., 2007). Coinhibitory 
receptors and their ligands provide alternate valuable immune checkpoints for controlling T 
cell responses. Programmed cell death protein 1 (PD-1, or CD279) is an important cell 
surface receptor that down-regulates the immune system and promotes self-tolerance by 
suppressing T cell inflammatory activity. 
Therapeutic approaches for inducing transplant tolerance 
Many approaches can exploit the mechanisms of self-tolerance to induce tolerance 
during transplantation. During the development of spontaneous tolerance, which is rare and 
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sporadic in clinical transplantation, recipients are not treated with specific pharmacologic 
agents that promote tolerance. Instead, the grafts might be modified to reduce their 
immunogenicity (Gill et al., 1988), recipients might be treated with blood transfusions that 
introduce donor antigens (Gray, 1997; Bushell et al., 2003), or recipients might be gradually 
weaned from immunosuppression and found to not reject their grafts (Roussey-Kesler et al., 
2006; Newell et al., 2010). The mechanism for spontaneous tolerance is poorly understood 
but might be related to host exposure to alloantigens in a quiescent and nonimmunogenic 
state that induces regulatory cells. Some recipients that developed spontaneous tolerance 
showed increased suppressive activity (Gill et al., 1988) and CD4+ CD25hi T cells (Bushell 
et al., 2003; Yoshizawa et al., 2005), and some did not (Grazia et al., 2007), which makes the 
role for Treg cells in this mechanism ambiguous. 
 Bone marrow transplantation in combination with solid organ transplantation 
(typically kidney transplantation) offers a unique opportunity for inducing transplant 
tolerance through the mechanisms of both central tolerance and peripheral tolerance. 
Generally, the goal is to achieve mixed chimerism and subsequent clonal deletion of donor-
reactive T cells (Fehr et al., 2008; Spitzer et al., 2011; Morris et al., 2015). The somewhat 
extensive conditioning regimen that is required to prepare the recipient pre-kidney transplant 
will likely restrict this tolerance-promoting strategy to cases of living donor donation where 
donation can be scheduled. While this approach holds promise for developing donor-specific 
tolerance, it carries the risk of acute and chronic graft-versus-host disease. 
Nonlytic monoclonal antibodies (mAbs) directed toward T cell surface molecules can 
promote transplant tolerance. CD3-specific antibodies induced tolerance in fully MHC-
mismatched experimental models of pancreatic islet and cardiac transplantation (Chatenoud 
and Waldmann, 2012; You et al., 2012; Goto et al., 2013). Nondepleting antibodies specific 
for CD4 and CD8 coreceptor molecules have also been shown to induce tolerance dependent 
on regulatory CD4+ T cells (Wise et al., 1998; Cobbold et al., 2004). 
 15 
 Monoclonal antibodies that target costimulatory molecules or their receptors have 
been of long-standing interest as a way to regulate immunity. Leukocyte function associated 
antigen-1 (LFA-1, or CD11α) is a T cell adhesion molecule important for the interaction 
between T cells and APCs, and was one of the earliest targets identified. Its blockade in small 
animal models generates dominant, transferrable, and donor-specific tolerance (Nicolls et al., 
2000). CD154 (or CD40 ligand)-specific mAbs induce tolerance to a variety of transplanted 
tissues and can be used in combination with other therapies, such as donor specific 
transfusion or anti-LFA-1 to generate robust donor-specific, durable tolerance (Nicolls et al., 
2002; Bishop et al., 2014; Nelsen et al., 2017). Blockade of the CD28 costimulatory receptor 
by a fusion protein of the Fc fragment of human IgG1 linked to the extracellular domain of 
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) selectively inhibits T cell activation 
through costimulation blockade and holds immense promise for clinical transplantation 
(Vincenti et al., 2016). 
Scope and Aims of this Project 
 The data reported in this dissertation represent my efforts to define basic 
immunological requirements for promoting transplant tolerance, and my efforts to elucidate 
clinically relevant pathways through which naïve and memory T cells contribute to islet 
allograft rejection. My work on this project is expected to close gaps in knowledge so that the 
transplantation research community can develop better strategies for intentionally directing 
immune responses toward successful transplant tolerance as well as effectively preventing 
immune-mediated graft rejection. 
 As a brief overview of this dissertation, Chapter II describes the materials and 
methods used for data collection and analysis. Chapter III reports on antigen-specific T cell 
recognition pathways that are individually sufficient to reject murine islet allografts. Chapter 
IV uncovers the mechanisms by which tolerance develops following treatment with a therapy 
that targets T cell surface molecules. Chapter V introduces the tolerance barrier of donor-
reactive immune memory and identifies a novel alternate pathway through which host 
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immunity can block tolerance independent of preexisting anti-donor specificity. Chapter VI 
summarizes my findings and presents a comprehensive model for how transplant tolerance 
develops. The model explains why tolerance is vulnerable to disruption by a variety of 
stimuli and how that vulnerability illustrates a period of metastable tolerance. Finally, in 
Chapter VI, I draw from the interconnected implications of my work and propose future 
directions toward the development of next-line tolerance-promoting therapies.  
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Table 1-1. Reported numbers of allografts transplanted or distributed in one year1. 
Allograft Number transplanted References 
Organsa 33,599 Organ Procurement and Transplantation 
Network 
Corneas 48,792 Eye Bank Association of America 
 Number of recipients  
Hematopoietic cells 8,348 Center for International Blood and Marrow 
Transplant Research 
Pancreatic islet cells 36 Collaborative Islet Transplant Registry 
 Number distributed  
Tissuesb 2,110,200 American Association of Tissue Banks 
1Data are reported for the years 2016 (organs; United States), 2015 (corneas; United States), 2013 
(hematopoietic cells; United States), 2013 (pancreatic islet cells; North America), and 2007 
(tissues; nationally and internationally from United States). 
aOrgan transplantation includes heart, kidney, lung, liver, intestine, and pancreas. 
bTissue transplantation includes skin, bone, adipose, cartilage, tendon, ligaments, heart valves, 
veins, and other tissues. 
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Table 1-2. Adverse side effects of commonly used immunosuppressive agents. 
Immunosuppressants Side effects 
Immunophilin-binding drugs  
Calcineurin inhibitors  




Diabetes (more common with tacrolimus) 
Renal insufficiency 
Osteoporosis 
Nausea, abdominal pain, diarrhea 
Hirsutism (with cyclosporine) 
Gingival hyperplasia (with cyclosporine) 
Mammalian target of rapamycin (mTOR) inhibitors 




Abdominal pain, diarrhea, constipation 
Dermatitis 
Diabetes 
Inhibitors of de novo purine synthesis  
Mycophenolate mofetil Bone marrow suppression 
Abdominal pain, nausea, diarrhea 
Neurotoxicity 
Headache, insomnia, dizziness 
Antimetabolites  
Azathiorpine Bone marrow suppression 









References: (Issa and Alkhouri, 2015; Li and Jevnikar, 2016) 
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H-2K H-2D H-2L 
 
I-A I-E 
C57BL/6 B6 b b b null 
 
b b 
BALB/cByJ BALB/c d d d d 
 
d d 
BALB/c-H2dm2 dm2 d d d null 
 
d d 
C3H/He C3H k k k null 
 
k k 






Figure 1-1. Host T cell receptor (TCR) recognition of donor antigens. 
Donor antigens can activate alloreactive recipient T cells via three distinct antigen-
presentation pathways. (A) In the direct pathway, T cells recognize intact donor MHC 
molecules presenting donor-derived antigens on donor antigen-presenting cells (APCs). (B) 
In the indirect pathway, T cells recognize processed alloantigens (donor-derived MHC and 
minor antigen peptides) presented by self-MHC molecules on recipient APCs. (C) In the 
semidirect pathway, T cells recognize acquired donor MHC molecules displayed on recipient 
APCs.  
  
























Table 1-4. The predominant roles for primary responses by polyclonal CD8+ or CD4+ T 
cells that lead to allograft rejection vary with the type of transplant. 
Transplant 
Necessary  Sufficient  
CD8+ CD4+  CD8+ CD4+ References 
Organ    
  
 
Heart N Y  N Y (Pietra et al., 2000)a†‡§ 
(Youssef et al., 2004)b* 
Kidney N Y  N Y (Bolton et al., 1989)c§ 
Lung N N  Y Y (Gelman et al., 2008)bd*‡ 
(Krupnick et al., 2014)b*§ 
Liver N N  Y Y (Bumgardner et al., 1998)e† 
(Ogura Y, 2001)f‡ 
Small bowel N N  Y Y (He et al., 1999)g†‡ 
Pancreas DNF Y  N DNF (Yin et al., 2002)h‡ 
Tissue       
Skin N N  Y Y (Youssef et al., 2004)b* 
Cellular       
Islet N/Y Y  N Y/N (Shizuru et al., 1987)h‡ 
(Hao et al., 1988)i‡ 
(Gill et al., 1989)j§ 
(Gill et al., 1994)a§ 
(Wolf et al., 1995)a‡§ 
Abbreviation for mediating rejection: N, no. Y, yes. DNF, data not found. Y/N, ambiguous: most 
reject (~50-85%); some do not reject. 
Strain combinations of donors:recipients: aB6:BALB/c, bBALB/c:B6, cDA(rat):PVG(rat), 
dB6:CBA, eFVB/N:B6, fDA(rat):Lewis(rat), gB6C3F1:B6, hA/J:B6, iBALB/c:CBA, 
jBALB/c:B10. 
Recipients: *CD8-/- or CD4-/-, †MHC class I-/- or MHC class II-/-, ‡CD8- or CD4-depleted by 
monoclonal antibodies, §SCID or Rag-/- or congenitally athymic adoptively transferred with 






MATERIALS AND METHODS 
Mice 
C57BL/6 (B6, H-2b), B6-Tg(CAG-OVA)916Jen/J (B6-OVA), B6.129S7-
Rag1tm1Mom (Rag1-/-), B6-Tcrα-/-, B6-Tcrβ-/-, B6-µMT-/-, B6-GFP, B6-Foxp3-GFP, B6-
CD45.1, BALB/c ByJ (BALB/c, H-2d), BALB/c dm2 (dm2, H-2d), and C3H/HeJ (C3H, H-
2k) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). B6-CD45.2 OT-I 
Rag1-/- and B6-CD45.2 OT-II Rag-/- T cell receptor transgenic (TCR Tg) mice were 
purchased from Taconic Biosciences (Hudson, NY). The following mice were generously 
gifted to us: 2C TCR Tg mice from Dr. Richard Miller (Toronto, Canada); 4C TCR Tg mice 
from Dr. Sang-Mo Kang (University of California San Francisco); TCR75 TCR Tg mice 
from Dr. Anita Chong (The University of Chicago); and DEREG mice from Dr. Eric 
Clambey (University of Colorado Anschutz Medical Campus). 
B6-OVA mice express the membrane-bound chicken ovalbumin (OVA) gene under 
the direction of the chicken beta actin promoter coupled with the cytomegalovirus 
immediate-early enhancer (Ehst et al., 2003). B6-OVA and BALB/c mice were intercrossed, 
and OVA-transgene-positive offspring were backcrossed with BALB/c mice for five to seven 
generations to generate OVA-expressing transgenic BALB/c (BALB/c-OVA) mice. OVA-
transgene-negative littermates were used as controls where indicated. 
OT-I TCR Tg mice express CD8+ T cells that recognize the OVA-derived peptide 
254-267 (SIINFEKL), which binds Kb molecules (Hogquist et al., 1994). OT-II TCR Tg 
mice express CD4+ T cells that recognize the OVA-derived peptide 323-339 
(ISQAVHAAHAEINEAGR), which binds I-Ab molecules (Barnden et al., 1998). B6-
CD45.2 OT-I Rag1-/- and B6-CD45.2 OT-II Rag1-/- mice were intercrossed with B6-CD45.1 
mice to generate B6-CD45.1 OT-I Rag1-/- and B6-CD45.1 OT-II Rag1-/- mice.  
2C TCR Tg mice express CD8+ T cells with TCR specificity for Ld, a MHC class I 
antigen (Sha et al., 1988). 4C TCR Tg mice express CD4+ T cells with TCR specificity for I-
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Ad, a MHC class II antigen (Brennan et al., 2008). TCR75 TCR Tg mice express CD4+ T 
cells with TCR specificity for a peptide derived from MHC class I (Kd54-68) presented in the 
context of I-Ab, a MHC class II antigen (Honjo et al., 2004b).  
B6-GFP mice express a transgene encoding green fluorescent protein (GFP) under 
control of the human ubiquitin C promoter (Schaefer et al., 2001). 
FoxP3-GFP mice express a bicistronic cassette encoding the regulatory T cell-specific 
forkhead type transcription factor FoxP3 and enhanced GFP under control of the endogenous 
Foxp3 promoter (Lin et al., 2007). FoxP3-GFP mice were intercrossed with B6-CD45.1 mice 
to generate B6-CD45.1 FoxP3-GFP mice. 
“Depletion of regulatory T cell” (DEREG) mice express the bacterial artificial 
chromosome (BAC) encoding the complete mouse FoxP3 gene locus and diphtheria toxin 
receptor (DTR)-enhanced GFP fusion protein (Lahl et al., 2007). Female heterozygous 
DEREG mice were intercrossed with male B6 mice. Male hemizygous DEREG offspring 
were used in experiments with transgene-negative male littermates as controls (denoted B6 
mice). 
All mice were maintained under specific pathogen-free conditions at the University of 
Colorado Anschutz Medical Campus (AMC). Except for BALB/c mice, all experiments used 
mice from established colonies that were bred in-house. 
Streptozotocin Induction of Diabetes 
Three to six days before transplantation, mice were rendered diabetic by intravenous 
(i.v., retroorbital) injection of the beta cell toxin, streptozotocin (Sigma-Aldrich [St. Louis, 
MO] or Cayman Chemical [Ann Arbor, MI]). Young mice (8- to 12-weeks old) were treated 
with 180 mg/kg. Aged mice (18- to 30-weeks old) were treated with 170 mg/kg, except mice 
≥33.0 g were injected with a maximum dose of 5.61 mg to avoid SZ-related toxicity. 
Pancreatic Islet Cell Transplantation 
Islet isolation and transplantation was performed as previously described (Nicolls et 
al., 2000). Female BALB/c donor pancreata were injected with collagenase (Type V [Sigma-
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Aldrich] or CIzyme RI [VitaCyte, Indianapolis, IN]), digested by static incubation at 37°C, 
and purified over Histopaque (Sigma-Aldrich) or Lympholyte 1.1 (Cedarlane Labs, 
Burlington, NC) gradients. 400-450 hand-picked islets were drawn up into BTPE-50 
polyethylene tubing (Instech Laboratories, Plymouth Meeting, PA), concentrated by 
centrifugation of the tubing, and advanced by a micrometer into the left renal subcapsular 
space of SZ-induced diabetic recipient mice. Rejection was defined as the first day of 
consecutive hyperglycemic blood glucose values of  >15.0 mM (>270 mg/dL). In long-term 
euglycemic hosts, confirmation of graft-dependent blood glucose control was determined 
with nephrectomy of the graft-bearing kidney followed by return to hyperglycemia.  
Skin Transplantation 
 BALB/c skin grafts were transplanted onto male recipients as previously described 
(McFarland and Rosenberg, 2009). Full-thickness skin was acquired from the ventral surface 
of donor mice. Graft beds were prepared on the left shoulder of anesthetized recipient mice 
by excising skin equivalent to the size of the donor graft (∼1 cm2). Grafts were held in place 
with Vetbond tissue adhesive glue (3M, St. Paul, MN) and covered with Vaseline-coated 
gauze (Covidien, Mansfield, MA) and triple antibiotic ointment (Actavis Mid Atlantic, 
Lincolnton, NC). The grafted area and thorax of the mouse was wrapped with adhesive wrap 
for 7 days post-transplant (Thermo Fisher Scientific, Waltham, MA). Skin grafts were 
assessed for acceptance or rejection up to 60 days after transplantation. Time of rejection was 
defined as the day when a necrotic donor graft completely fell off a recipient. 
Alloreactive T Cell Adoptive Transfer 
Single cell suspensions of pooled spleen and mesenteric lymph node cells were 
prepared from CD4-depleted 2C Tg mice, CD8-depleted 4C Rag1-/- Tg mice, and CD8-
depleted TCR75 Rag1-/- Tg mice. Various numbers of cells were adoptively transferred i.p. 
into B6 Rag1-/- hosts or i.v. into B6 hosts. 
 To determine deletion of donor-specific CD8+ T cells, 5 x 106 spleen and lymph node 
cells from CD4-depleted B6-CD45.1 2C TCR Tg mice were injected i.v. into B6 hosts 
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vaccinated as described in the Vaccinations section. Hosts were left untreated or were treated 
with DST and anti-CD154 therapies on the second day after adoptive transfer (see section on 
Tolerance-Promoting Treatments). At 7 days after DST treatment, host spleen cells were 
analyzed by flow cytometry to determine total numbers of 2C (CD45.1+ CD8+) T cells. 
Tolerance-Promoting Treatments 
To induce allograft tolerance using anti-CD154 as a monotherapy or combined with 
donor-specific transfusion (DST), transplant recipients were i.p. injected with CD154-
specific monoclonal antibodies (MR-1, BioXCell) at 250 µg/dose either on days -1, 2, 7, and 
9 (relative to day 0 transplant) or on days -7, -4, 0, and 4 with i.v. administration of 107 T 
cell-depleted donor splenocytes on day -7. Spleen cells from OVA transgene-positive 
BALB/c donors or their transgene-negative littermates were used for BALB/c-OVA DST or 
BALB/c DST, respectively. For B6-OVA plus BALB/c DST, spleen cells from OVA 
transgene-positive B6 donors and OVA transgene-negative BALB/c donors were used and 
separately injected 1 h apart. 
To induce allograft tolerance using anti-CD11α (LFA-1) monotherapy, transplant 
recipients were injected i.p. with LFA-1-specific monoclonal antibodies (KBA, ascites) at 
200 µg/dose on days 0, 1, 7, and 14 (relative to day 0 transplant). 
T Cell Responses to Local Alloantigen Challenge 
 Mice received 1 x 106 BALB/c splenocytes in HBSS injected subcutaneously into 
each hind footpad; control mice were mock injected with HBSS alone. After five days, the 
draining popliteal lymph nodes (popLNs) were carefully dissected and dissociated between 
frosted glass slides. Total live cell numbers were estimated using a hemocytometer and 
trypan blue for dead cell exclusion. Cells were analyzed by flow cytometry as previously 
described (see section on Antibodies, Tetramer Reagents, and Flow Cytometry). 
Antibodies, Tetramer Reagents, and Flow Cytometry 
T cells were analyzed for antigen-specific production of intracellular cytokines by 
stimulating for 4 h with γ-irradiated target cells in the presence of brefeldin A. Crystallizable 
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fragment (Fc) receptors were blocked with anti-FcγRII/III (2.4G2; ascites). Tetramer-positive 
cells were detected by incubation with anti-CD8α (53-6.7) and OVA257-264/Kb tetramers 
conjugated to Brilliant Violet 421 (National Institutes of Health Tetramer Core Facility) 
(1:100 dilution) for 15 min at 37°C. Adoptively transferred TCR Tg cells were detected with 
anti-Vβ8.1/8.2 (MR5-2 for 2C cells), anti-Vα2 (B20.1, OT-I cells), anti-Vβ13 (MR12-3, 4C 
cells), or anti-Vβ8.3 (1B3.3, TCR75 cells). Surface markers were identified with anti-CD45 
(30-F11), anti-CD45.2 (104), anti-CD45.1 (A20), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-
CD44 (IM7), anti-PD-1 (J43), anti-CD62L (MEL-14), anti-CD122 (5H4), anti-CD11α (2D7), 
anti-CD3ε (145-2C11), and anti-CD19 (eBio1D3). Intracellular staining for cytokines, 
transcription factors, and nuclear proteins was performed with a FoxP3/transcription factor 
staining kit according to manufacturer instructions (eBioscience, San Diego, CA), and with 
anti-TNFα (MP6-XT22), anti-IFN-γ (XMG1.2), anti-FoxP3 (FJK16s), anti-T-bet (4B10), 
and anti-Ki-67 (B56). Isotype control antibodies or fluorescence minus one controls were 
used wherever possible to help objectively set gates. All antibodies were from BioLegend 
(San Diego, CA), BD Biosciences (San Jose, CA), or eBioscience. Dead cells were excluded 
by Fixable Viability Dye (eBioscience). Ultra Comp ebeads (eBioscience) were used to 
create compensation controls. FACS data were collected with a LSRII flow cytometer and 
FACSDiva software (BD Biosciences) and analyzed with FlowJo version 9.7.7 and 9.9.5 
software (TreeStar Inc., Ashland, OR). 
Regulatory T Cell Depletion 
DEREG mice carry a transgene for DTR and enhanced GFP under the control of an 
exogenous Foxp3 locus. To deplete FoxP3+ cells, hemizygous DEREG males were i.p. 
injected with diphtheria toxin (DT, Sigma) in PBS. For donors of FoxP3- cells, 1 µg DT was 
injected two days prior to sacrifice. For islet transplant recipients, 1 µg or 0.5 µg DT was 
injected one day post-transplant. Blood was collected by submandibular puncture and 
peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry for GFP 
expression to verify depletion of FoxP3+ (GFP+) cells. 
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Where indicated, FoxP3- cells were obtained from FoxP3-GFP mice by dumping 
FoxP3+ (GFP+) cells via fluorescence-activated cell sorting (FACS) of live cells. Purified 
cells were analyzed by flow cytometry for GFP expression to verify removal of FoxP3+ 
(GFP+) cells. 
Regulatory T cell Induction 
 Induction of FoxP3 expression in FoxP3- precursors was determined during in vitro 
antigen-specific stimulation. FoxP3- (GFP-) precursor cells were isolated from spleen and 
lymph nodes of DEREG mice or FoxP3-GFP mice (see section on Regulatory T Cell 
Depletion). Purified GFP- cells were labeled with eFluor670 proliferation dye according to 
the manufacturer instructions (eBioscience, San Diego, CA). Responder cells (5 x 105) were 
cultured for five days with γ-irradiated BALB/c splenocytes (2 x 106) in supplemented 
Eagle’s minimum essential medium (EMEM). CD154-specific antibodies were titrated into 
the culture. For a positive control, FoxP3 expression was induced with 5 ng/ml recombinant 
human TGFβ and 20 ng/ml recombinant human IL-2, as previously described (Davidson et 
al., 2007; Zheng et al., 2007). 
Analysis of Graft-Infiltrating Cells 
Graft-infiltrating cells were obtained from islet grafts of transplanted recipients. To 
harvest the graft, the kidney capsule surrounding the graft site was carefully cut with 
microscissors, reflected (carrying with it the adhered allograft), removed, digested for 30 min 
at 37°C with 2.4 units/ml Dispase II (Roche, Basel, Switzerland), and gently dissociated 
between frosted glass slides before collecting cells and estimating total live cell numbers 
using a hemocytometer and trypan blue for dead cell exclusion. Cells were analyzed by flow 
cytometry as previously described (see section on Antibodies, Tetramer Reagents, and Flow 
Cytometry). 
Vaccinations 
To generate antigen-specific immunity, randomized groups of 8- to 12-week-old co-
housed B6 male littermates were intraperitoneally (i.p.) injected with one of three 
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vaccinations. OVA/adjuvant-primed (OVA/Adj’) mice received 200 µg endotoxin-free OVA 
(Sigma-Aldrich, St. Louis, MO) plus a subunit adjuvant of 50 µg polyinosinic-polycytidylic 
acid sodium salt (Sigma-Aldrich) and 50 µg agonistic CD40-specific antibody (FGK45, 
BioXCell, West Lebanon, NH) in phosphate-buffered saline, as previously described 
(Ahonen et al., 2004a). Adjuvant-primed (Adj’) mice received the subunit adjuvant alone. 
BALB/c-primed (BALB/c’) mice received 2 x 107 BALB/c splenocytes in Hanks balanced 
salt solution (HBSS). Where indicated, CD8+ or CD4+ T cells were depleted during 
vaccination with CD8α-specific (2.43; BioXCell) or CD4-specific (GK1.5; BioXCell) 
monoclonal antibodies (10 mg/kg, days -4, -2, 3, and 7 relative to vaccination). Vaccinated 
B6 mice were used in experiments within 30 to 150 days postimmunization (median 56 days).  
Detection of OVA-Specific Immunoglobulin 
Immunolon II plates (ThermoScientific, Waltham, MA) were coated with 100 µg/mL 
OVA (Sigma-Aldrich) and blocked with 1% bovine serum albumin and 0.05% NaN3. Sera 
were serially diluted from 1:50 dilution and assayed for anti-OVA reactivity against the 
plates by incubation for 2 h at room temperature. Bound immunoglobulin (Ig) was detected 
with a goat polyclonal anti-mouse Ig detection antibody conjugated to alkaline phosphatase 
(SouthernBiotech, Birmingham, AL) and visualized at 405 nm using a para-nitrophenyl 
phosphate substrate (Sigma-Aldrich) and Infinite 200 PRO plate reader (Tecan, Mannedorf, 
Switzerland). 
Detection of Donor-Specific T cells 
Purified splenic T cells were obtained using negative selection magnetic enrichment 
(Stemcell Technologies, Cambridge, MA). T cells were cultured for 18 h in serum-free 
medium at 1 x 103 to 2 x 105 cells/well and stimulated with 3 x 105 γ-irradiated BALB/c, B6-
OVA, or B6 splenocytes. IFN-γ-secreting cells were detected by enzyme-linked immunospot 
(ELISPOT) silver staining (U-Cytech biosciences, Urecht, Netherlands) and counted with use 
of a Bioreader 4000 Pro-X plate reader (Bio-Sys Laboratories, Pasadena, CA). 
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Alloantibody Detection 
 Flow cytometric assessment of donor-reactive IgG antibodies was performed as 
previously described (Kwun et al., 2012) with modifications. BALB/c, B6-OVA, and B6 
thymocytes were blocked with 1% fetal bovine serum, 0.01% NaN3, and FcγRII/III. Sera 
(1:25 dilution) from vaccinated mice were incubated with 1 x 105 donor thymocytes for 20 
min at 4°C, then washed. Bound IgG was detected by staining samples with fluorescein 
isothiocyanate (FITC)-conjugated goat polyclonal anti-mouse IgG for 20 min at 4°C. After 
washing, T cells were stained with anti-CD3ε. The alloantibody production of each serum 
sample was measured as the percent donor T cells that stained positive with FITC-anti-mouse 
IgG. 
Bone Marrow Chimeras 
Bone marrow chimeric heart donors were generated by irradiating BALB/c female 
mice twice at 400 radiation-absorbed dose (4 Gray), 4 h apart, then intravenously injecting 6 
to 8 x 106 bone marrow cells from female BALB/c or BALB/c-OVA donors to create 
BALB/c-BALB/c or BALB/c-OVA-BALB/c chimeras, respectively. Bone marrow chimeras 
were allowed to reconstitute for 9-15 weeks. Chimerism was validated by flow cytometric 
analysis of the expression of OVA by CD45+ blood cells. 
Heterotopic Cardiac Transplantation 
For tolerance induction experiments, hearts from chimeric BALB/c mice were 
transplanted heterotopically into vaccinated B6 mice and recipients received anti-CD154 
monotherapy (see section on Tolerance-Promoting Treatments). Vascularized grafts were 
transplanted according to standard microsurgical techniques (Corry et al., 1973; Plenter et al., 
2013). Briefly the harvested donor heart was placed in 4°C saline until transplantation. An 
end-to-side anastomosis of the donor aorta to the recipient aorta and an end-to-side 
anastomosis of the donor pulmonary artery to the recipient inferior vena cava were made 
using running 10-0 nylon sutures. Heart graft survival was monitored daily by palpation, with 
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completion of rejection defined as cessation of detectable beat and confirmed by laparotomy 
under anesthesia.  
Memory OT-I T Cells 
To generate antigen-experienced OVA-reactive OT-1 T cells, B6-Rag1-/- hosts were 
adoptively transferred with 107 B6-CD45.1 OT-1 Rag1-/- spleen cells and immunized with 
the OVA/adjuvant vaccine (see section on Vaccinations). Within 18 d, transferred T cells 
were purified from spleen and lymph nodes via magnetic negative selection, checked by flow 
cytometry to be CD44hi, and 2-4 x 106 purified OT-1 cells (73–84% purity) were then i.v. 
injected into naïve 8- to 12-week-old male B6 mice. All B6 mice that were adoptively 
transferred with memory OT-I T cells (OTIM mice) were bled and analyzed with the use of 
flow cytometry for OT-I engraftment. Those with OT-I cells engrafting at ≥0.2% of 
peripheral CD8+ CD44hi T cells were used in experiments within 30-60 days after adoptive T 
cell transfer. 
Statistical Analysis 
Statistical analyses were performed using Prism version 6.05 for Windows (GraphPad 
Software, La Jolla, CA). Results for cell numbers, frequencies, sera Ig titers, and 
representative ELISPOT data are shown as the mean ± SD; results for pooled ELISPOT data 
are shown as the mean ± SEM of averaged quadruplicate measures. Differences among 
groups were analyzed using either an unpaired two-tailed Student t-test (two groups) with 
Welch’s correction or a two-way ANOVA (more than two groups) with posttest multiple t-
test comparisons and Holm-Sidak correction. Allograft survival data were analyzed using the 
Kaplan-Meier method with statistical differences determined by the log-rank test and Cox 
regression model. P values of <0.05 were considered significant. 
Study Approval 
All animal care and experiments conformed to National Institutes of Health 




PATHWAYS FOR GRAFT RECOGNITION BY HOST T CELLS 
CHAPTER OVERVIEW 
• Donor-reactive T cells reject pancreatic islet cell transplants. 
• Multiple T-cell recognition pathways can operate simultaneously. 
• Alloreactive direct CD8+, direct CD4+, and indirect CD4+ T cells are individually 
sufficient to reject islet allografts. 
• Combination therapies -- rather than a single “magic bullet” therapy -- might be 
necessary to control all pertinent alloreactive effector T cell pathways. 
Introduction 
 The health of patients who receive solid organs, tissues, or cellular transplants often 
depends on functional and long-term survival of their allografts. Unfortunately, several 
barriers can cause graft dysfunction and block graft survival. These include the state of the 
tissue after donation, ischemia reperfusion injury after implantation, ongoing metabolic 
disease in the recipient, and immune-mediated rejection. Among immunologic hurdles, T 
cells represent a major challenge because an estimated 1-10% of an individual’s T cells can 
recognize and respond to non-self (i.e. donor) major histocompatibility complex (MHC) 
molecules (Brondz and Snegirova, 1971; Lindahl and Wilson, 1977; Suchin et al., 2001). 
When compared with the much lower estimated precursor frequency of 0.0001% of T cells 
being specific for a given foreign antigen, donor MHC-reactive T cells can be an astounding 
104-105 times more prevalent in the repertoire of transplant recipients before transplantation 
(Givan et al., 1999; Blattman et al., 2002; Moon et al., 2007; Obar et al., 2008).  
 Such a large precursor frequency raises concerns about the effector roles that 
alloreactive T cells play in transplantation and their impact on graft survival. As described in 
Chapter I, Table 1-4, the specific CD4+ or CD8+ T cell subsets that are necessary and/or 
sufficient for rejection vary depending on which organs, tissues, or cells are transplanted. 
Unfortunately, the field seems to search for a “magic bullet” therapy that will block all T cell 
recognition pathways for all transplants. Yet the clinical difficulty in inhibiting alloreactive T 
cells could be that some therapies block one effector pathway while another uninhibited 
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pathway remains sufficient to destroy the graft. Combination therapies may be necessary to 
simultaneously inhibit several pathways that can individually target a transplant. Thus, what 
arguably lies at the heart of developing more effective anti-rejection strategies for transplant 
recipients could be a more thorough understanding of how T cells recognize and target 
particular types of allografts. 
T cell receptors (TCR) recognize donor antigens via different antigen-presentation 
pathways. As described in Chapter I, Figure 1-1, host T cells can react to donor antigens 
through donor MHC-restricted or self MHC-restricted TCRs (direct or indirect pathways, 
respectively). Modeling direct or indirect CD4+ or CD8+ T cells via TCR transgenic (Tg) 
mice has greatly expanded our understanding of how recognition pathways differentially 
contribute to the demise of a transplant. For example, polyclonal CD4+ T cells alone can 
reject skin and cardiac allografts (Krieger et al., 1996; Pietra et al., 2000; Youssef et al., 
2004). Yet the TCR specificities that CD4+ T cells use for immune recognition of each graft 
diverge: Direct CD4+ TCR Tg T cells can acutely reject skin but not cardiac allografts, 
whereas indirect CD4+ TCR Tg T cells can acutely reject both skin and cardiac allografts 
(Sayegh et al., 2003; Baratin et al., 2004; Honjo et al., 2004b; Brennan et al., 2008; Brennan 
et al., 2009). Compared to our understanding about pathways for heart and skin rejection, 
relatively little is known about the pathways for T cell recognition of donor antigens derived 
from islet allografts (Table 3-1). 
In the current study, we determined the antigen-specific requirements for T cell 
recognition of islet allografts in non-autoimmune diabetic recipients. We transplanted 
allogeneic BALB/c islet cells into streptozotocin (SZ)-treated recombinase-deficient 
(Rag1-/-) B6 recipients and then adoptively transferred Tg T cells expressing singular 
specificities of alloreactive TCRs. Using this animal model, we tested whether direct CD8+, 
indirect CD8+, direct CD4+, or indirect CD4+ T cells are individually sufficient to reject 
allogeneic islet cells, independently of additional cellular and humoral adaptive immunity. 
We also developed an adoptive transfer model system using TCR Tg cells in immune 
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competent recipients, whereby alloreactive T cell immunity can be monitored under 
tolerance-promoting and tolerance-breaking conditions. 
Results 
Immune competent transplant recipients acutely reject MHC-mismatched islet cells 
 Seminal studies in the years 1980, 1990, and 2000 showed that transplantation of 
human pancreatic islet cells into diabetic recipients could normalize poorly controlled blood 
glucose levels (Najarian et al., 1980; Scharp et al., 1990; Oberholzer et al., 2000; Shapiro et 
al., 2000). Our laboratory’s small animal model of islet cell isolation and transplantation 
similarly demonstrates that murine islets can normalize blood glucose in diabetic recipients. 
Islet cells transplanted into recipients rendered diabetic by SZ injection typically reduced 
blood glucose levels from ≥33.3 mM to <15.0 mM shortly after transplantation (Figure 3-1A). 
As shown, graft-dependent glycemic control can be achieved using islet cells from MHC-
identical donors or MHC-incompatible donors (called isografts or allografts, respectively). 
While long-term control is achieved with isografts, acute graft loss occurred in all recipients 
of allogeneic islet cells, as indicated by the rapid return of diabetes (Figure 3-1B). 
Acute allograft rejection requires donor-reactive host T cells but not B cells 
 As shown, MHC-incompatible tissues are acutely rejected in immune competent 
individuals. It is already well known that islet allograft rejection depends on host adaptive 
immune responses, and specifically requires T cell immunity (Zitron et al., 1981; Diamond 
and Gill, 2000). To formally demonstrate these requirements, we analyzed BALB/c islet graft 
survival in Rag1-/- mice that lack functional T and B lymphocytes. Rag1-/- recipients 
uniformly accepted BALB/c islet cell transplants (Figure 3-2A), indicating that adaptive 
immunity is essential for islet allograft rejection. 
 This experiment did not distinguish the roles of T versus B lymphocytes. Their 
individual contributions to allograft rejection were evaluated using mice deficient in 
conventional T cells but replete with B cells (Tcrα-/- and Tcrβ-/- mice), or mice deficient in B 
cells but replete with T cells (µMT-/- mice). Eight-to-twelve week-old Tcrα-/-, Tcrβ-/-, and 
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µMT-/- SZ-induced diabetic mice received BALB/c islet transplants and were monitored for 
graft rejection. All Tcrα-/- and Tcrβ-/- recipients accepted BALB/c islet grafts, whereas 
µMT-/- mice rejected them (Figure 3-2A). B cells are therefore insufficient and dispensable 
for islet allograft rejection, while T cells expressing αβ TCRs are sufficient and necessary for 
allograft rejection. This is consistent with the important role that conventional T cells play in 
mediating rejection of vascularized organ, tissue, and cellular transplants. 
We further demonstrate that T-cell involvement in allograft rejection requires T cell 
receptors that are specific for donor-derived epitopes. TCR Tg OT-I Rag1-/- and OT-II 
Rag1-/- mice respectively generate CD8+ and CD4+ T cells that recognize antigens from the 
main protein of chicken egg white, ovalbumin (OVA) (Hogquist et al., 1994; Barnden et al., 
1998). OT-I Rag1-/- and OT-II Rag1-/- mice rejected full-thickness skin grafts from 
transgenic B6-OVA mice that express membrane bound OVA under the control of the beta 
actin promoter (Ehst et al., 2003). However, all OT-I Rag1-/- and OT-II Rag1-/- recipients 
indefinitely accepted full-thickness BALB/c skin (which does not express the target protein 
OVA) (Figure 3-2B). In contrast, positive control immune competent B6 recipients of 
BALB/c skin transplants acutely rejected the allografts (Figure 3-2B). Since T cells in OT-I 
Rag1-/- and OT-II Rag1-/- mice did not reject transplanted allogeneic tissues through 
nonspecific or TCR-independent mechanisms, this study indicates that monoclonal 
populations of host T cells must specifically recognize and respond to alloantigens to mediate 
allograft rejection. 
Direct CD8+, direct CD4+, and indirect CD4+ T cells are individually sufficient to kill 
BALB/c islets 
 Next, we investigated several monoclonal populations of alloreactive CD8+ or CD4+ 
T cells to determine which recognition pathways (direct or indirect) are individually 
sufficient to reject allogeneic islet transplants after adoptive transfer of TCR Tg T cells into 
B6 Rag1-/- recipients. Table 3-2 summarizes the TCR Tg mouse models utilized in these 
studies. The table also lists our predictions for whether these singular T cell specificities 
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would be sufficient to target certain islet allografts; refer to Chapter I, Table 1-3, for a full 
description of donor haplotypes. Except for 2C mice, all TCR Tg mice were bred to the B6 
Rag1-/- background to exclude the possibility of a second endogenous rearranged TCR 
contributing to alloreactivity. 
Our laboratory previously determined that B6 SCID or Rag1-/- recipients adoptively 
transferred with primed, polyclonal alloreactive CD8+ T cells could reject BALB/c islets 
(Diamond and Gill, 2000; Sleater et al., 2007). For the current study, we tested whether naïve, 
monoclonal CD8+ TCR Tg T cells with direct reactivity to intact donor MHC class I-peptide 
complexes (Ld-reactive 2C cells) were sufficient to kill islet allografts. B6 Rag1-/- mice were 
rendered diabetic with SZ, transplanted with BALB/c or specificity control dm2 islets, 
monitored to ensure initial graft function, and then adoptively transferred with purified 2C Tg 
T cells on post-operative day 5 (d5). 2C cells acutely rejected Ld-expressing BALB/c 
allografts but not control dm2 islets, which lack expression of the target Ld MHC antigen 
(Figure 3-3A). Control transplanted mice that were not adoptively transferred with Tg cells 
indefinitely accepted their allografts (Figure 3-3A). Thus, directly alloreactive CD8+ T cells 
are sufficient to reject islet allografts. 
 An alloreactive Tg mouse model of indirect CD8+ T cell recognition does not yet 
exist. To test whether indirect CD8+ T cells are sufficient to reject islet allografts, we utilized 
a xenogeneic system whereby OVA-reactive Kb-restricted CD8+ (OT-I) TCR Tg T cells 
respond to processed peptides from OVA-expressing BALB/c (BALB/c-OVA, Kd) islet 
donors. B6 Rag1-/- mice received BALB/c-OVA islets, were adoptively transferred with OT-
I Rag1-/- cells on d5, and indefinitely accepted their transplants (Figure 3-3B). In contrast, 
adoptively transferred OT-I Rag1-/- cells killed positive control OVA-expressing Kb (B6-
OVA) target islets (Figure 3-3B), indicating that CD8+ T cells can be sufficiently activated in 
B6 Rag1-/- mice, perhaps via direct recognition or cross-priming by donor APCs from the 
transplant. Failure of the Tg cells to reject BALB/c-OVA islet allografts indicates that 
indirect CD8+ T cells are not sufficient to reject islet grafts. 
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Next we tested whether directly alloreactive CD4+ T cells were sufficient to reject 
allogeneic islet grafts. CD4+ TCR Tg T cells with direct reactivity to intact donor MHC class 
II-peptide complexes (I-Ad-reactive 4C Rag1-/- cells) were adoptively transferred on d5 into 
B6 Rag1-/- recipients of either I-Ad-expressing BALB/c islets or negative control C3H islets. 
Subsequent results of graft survival were mixed, with 1/4 (25%) of BALB/c islet recipients 
rejecting the transplants (Figure 3-3C). Because islet parenchymal cells do not express MHC 
class II and graft-derived APCs were likely rapidly eliminated by host NK cells before 
adoptive transfer of Tg T cells on d5 (Garrod et al., 2010), the observed lack of rejection 
could be due to the unavailability of donor antigens for ongoing targeting by directly 
alloreactive CD4+ T cells. Hence we tested whether transferring Tg T cells two days prior to 
transplantation (d-2) would increase their reactivity against the allograft. When transferred 
prior to transplantation, 4C Rag1-/- cells were only marginally capable of rejecting BALB/c 
islet transplants (Figure 3-3C). Regardless, directly alloreactive CD4+ T cells can still reject 
islet allografts albeit with much less vigor than the other tested pathways. 
Finally, we tested whether CD4+ TCR Tg T cells with indirect reactivity to processed 
donor MHC class I peptides presented by host MHC class II (Kd-reactive I-Ab-restricted 
TCR75 Rag1-/- cells) were sufficient to reject allogeneic islets. TCR75 Rag1-/- cells were 
adoptively transferred on d5 into B6 Rag1-/- recipients of Kd-expressing BALB/c or Kd-
expressing NOD Rag1-/- islets, or negative control C3H islets. TCR75 Rag1-/- cells acutely 
rejected both kinds of Kd-expressing transplants but not the specificity control grafts (Figure 
3-3D). Thus, indirectly alloreactive CD4+ T cells can reject islet allografts. 
Overall, our results indicate that direct CD8+, direct CD4+, and indirect CD4+ T cells 
can individually target and reject islet allografts. 
Indirect CD4+ T cell-mediated rejection of islet allografts is IFN-γ  independent 
 The molecular effector mechanisms required for allograft rejection can vary among 
immune cell subsets. However, IFN-γ appears to be generally required for pathways of direct 
donor recognition. For example, donor IFN-γ receptors were critical for CD4+ T cell-
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mediated cardiac allograft rejection (Wiseman et al., 2001). Directly alloreactive CD8+ T 
cells required IFN-γ to reject islet allografts (Diamond and Gill, 2000). IFN-γ was also 
required during NK cell-mediated chronic rejection of cardiac allografts in the presence of 
anti-donor MHC-specific antibodies (Lin et al., 2016). Since IFN-γ is a critical 
proinflammatory cytokine during these pathways to allogeneic heart and islet cell rejection, 
we tested whether the indirect pathway also depends on IFN-γ for islet allograft rejection. 
Surprisingly, blockade of IFN-γ did not attenuate BALB/c islet allograft rejection in B6 
Rag1-/- hosts adoptively transferred with TCR75 Rag-/- cells (Figure 3-4). Thus, whereas the 
production of IFN-γ is a rate-limiting step in the process of direct CD4+ and CD8+ allograft 
rejection, this requirement does not extend to indirect CD4+ T cell effector mechanisms 
against islet allografts. 
Monitoring alloreactive T cells via an adoptive transfer model system 
 Having identified the key players in T cell recognition and rejection of islet allografts, 
we next developed an adoptive transfer model to study T cell activation during tolerance-
promoting and tolerance-breaking conditions in vivo. We wanted a model system whereby 
we could transfer TCR Tg T cells into immune competent B6 recipients of BALB/c islet 
allografts and monitor the alloreactive T cell response without perturbing the response due to 
inappropriate precursor frequencies. We planned to use this model system most often for 
experiments presented in Chapter V that utilized a common tolerance-promoting protocol 
(Parker et al., 1995; Markees et al., 1998) in which recipients were treated pre-transplant with 
anti-CD154 mAb plus donor specific transfusion (DST) (Figure 3-5A). Diabetic B6 mice 
treated with BALB/c DST and anti-CD154 combination therapy can indefinitely accept 
BALB/c islet allografts (Figure 3-5B). 
Compared with the relatively high frequency of direct alloreactivity (estimated at 1-
10%), indirect alloreactive T cells represent a low natural precursor frequency (estimated at 
0.0001%) that might be easily perturbed by adoptive transfer of additional indirect cells. The 
vigor with which indirect TCR75 Tg cells reject islet allografts further suggests that an 
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inappropriate transfer might overwhelm tolerance induction. A titration of adoptively 
transferred TCR75 Tg cells into B6 recipients showed that 10,000 TCR75 cells consistently 
permitted the development of tolerance (Figure 3-6A). We next determined whether 
simultaneous transfer of a mixture of indirect CD4+, direct CD8+, and direct CD4+ TCR Tg 
cells (hereafter referred to as “Tg trio” cells) would perturb immunity and tolerance induction. 
Adoptive transfer of 10,000 TCR75, 1 million 2C, and 1 million 4C Tg cells impacted neither 
islet allograft rejection in untreated B6 hosts nor tolerance induction in DST/anti-CD154-
treated recipients (Figure 3-6B). 
Finally, we tested adoptive transfer of Tg trio cells into immunized B6 mice that were 
generated and treated according to the model system developed in Chapter V. Briefly, B6 
mice were vaccinated and, after generation of immune memory, were tested for whether 
adoptive transfer of Tg trio cells perturbed either unmodified islet allograft rejection or 
tolerance induction mediated by OVA-expressing BALB/c DST and anti-CD154 mAb. Acute 
graft survival (7 days post-transplant) remained unchanged in control recipients where they 
did not receive transferred cells (Figure 3-7A). Adoptive transfer of an ideal combination of 
Tg trio (10,000 TCR75, 5 million 2C, and 5 million 4C) cells also did not impact graft 
survival in untreated or therapy-treated B6 hosts (Figure 3-7B). In contrast, adoptive transfer 
of 50-fold more indirect CD4+ Tg cells and 5-fold less direct CD8+ and CD4+ Tg cells 
rapidly attenuated tolerance induction in this model. This validated our previously described 
concerns that early tolerance induction can be sensitive to overload by indirectly alloreactive 
T cells (Figure 3-7B). 
Discussion 
The sufficiency of singular TCR specificities to target islet allografts using direct or 
indirect recognition pathways was not previously known. To our knowledge, we are the first 
to present concurrent evidence that direct CD8+, indirect CD4+, and to a lesser extent, direct 
CD4+ T cells are each individually capable of rejecting transplanted islets. Our preliminary 
experiments suggest that indirect CD8+ T cells are not sufficient for islet rejection. 
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We found here and previously (Stegall et al., 1999; Diamond and Gill, 2000) that 
direct CD8+ 2C TCR Tg cells can reject allogeneic islet targets in immune-deficient hosts. 
This might seem surprising since the activation of naïve CD8+ T cells often relies on CD4+ T 
cell help (Choi et al., 2001; Ford et al., 2008; Ryu et al., 2009). Indeed, while help is not a 
universal requirement for all types of allograft rejection (Table 1-4), most studies for islet 
transplantation show that islet allografts do not initiate CD4-independent (CD8-dependent) 
immune responses in vivo. However, CD8+ T cell depletion attenuates islet allograft rejection. 
Given this ambiguity for dual roles of CD4+ and CD8+ T cells in islet rejection compared 
with more clear singular requirements for rejecting other tissues, it is likely that both subsets 
contribute to islet allograft destruction by CD4+ T cell help to activate CD8+ T cells which in 
turn mediate graft destruction. 
Directly alloreactive CD8+ T cells typically require sensitization to donor antigens to 
reject islet allografts when CD4+ T cells are absent (Prowse et al., 1983; Warren et al., 1984; 
Diamond and Gill, 2000; Ninova et al., 2005; Sleater et al., 2007). However, CD4+ T cell 
help was not required for rejection by unprimed monoclonal 2C Tg cells in this model. This 
might indicate that the lymphopenic environment of Rag1-/- hosts promoted CD8+ T cell 
activation. Although not investigated in the current study, adoptive transfer of 2C Tg cells 
into B6 SCID mice that were transplanted with BALB/c islets showed markers of activation 
and differentiation, indicated by increased levels of IL-2R, LFA-1, and dense graft 
infiltration by the cytotoxic cells (Stegall et al., 1999). Alternatively, 2C Tg cells may have 
been able to reject islet allografts because 2C cells were present at high frequency, which was 
sufficient to induce cardiac allograft rejection in other models (Brennan et al., 2008; Harper 
et al., 2015). Since CD4+ T cells are typically necessary for cardiac allograft rejection (Pietra 
et al., 2000; Youssef et al., 2004), the unusual findings by Brennan et al. (2008) and Harper 
et al. (2015) demonstrate the probable characteristic that CD8+ T cells either need more 
aggressive responses per cell or a greater number of responding cells to mediate islet or 
cardiac allograft rejection alone. It is not surprising then to us that 2C Tg cells are sufficient 
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to reject islet cells in Rag1-/- mice given that CD8+ T cells typically play a major role as 
effector cells in islet rejection, their TCR can directly react to the abundant graft expression 
of the donor MHC class I, and homeostatic proliferation and other factors might contribute to 
CD4-independent activation. 
We found that indirect CD8+ T cell recognition of donor antigens was insufficient to 
reject islet allografts. The indirect pathway requires cross-presentation and cross-priming 
(Bevan, 1976) plus cognate CD4+ T cell help for optimal CD8+ T cell priming via DC 
licensing (Bennett et al., 1997; Ryu et al., 2009). In replete B6 mice, host APCs cross-present 
exogenous OVA antigens derived from BALB/c-OVA cells to generate cross-primed, 
SIINFEKL-reactive, Kb-restricted, IFN-γ producing, cytotoxic CD8+ T cells (Wang et al., 
2011). To activate indirect CD8+ T cells in our B6 Rag1-/- model system, cross-presentation, 
dendritic cell (DC) licensing, and cross-priming would need to occur in the absence of CD4+ 
T cell help. Wang et al. (2011) showed that cross-presentation of BALB/c-OVA antigens can 
occur without CD4+ T cells, but CD8+ T cells are suboptimally activated without help.  
The suboptimal activation of CD8+ T cells because CD4-deficient hosts cannot 
effectively license cross-presenting DCs could explain the failure of OT-I Tg cells to be 
sufficient in rejecting BALB/c-OVA islets. To ensure cross-priming and thereby test whether 
primed indirect CD8+ T cells are sufficient to reject islet allografts, we could inject recipients 
with a subunit adjuvant-based vaccination protocol that generates CD4-independent primary 
CD8+ T cell immune responses (Ahonen et al., 2004b; Edwards et al., 2013). We hypothesize, 
however, that maximizing cross-priming still would not lead to indirect CD8+ T cells 
rejecting islet grafts because Kb-restricted OT-I TCR cannot directly engage BALB/c-OVA 
graft cells. Primed CD8+ T cells mediate allograft rejection through a “two-hit” approach 
involving cytokine production and contact-dependent cytotoxicity, where first IFN-γ 
conditions the target cell and renders it sensitive to the second lethal release of FasL 
signaling, and/or perforin and granzymes (Diamond and Gill, 2000; Sleater et al., 2007). 
Thus while indirect CD8+ T cells are presumably activated during transplantation in immune 
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competent hosts, we predict that their inability to contact the target islet cells makes them 
nonpathogenic bystanders during islet allograft rejection. 
We had predicted that direct CD4+ T cells would not be sufficient to reject islet 
parenchymal cells because islets lack expression of the target MHC class II. However, we 
found that direct CD4+ T cells were marginally capable of rejecting allogeneic islet cell 
targets, regardless of whether the cells were transferred pre-transplant or on post-operative 
day 5. Testing both early and late transfers and finding similar rates of rejection was helpful 
in establishing that marginal rejection is likely not accounted for by rapid attenuation of 
donor APCs due to NK cells eliminating allogeneic passenger leukocytes (Garrod et al., 
2010). Even after donor passenger leukocytes are eliminated from the host, antigenic targets 
for the direct CD4+ T cell pathway can persist because intraislet endothelial cells express 
donor MHC class II in the vasculature of the graft, which is a composite of donor- and host-
derived blood vessels beginning 2-4 days post-transplant (Brissova et al., 2004). Priming of 
directly reactive CD4+ T cells can also persist via the semidirect recognition pathway, 
wherein host APCs can present intact donor MHC class II molecules that were acquired 
through the natural transfer of exosomes from endothelial cells (Liu et al., 2016). 
Of note, some islet allografts survived in recipients adoptively transferred with 4C Tg 
cells. It is clear that the TCR of the Tg cell is intrinsically capable of graft rejection because 
the 4C Tg cell is sometimes sufficient to reject islet grafts and is certainly sufficient to reject 
skin grafts. Among three different transgenic mouse models of direct CD4+ T cell 
alloreactivity (the 4C, ABM, and 2.102 Tg mice), all were able to reject skin grafts but none 
acutely rejected heart allografts (Sayegh et al., 2003; Baratin et al., 2004; Brennan et al., 
2008). This suggests that TCR-independent effects predominantly influence whether 
alloreactive T cells reject transplanted tissues. For example, providing additional priming to 
4C Tg cells by infusing donor-derived DCs augmented their reactivity such that they could 
acutely reject cardiac allografts (Brennan et al., 2008). Therefore, in isolation, direct CD4+ T 
cells may or may not be effector cells, but with increased priming or in the presence of other 
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activated alloreactive cells in an immune competent individual, they might become 
decisively pathogenic against an islet allograft. It would be interesting to test this more fully 
in our islet allograft model. 
Finally, we found that indirect CD4+ T cells were sufficient to vigorously reject islet 
allografts in the B6 Rag1-/- host. This finding is reminiscent of other studies from our 
laboratory where the indirect pathway was required for rejection of xenogeneic islet grafts 
and autoimmune-mediated rejection of MHC-deficient islet grafts (Gill, 1992; Rayat et al., 
2003; Kupfer et al., 2005; Kupfer et al., 2008; Plenter et al., 2012). To take one example 
from among these: In the setting of autoimmune responses modeled in a SCID mouse, 
directly islet-reactive CD4+ T cells (BDC-2.5 TCR Tg cells) were sufficient to kill self-
MHC-expressing (syngeneic, NOD) islets; this is expected for autoimmune disease 
recurrence. Intriguingly, however, this same T cell specificity was also sufficient to reject 
allo-MHC-expressing (allogeneic, B6) islets that were deficient in MHC class II (Kupfer et 
al., 2005). Such donor MHC-independent rejection implicates host-dependent antigen 
presentation for initial priming, much like how conventional priming occurs during 
presentation of foreign antigens. More importantly, indirect recognition for rejection at the 
graft site (of allografts or xenografts) implicates the necessary involvement of additional 
cytotoxic effector cells that directly kill the target, because exclusively self-MHC-restricted 
indirect CD4+ T cells cannot themselves physically contact donor MHC-expressing islets. 
Surprisingly, unlike the requirement of the proinflammatory cytokine, IFN-γ, when 
direct CD4+ T cells mediate rejection, indirect CD4+ T cells can mediate islet allograft 
rejection without IFN-γ in our experiments. TCR75 Tg cells vigorously rejected islet 
allografts independently of a requirement for IFN-γ and with similar kinetics as recipients 
transferred with TCR75 Tg cells that were not treated with IFN-γ blockade. However, visual 
inspection of the graft sites revealed a pronounced difference in appearance, with the lesion 
in anti-IFN-γ-treated mice estimated to contain at least ten-fold more cells than in the 
unmodified lesion (data not shown). We have submitted these samples for histological 
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analysis to determine whether these cells might actually be peri-transplant, rather than 
infiltrating the islets, as IFN-γ was previously shown to be required for immune cell entry 
into an islet transplant (Diamond and Gill, 2000). 
In total, the data from this chapter demonstrate that the adaptive immune system 
contains redundant recognition pathways that are likely difficult to completely circumvent in 
clinical transplantation. Moreover, in the context of currently published literature, various 
types of allografts display differential susceptibility to each of these recognition pathways, so 
a singular “magic bullet” therapy may not protect all transplants. 
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Table 3-1. Unprimed donor-reactive T cells of singular specificities are sufficient to 












Heart N DNF N Y (Honjo et al., 2004a; Brennan et al., 2008) 
Skin Y DNF Y Y (Ninova et al., 2005; Brennan et al., 2008; 
Brennan et al., 2009) 
Islet Y DNF DNF DNF (Stegall et al., 1999; Diamond and Gill, 2000) 
1Published studies in which B6 Rag1-/- recipients of allografts were adoptively transferred with the 
same specificities of TCR Tg Rag1-/- cells that we utilize in our current study. 






Figure 3-1. SZ-induced diabetic B6 mice reject BALB/c pancreatic islet cell transplants. 
Eight-to-twelve week-old C57BL/6J WT male mice were rendered diabetic with the islet β 
cell-specific toxin, streptozotocin (SZ), and transplanted with pancreatic islet cells from 
syngeneic donors (B6, H-2b, n=5) or allogeneic donors (BALB/c, H-2d, n=8). After 
transplantation (TP), blood glucose was measured at least once per week to determine graft 
survival. The first day of two consecutive days >15 mM was considered the day of graft 
rejection. (A) Blood glucose curves show glycemic control in two recipients (one 
representative mouse per group) before and after the day of TP (designated day 0). Graft-
dependent euglycemia is verified by return of hyperglycemia after nephrectomy of the graft-
bearing kidney at 100 days after TP (arrowhead). (B) Graft survival curves show days of 
isograft versus allograft survival in SZ-treated B6 recipients (median survival time, MST ≥ 
100 days vs. 12 days, respectively). ***p<0.001, Kaplan-Meier method with log-rank test 




Figure 3-2. Allograft rejection requires donor-reactive T cells. 
(A) Survival of BALB/c islets transplanted into diabetic B6 Rag1-/- (n=7), Tcrα-/- (n=3), 
Tcrβ-/- (n=3), and µMT-/- (n=2) mice. (B) Survival of full-thickness ventral trunk BALB/c 
skin transplanted onto B6 (n=3), OT-I TCR Tg Rag1-/- (n=3), and OT-II TCR Tg Rag1-/- 





Table 3-2. Predictions for whether transgenic mouse models of direct or indirect 












Direct CD8+ 2C QLSPFPFDL/Ld Y N -- -- -- 
Indirect CD8+ OT-I SIINFEKL/Kb -- -- N -- -- 
Direct CD4+ 4C (Unknown)/I-Ad N -- -- -- N 
Indirect CD4+ TCR75 Kd54-68/I-A
b Y -- -- Y N 
Y, rejection predicted. N, no rejection predicted. --, not tested in this study. 
Pertinent information regarding donor haplotypes: 
Ld is a MHC class I antigen expressed by BALB/c mice. The Ld locus is deleted in dm2 mice. 
Kb is a MHC class I antigen expressed by B6 mice. 
I-Ad is a MHC class II antigen expressed by BALB/c mice. 
Kd is a MHC class I antigen expressed by BALB/c and NOD mice. 






Figure 3-3. Direct CD8+, direct CD4+, and indirect CD4+ T cells can individually reject 
islet allografts. 
Diabetic B6 Rag1-/- mice were transplanted with allogeneic islets and intraperitoneally 
adoptively transferred with 5 x 106 CD45.1 TCR Tg T cells on the indicated day (d) before 
or after transplantation. (A) Survival of Ld-expressing BALB/c islets (n=15) compared with 
control dm2 islets (which lack the target antigen, Ld, n=4) in recipients adoptively transferred 
with Ld-reactive (direct) CD8+ 2C Tg T cells. Control mice received BALB/c islets (n=6) or 
dm2 islets (n=5) alone. (B) Survival of OVA-expressing BALB/c islets (n=2) transplanted 
into recipients of OVA-reactive Kb-restricted (indirect) CD8+ OT-I T cells. Recipient of 
OVA-expressing B6 islets (n=1) serves as positive control for islet graft rejection. (C) 
Survival of I-Ad-expressing BALB/c islet grafts transplanted into recipients adoptively 
transferred with I-Ad-reactive (direct) CD4+ 4C T cells either two days pre-transplant (n=5) 
or five days post-transplant (n=4). Recipients of C3H (H-2k) islets (n=2) serve as third-party 
specificity controls. Note the x-axis indicates days post-transplant rather than days post 
adoptive cell transfer. (D) Survival of Kd-expressing BALB/c (n=5) and NOD Rag1-/- islets 
(n=3) compared with third-party C3H islets (n=2) in recipients adoptively transferred with 
Kd-reactive I-Ab-restricted (indirect) CD4+ TCR75 T cells. *p<0.05, **p<0.01, Kaplan-
Meier method with log-rank test and Cox regression model. Panel (A) courtesy of C. Gelhaus. 
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Figure 3-4. IFN-γ  is not required for indirect CD4+ T cell-mediated allograft rejection. 
Diabetic B6 Rag1-/- mice were transplanted with BALB/c islets, adoptively transferred with 
5 x106 CD45.1 TCR75 Rag1-/- Tg T cells on post-operative 5, and injected with 1 mg anti-
IFN-γ mAb on post-operative days 5, 8, and 11. Survival of BALB/c islets in recipients 
treated with anti-IFN-γ (n=2) compared with control untreated recipients (n=5; previously 
shown in Figure 3-3D), or control transplant recipients not adoptively transferred with Tg T 
cells (n=8). Kaplan-Meier method with log-rank test and Cox regression model. 
  






















Figure 3-5. Tolerance-promoting therapy, DST/anti-CD154 mAb, extends islet allograft 
survival in immune competent B6 recipients. 
(A) Scheme for inducing tolerance to BALB/c islet transplants in B6 mice using CD154-
specific monoclonal antibodies and an intravascular injection of 107 donor-derived spleen 
cells for donor-specific transfusion (DST) treatment. (B) Survival of BALB/c islets 
transplanted into eight-to-twelve week-old diabetic B6 mice (n=3) that were treated as 
described in (A) with BALB/c DST, compared with control untreated recipients (n=8; 
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Figure 3-6. Low precursor frequency of indirect CD4+ T cells does not readily disrupt 
DST/anti-CD154 tolerance-promoting therapy in B6 recipients. 
Eight-to-twelve week-old diabetic B6 mice were adoptively transferred with TCR Tg T cells 
two days prior to treatment with BALB/c DST/anti-CD154 therapy, which was administered 
as described in Figure 3-5A. (A) Survival of BALB/c islets transplanted into recipients that 
were adoptively transferred with 10,000 (n=3) or 100,000 (n=3) TCR75 cells. (B) Survival of 
BALB/c islets transplanted into recipients that were adoptively transferred with the “Tg Trio” 
-- a combination of 10,000 TCR75, 1 million 2C, and 1 million 4C cells -- and then treated 
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Figure 3-7. Determining the combination of adoptively transferred “Tg Trio” cells that 
does not trigger early islet allograft rejection in B6 vaccinated recipients. 
Eight-to-twelve week-old male B6 mice were vaccinated with an adjuvant or 
ovalbumin/adjuvant about 60 days prior to transplantation with BALB/c islets (this 
vaccination model is described in detail in Chapter V; recipients here are not distinguished 
based on the vaccination received because results did not differ between the two groups). 
Where indicated, mice were adoptively transferred with TCR Tg T cells two days before 
treatment with an ovalbumin-expressing BALB/c (BALB/c-OVA) DST and anti-CD154, 
which was administered as described in Figure 3-5A. Graft survival was monitored for 100 
days (A) or 7 days (B) after transplantation, but only short-term graft survival (7 days) is 
assessed here in order to determine the acute effects of DST/anti-CD154 treatment and 
adoptive transfer of “Tg Trio” cells. (A) Survival of BALB/c islets transplanted into 
vaccinated and untreated recipients (n=14) compared with DST/anti-CD154-treated 
recipients (n=34). (B) Survival of BALB/c islets in vaccinated and DST/anti-CD154-treated 
recipients that were adoptively transferred with 10,000 TCR75 + 5 million 2C + 5 million 4C 
cells (n=9) compared with a less optimal combination of 500,000 TCR75 + 1 million 2C + 1 
million 4C cells (n=6). Vaccinated control recipients were transplanted and left untreated 
after adoptive transfer with optimal numbers of “Tg trio” cells (n=4) to demonstrate that the 
transferred cells did not accelerate unmodified graft rejection. 
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CHAPTER IV 
EARLY REQUIREMENTS FOR TOLERANCE INDUCTION 
CHAPTER OVERVIEW 
• Ideal antirejection agents in clinical transplantation would involve transient 
administration of non-toxic immune-modulating therapies that induce tolerance. 
• We define transplant tolerance as a donor-specific change in an immune competent 
recipient that permits durable allograft survival. 
• Anti-CD154 monoclonal antibody therapy restrains early T cell reactivity rather than 
converting naïve T cells to a regulatory phenotype or deleting them. 
• Tolerance is vulnerable to early but not late disruption. 
• Tolerance induction requires early PD-1 signaling or FoxP3+ Treg cells. 
• The “switch” model proposing rapid deviation in T cell fate and immediate 
generation of tolerance cannot account for our data. A new model is needed. 
Introduction 
 Chapter III described three T-cell recognition pathways that can individually 
contribute to islet allograft rejection. By understanding these pathways and the effector roles 
of donor-reactive T cells, we can gain clues about how to target effector T (Teff) cells in 
order to best control their responses against allografts. Various immune therapies used in 
clinical transplantation suppress systemic T cell responses. Commonly used agents include 
calcineurin inhibitors (CNIs), interleukin-2 (IL-2) receptor inhibitors, mechanistic target of 
rapamycin (mTOR) protein inhibitors, inhibitors of de novo purine synthesis, and low-dose 
steroids. Unfortunately, the side effects from immunosuppressive drugs are often poorly 
tolerated (Chapter I, Table 1-2) and toxicities can arise in chronically treated recipients 
(Anghel et al., 2013; Girlanda, 2013). New advances in safer, effective, and short-term 
treatments that result in long-term transplant survival thus remain a fundamental goal in 
transplantation research. 
The most promising approach for controlling graft-reactive T cells may be to induce 
immune tolerance to the graft. Transplant tolerance was first defined as immune 
nonresponsiveness to donor antigens in animal models (Billingham et al., 1953). In human 
transplantation, “operational tolerance” has been defined as successful weaning from 
immunosuppression with stable graft function for one year or more. Our laboratory defines 
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transplant tolerance as an antigen (donor)-specific change in an immune competent recipient 
that permits indefinite allograft survival. Although our definition of tolerance is fairly generic, 
we intentionally avoid associating a mechanism with the outcome of tolerance without 
experimental evidence for that mechanism. In this chapter, we aimed to determine the 
mechanisms that lead to tolerance following therapy treatment rather than ostensibly 
presuming the mechanism(s) a priori. 
Many transiently administered agents can promote long-term host tolerance. We 
focused on one agent that blocks costimulatory molecule signaling in a pathway that has been 
of great interest in transplantation research. CD154 (also called CD40 ligand) is a type II 
membrane protein of the TNF superfamily of molecules that is predominantly expressed by 
activated CD4+ T cells after TCR stimulation (Armitage et al., 1992; Hollenbaugh et al., 
1992; Lane et al., 1992; Noelle et al., 1992; Hermann et al., 1993). The interaction between 
CD40/CD154 is pivotal for the induction of humoral and cellular immune responses in 
humans and mice. As our laboratory and others have shown, targeting this pathway through 
transient administration of anti-CD154 monoclonal antibodies (mAb) achieves indefinite 
allograft tolerance. The resulting tolerance has been well characterized as durable, donor-
specific, and transferable when used during islet cell transplantation (Nicolls et al., 2002). 
 While the end result of tolerance after anti-CD154 mAb has been described, the exact 
mechanism through which the therapy actually mediates tolerance induction is still not clear. 
Various mechanisms have been proposed, including T cell deletion, anergy, or conversion to 
regulatory phenotypes (Wells et al., 1999; Iwakoshi et al., 2000; Quezada et al., 2005; Ferrer 
et al., 2011). As a result of these reports, a long-held paradigm has emerged describing the 
mechanism for tolerance by anti-CD154 mAb treatment as suppression of T cell reactivity 
with simultaneous deviation of T cell fate toward an altered phenotype (Figure 4-1). We refer 
to this mechanism as the “switch” model because it proposes a rapid deviation (or switch) in 
T cell fates. We note that this model also implies that tolerance is immediately generated in 
one step. 
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Our studies presented here focus on investigating the proximal impact of CD154-
specific therapy on T cells as they respond to donor antigens. We sought to answer two key 
questions. First, what is the early role of the therapy in directing tolerance induction? Second, 
what immune responses promote tolerance induction? During our studies, we found that 
many of the previously described mechanisms of tolerance (i.e. deletion, anergy, and 
conversion to regulatory phenotypes) were not evident in our animal model of islet cell 
transplantation and costimulation-blockade therapy. We also found that tolerance induction 
fails when certain key pathways are blocked. Given that our data are inconsistent with a 
mechanism of rapid deviation in T cells fates, we propose that a new model is needed to 
explain the mechanisms leading to development of tolerance. 
Results 
Tolerance-promoting agents lead to long-term graft survival in naïve immune 
competent hosts 
 Monoclonal antibodies (mAbs) that target T cell-surface molecules can promote 
tolerance in small animal models. Our laboratory has extensively used anti-CD154 and anti-
LFA-1 mAbs to promote islet allograft tolerance in murine recipients (Nicolls et al., 2000; 
Nicolls et al., 2002; Beilke et al., 2005; Grazia et al., 2005; Bishop et al., 2014; Nelsen et al., 
2017). We recently tested different dosing regimens of anti-CD154 mAb in B6 recipients of 
BALB/c islets. Our results demonstrate an optimal 10-day course administered at 250 µg/day 
on days -1, 2, 7, and 9 (with day 0 being the day of transplantation) that yields 56-68% of 
allografts surviving ≥100 days (Figure 4-2A and B). Peri-transplant treatment with anti-LFA-
1 at 200 µg/day on days 0, 1, 7, and 14 also extended the survival of BALB/c islets with 20% 
of allografts surviving ≥100 days (Figure 4-2B). In previous experiments that used the same 
regimen of anti-LFA-1 mAb, 60% of BALB/c islets survived ≥100 days in B6 recipients 
(Nicolls et al., 2002). Thus, long-term survival of BALB/c islets in B6 recipients arises after 
transient treatment with either anti-CD154 or anti-LFA-1 mAbs. 
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Therapies predominantly restrain early T cell responses rather than deviate fate 
 Acute islet allograft rejection in untreated B6 mice is associated with strong CD4+ 
Th1 and CD8+ Tc1 cellular responses. Here, we used a footpad assay to determine the 
proximal fate of adoptively transferred GFP+ naïve T cells as they responded to local 
challenge with BALB/c alloantigens in the draining popliteal lymph node (popLN) during 
treatment with anti-CD154 or anti-LFA-1 mAbs (Figure 4-3A). An unmodified acute 
response to subcutaneous injection of alloantigens follows the “default” differentiation 
pathway described in Figure 4-1. Namely, we find increased total numbers of lymphocytes, 
CD4+ T cells, and CD8+ T cells, plus extensive proliferation and coproduction of the type 1 
inflammatory cytokines, IFN-γ and TNFα (Figure 4-3B-E and data not shown). The addition 
of anti-CD154 or anti-LFA-1 mAb during BALB/c stimulation maintained lymphocyte 
numbers in the popLN comparable to control unstimulated mice (Figure 4-3B-D). Notably, 
the proliferation of CD4+ and CD8+ T cells was reduced but not completely abrogated in the 
presence of either therapy (data not shown), as was the frequency of differentiated T cells 
(marked by co-production of IFN-γ and TNFα) (Figure 4-3E). 
 Interestingly, other work in our lab showed that proliferated CD4+ and CD8+ T cells 
expressed markers of activation, such as CD44hi and CD62Llo, in therapy-treated hosts 
(Wang, 2013). No detectable IL-4- or IL-10-producing CD4+ T cells were found in the 
draining lymph node following alloantigen challenge and treatment with anti-CD154 or anti-
LFA-1 mAb (Wang, 2013). Moreover, in the islet transplant model, B6 recipients of BALB/c 
islets failed to produce donor specific antibody following treatment with anti-CD154 mAb, 
indicating that the therapy can block follicular helper T cells from providing help to B cells 
(Bishop et al., 2017). Thus, we find that anti-CD154 and anti-LFA-1 mAbs predominantly 
restrain T cell responses, and the few responders have retained Th1 and Tc1 characteristics 
rather than deviated fates, such as Th2 phenotypes. 
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Anti-CD154 monotherapy does not convert early T cell fate toward FoxP3+ lineage 
The peripheral conversion of naïve alloreactive T cells to induced regulatory T (iTreg) 
cells is a proposed mechanism for how anti-CD154 mAb mediates tolerance induction. 
However, conflicting evidence leaves the question open for whether anti-CD154 mAb 
actually induces FoxP3+ cells from uncommitted CD4+ T cells. Two independent groups 
obtained different results from the same xenogeneic system utilizing RAG-deficient OVA-
reactive CD4+ OT-II T cell receptor transgenic (TCR Tg) mice. Ferrer et al. (2011) described 
the conversion of FoxP3- OT-II TCR Tg precursors to iTreg cells when they found increased 
frequencies of CD25hi FoxP3+ OT-II Tg cells in the draining lymph node fourteen days after 
skin transplantation and anti-CD154 treatment (Ferrer et al., 2011). When we conducted 
similar studies that also used FoxP3- OT-II Tg cells, we did not find evidence of such 
conversion (Wang, 2013). To expand on these studies with a new approach, we developed an 
allogeneic model system using RAG-sufficient polyclonal T cells and tested whether CD154-
specific antibodies were sufficient to generate FoxP3+ cells from FoxP3- precursors. 
We enriched FoxP3- precursors from two distinct mouse strains via separate 
approaches. In the first method, we used bacterial artificial chromosome-transgenic B6 mice 
that express diphtheria toxin receptor (DTR) and enhanced green fluorescent protein (GFP) 
under the control of an exogenous FoxP3 promoter (Lahl et al., 2007). These “depletion of 
regulatory T cell” (DEREG) mice were selectively depleted of DTR-expressing FoxP3+ 
(GFP+) cells by intraperitoneal injection with ≤1 µg diphtheria toxin (DT) (Figure 4-4A). In 
the second method, we used transgenic B6 mice that express a bicistronic cassette encoding 
both FoxP3 and enhanced GFP under control of the endogenous FoxP3 promoter (Haribhai et 
al., 2007). From these FoxP3-GFP mice, we sorted out splenic and peripheral lymph node 
GFP+ cells (Figure 4-4B). Through either approach, we consistently obtained enriched 
populations of GFP- cells that were 98.3 to 100% pure (Figure 4-4C). 
Next we evaluated the early induction of FoxP3 expression during in vitro treatment 
with anti-CD154 mAb. We reasoned that if the therapy was directly responsible for 
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“switching” T cell fate to generate iTreg cells then we should observe this result in tissue 
culture conditions. Purified GFP- cells were labeled with proliferation dye and cultured for 
five days with BALB/c stimulators plus increasing concentrations of anti-CD154 mAb. The 
highest therapeutic dose characteristically restrained T cell responses as previously described. 
GFP expression was used as a surrogate marker to report the induction of FoxP3 expression. 
Purified GFP- CD4+ T cells did not show elevated GFP expression in response to BALB/c 
cells after treatment with anti-CD154 mAb (Figure 4-5). Compared with cells cultured in 
media alone, GFP expression was observed in CD4+ T cells cultured with the positive control 
induction cytokines, TGF-β and IL-2 (Figure 4-5). Thus we find that GFP- (FoxP3-) cells can 
express FoxP3-GFP if appropriately induced, but failed to convert due to anti-CD154 
treatment alone. 
Since anti-CD154 mAb did not induce Treg cells in vitro, we tested for early 
induction of FoxP3 during in vivo treatment. Purified GFP- cells were labeled with 
proliferation dye and adoptively transferred to CD45 congenic hosts, which were challenged 
with BALB/c splenocytes in the footpad and treated with anti-CD154 mAb. As previously 
described, anti-CD154 mAb again restrained lymphocyte responses (Figure 4-6A). Notably, 
however, anti-CD154 therapy did not lead to early FoxP3 expression among adoptively 
transferred GFP- precursors (Figure 4-6B and C). Again, our evidence predominantly 
suggests that anti-CD154 mAb promotes early Teff cell restraint rather than directly 
mediating immune deviation. 
Up to this point, we assessed FoxP3- precursors for anti-CD154-mediated conversion 
to FoxP3+ Treg cells in response to BALB/c splenocytes. Surprisingly, we found no evidence 
of such conversion in vitro or in vivo. Ferrer et al. (2011) reported that 16.57% ± 2.68% of 
FoxP3- OT-II Tg precursors converted to CD25+FoxP3+ by fourteen days after skin 
transplantation and anti-CD154 mAb. We therefore hypothesized that FoxP3- T cells 
required time and interaction with a transplant during anti-CD154 therapy in order to convert 
to FoxP3+ induced Treg cells. To test this concept, we purified GFP- (FoxP3-) cells from 
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DEREG mice by DT-depletion, adoptively transferred them to naïve B6 mice, transplanted 
the hosts with BALB/c islets, and administered anti-CD154 therapy. GFP- precursors isolated 
from tolerant mice that had accepted their transplants >100 days still did not express splenic 
FoxP3 via the GFP reporter (Figure 4-7). If these preliminary results repeat, then we can 
conclude that CD154-specific antibodies fail to generate de novo FoxP3+ cells from FoxP3- 
precursors even in tolerant mice over time and in the presence of an islet allograft. 
Tolerance stabilizes over time 
Having established that a tolerance-promoting therapy does not immediately “switch” 
T cell fate, we turned our investigations toward understanding how tolerance develops after 
Teff cells are therapeutically restrained. We hypothesized that tolerance requires time for 
host-dependent regulatory mechanisms to form to continue controlling Teff cells after 
transient therapy treatment ends. We know that early after transplantation, tolerance-
promoting regimens are vulnerable to disruption by inappropriate host stimulation, such as 
TLR agonists (Chen et al., 2006; Thornley et al., 2006). We reasoned that if tolerance 
requires time to fully develop, then the emerging tolerant state would be initially vulnerable 
to the disruptive stimulus of TLR ligation but tolerance would eventually evolve to endure 
the same challenge at later time points. 
First, we tested the TLR3 agonist, polyinosinic:polycytidylic acid [poly(I:C)], for its 
propensity to block early tolerance induction in our animal model. SZ-induced diabetic B6 
mice were transplanted with BALB/c islet allografts and treated with CD154-specific 
antibodies. Near the time of transplantation (post-operative day 2), recipients were 
intraperitoneally injected with 50-100 µg poly(I:C) or control PBS. Injection of the synthetic 
dsRNA agonist blocked tolerance induction in most but not all animals (Table 4-1). 
For a stronger and especially challenging stimulus, we tested the tolerance-disrupting 
potential of a subunit-based adjuvant comprised of poly(I:C) and agonistic CD40-specific 
antibodies (Ahonen et al., 2004b). Since this adjuvant is partially comprised of CD40-
specific antibodies that could merely stimulate the opposite signaling pathway that CD154-
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specific antibodies target, we first tested whether the adjuvant disrupts tolerance promoted by 
anti-LFA-1 mAb therapy in a process independent from the CD40/CD154 axis. Diabetic B6 
mice were treated with the tolerance-promoting therapy, anti-LFA-1, and injected with 
adjuvant on the second day post-transplant. The adjuvant also blocked early tolerance in anti-
LFA-1 treated recipients (Figure 4-8), indicating that the capacity of the stimulation to 
disrupt tolerance-promoting processes was not a specific property of CD154-blockade. 
With this assurance, we returned to testing our proposed hypothesis that tolerance 
requires time to develop. Adjuvant was injected into transplanted and anti-CD154-treated 
recipients at varying time points after transplantation. When injected at the time of 
transplantation (day 0 or 2), the adjuvant blocked tolerance induction in nearly all recipients 
(Figure 4-9A). When given three weeks after transplantation -- which is nine days after the 
12-day median survival time for untreated allografts (Figure 3-1) -- the stimulation triggered 
rapid and uniform allograft rejection (Figure 4-9B). Importantly, at a later time point (day 60), 
this stimulation no longer elicited rejection of the established allograft (Figure 4-9C). Thus it 
appears that after the initial peri-transplant period marked by T cell restraint and 
susceptibility to disruption, a secondary phase of host tolerance develops that can resist 
disruptive stimuli. 
Peri-transplant stimulus reverses therapy-mediated restraint of Teff cell responses 
We hypothesized that the adjuvant triggered early demise of the islet allografts by 
activating alloreactive T cells that were restrained by the therapy. Alternatively, the adjuvant 
may have triggered graft death through independent innate responses. Distressed islet cells 
may have transiently expressed TLR3 and died by intrinsic induction of apoptotic pathways 
related to TLR3 ligation of poly(I:C) (Scarim et al., 2001; Liu et al., 2002; Dogusan et al., 
2008; Aida et al., 2011). The activation of macrophages through agonistic CD40 signaling 
could also induce IL-12 and nitric oxide (NO) production at cytotoxic levels for transplanted 
islet cells (Shu et al., 1995; Tian et al., 1995; Stout et al., 1996). It was therefore important to 
distinguish whether the adjuvant-associated loss of transplanted allogeneic islet cells 
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observed in Figure 4-9 was due to independent innate responses or the induction of a 
destructive T cell response. To test a requirement for adaptive immunity, we transplanted 
BALB/c islets into SZ-treated, diabetic B6 Rag1-/-
 
recipients and injected the adjuvant two 
days or twenty-one days after transplantation. No grafts were lost due to innate immune 
responses to the adjuvant alone (Table 4-2), so adaptive immunity was required to reject 
BALB/c islets in immune competent mice. 
We used a footpad assay to assess the proximal fate of adoptively transferred GFP+ 
naïve T cells in the draining popLN as they responded to BALB/c alloantigens during 
treatment with either anti-CD154 or anti-LFA-1 mAb and adjuvant administered on day 2. 
Compared with results previously shown in Figure 4-3, the tolerance-disrupting stimulus 
abolished initial T cell restraint by CD154-specific therapy, and partially reversed restraint 
by LFA-1-specific therapy. Despite anti-CD154 mAb, lymphocytes in the popLN of 
adjuvant-stimulated recipients were as numerous as untreated BALB/c-stimulated recipients, 
and T cells had proliferated and differentiated to co-produce IFN-γ and TNFα cytokines 
(Figure 4-10A-C). 
Preliminary experiments in transplant recipients treated with CD154-specific therapy 
revealed similar characteristics after administration of adjuvant on post-operative day 21. 
One control PBS-treated recipient demonstrated intragraft T cell restraint, whereas one 
adjuvant-treated recipient showed robust T cell activation as indicated by an increased 
frequency of activated and proliferating (CD44hi Ki-67+) CD8+ and CD4+ T cells (Figure 4-
11). The speed with which this reversal occurred was remarkable: The PBS-treated mouse 
remained normoglycemic (tolerant) throughout the experiment, whereas the adjuvant-treated 
mouse became hyperglycemic (rejecting) within 3 days after injection with the adjuvant. 
Thus, we conclude that transplant recipients are vulnerable to tolerance disruption 
through a protracted period that lasts at least three weeks post-transplant. Furthermore, 
alloreactive T cells are still clearly present in the host and have not been deleted or deviated 
toward an altered fate. They appear to be primed for rejection but are restrained from 
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attacking the graft. Altogether, this evidence strongly discredits many basic tenants of the 
“switch” model. 
Tolerance induction requires early PD-1 signaling and preexisting FoxP3+ cells 
 At this point, our data do not support the “switch” model presented in Figure 4-1 as 
the mechanism for therapy-mediated tolerance induction. Rather than deviating T cell fates 
toward alternate phenotypes, anti-CD154 mAb contributes to tolerance by restraining early T 
cell responses. We posit that this restraint creates a permissive environment for the natural 
mechanisms of peripheral regulation to operate. Since programmed death-1 (PD-1) signaling 
and FoxP3+ Treg cells are two common regulatory pathways that control immunity, we 
hypothesized that each one would be critical requirements for transplant tolerance induction. 
The coinhibitory receptor PD-1 plays an essential role in silencing CD4+ and CD8+ T 
cell responses. The PD-1 axis maintains peripheral self-tolerance by blocking the activation 
of high-affinity autoreactive CD4+ T cells that escape central tolerance (Jiang et al., 2016). 
Blockade of the PD-1/PD-L1 inhibitory pathway during chronic LCMV infection 
reinvigorated exhausted virus-specific CD8+ T cell responses, which lowered viral load 
(Barber et al., 2006). Neutralizing PD-1, PD-L1 or TGFβRII signaling in T cells also 
abrogated CD3 antibody-induced tolerance in a mouse model of islet allograft transplantation 
(Baas et al., 2016). Given its important role in silencing immune responses, we tested a 
requirement for early PD-1 signaling during treatment with anti-CD154 therapy.  
We found an essential role for PD-1 inhibition during tolerance induction when 
blockade of PD-1 interaction with PD-L1 resulted in nearly uniform graft rejection (Figure 4-
12A). Interestingly, additional preliminary experiments showed that by twenty-four days 
after BALB/c islet transplantation, fewer than half of graft-infiltrating T cells expressed PD-1 
in recipients treated with anti-CD154 mAb (Figure 4-12B). The frequency of intragraft CD4+ 
or CD8+ T cells that were proliferating and expressing PD-1 increased in a therapy-treated 
recipient that rejected its allograft after challenge with tolerance-disrupting adjuvant on the 
twenty-first day after transplantation (Figure 4-12B). Thus, we would differentiate the 
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requirement for PD-1 signaling during tolerance induction from the notion that high PD-1 
expression correlates with tolerance at this time point. 
FoxP3+ CD4+ Treg cells are critically important for peripheral self-tolerance and graft 
tolerance. Acute removal of Treg cells in autoimmune NOD mice after the establishment of 
target tissue protection mitigated the restraint of Teff cells, resulting in extensive tissue 
damage (Miska et al., 2014). Transient depletion of FoxP3+ cells induced rejection of long-
term accepted skin and heart allografts in a murine model of mixed hematopoietic chimerism 
(Shinoda et al., 2014). In a graft-versus-host model, CD4+ CD25+ Treg cells were required 
for tolerance induced via anti-CD154 mAb (Taylor et al., 2001). Here, we explored the 
requirement for FoxP3+ cells during tolerance induction after islet transplantation.  
DEREG mice and transgene-negative littermates (denoted as B6 mice) were 
transplanted with BALB/c islets and treated with anti-CD154 mAb. FoxP3+ cells were 
selectively depleted in DEREG mice via injection with DT one day after transplantation. 
PBS-injected DEREG recipients were included to control for non-depletion, and DT-injected 
B6 recipients were included to control for off-target side effects of DT. FoxP3-depleted 
recipients uniformly rejected their allografts after injection with 1 µg DT (Figure 4-13A). 
Non-depleted B6 mice injected with DT also rejected their grafts, suggesting that DT itself, 
rather than the loss of FoxP3+ cells alone, might contribute to blocking tolerance induction 
(Figure 4-13A). We had determined that 0.5 µg DT gave excellent peripheral depletion 
(Figure 4-4A), so we tested whether this diluted dose did not block tolerance induction in 
control mice. This DT treatment did not block tolerance in control non-depleted B6 mice, 
whereas FoxP3-depletion again blocked tolerance in DEREG mice (Figure 4-13B). 
Combining data from both experiments showed rapid acute rejection without FoxP3+ cells 
and gave greater confidence that Treg cells are essential for tolerance induction (Figure 4-
13C). Thus, our preliminary results highly suggest that preexisting host FoxP3+ cells are 
required for tolerance induction. 
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Discussion 
Agents that block costimulatory molecule signaling and subsequently promote 
durable immune tolerance in small animal models have been of great interest in 
transplantation research. Although frequently studied, the mechanism of tolerance induction 
during treatment with therapies that target the CD154/CD40 costimulatory axis remains 
somewhat obscure. One dominant hypothesis is that CD154-specific therapies convert 
previously uncommitted alloreactive T cells to FoxP3+ CD4+ Treg cells. Ferrer et al. (2011) 
propose that the inhibition of CD40 signaling through interrupted interaction with CD154 
conditions antigen-presenting cells (APC) such that the synaptic contact with cognate T cells 
instructs them to become regulatory cells rather than activated effectors. This hypothesis is 
based on the demonstration that peripheral FoxP3+ Treg cells can be generated from FoxP3
- 
precursors after exposure to tolerogenic plasmacytoid dendritic cells in graft draining lymph 
nodes (Ochando et al., 2006). Unlike results from Ferrer et al. (2011), our results indicated 
that OVA-reactive OT-II Rag1-/- TCR Tg cells did not express FoxP3 after stimulation with 
donor APCs and treatment with CD154-specific therapy in our hands (Wang, 2013). Another 
group similarly concluded the lack of Treg induction among alloreactive TCR75 TCR Tg 
cells in a skin transplantation model (Chai et al., 2015).  
I investigated this potential mechanism of tolerance induction further using a 
polyclonal allogeneic system. An initial input of purified FoxP3- precursors gave sensitive 
detection of de novo FoxP3 expression. Surprisingly, at no point during the course of 
responding to donor antigens in the presence of CD154-specific therapy did FoxP3- cells 
express appreciable FoxP3 either in short-term assays performed in vitro and in vivo, or after 
>100 days in tolerant transplanted recipients. One potential pitfall from these studies was that 
the largely purified (98.3-100% pure) FoxP3- cell populations harbored some contaminating 
preexisting FoxP3+ T cells. These residual FoxP3+ cells could have numerically increased 
due to expansion rather than de novo induction expression of the transcription factor. 
However, given that the precursors in our assays neither increased in frequency nor number 
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after treatment with anti-CD154 tolerance-promoting therapy, we conclude that residual 
FoxP3+ cells after purification were not confounding. Thus our primary data do not support a 
mechanism for rapid anti-CD154-mediated conversion of T cells to an induced Treg 
phenotype. 
During some tolerance induction regimens, such as combined CD154-specific therapy 
with donor specific transfusion (DST) or combined kidney and bone marrow transplantation 
in humans, the mechanism of tolerance induction reportedly involves clonal deletion and/or 
anergy of donor-reactive T cells (Pearson et al., 1992; Markees et al., 1998; Iwakoshi et al., 
2000; Nijagal et al., 2013; Morris et al., 2015). In experiments not presented here, we 
investigated clonal deletion of alloreactive 2C TCR Tg cells in mice treated with anti-CD154 
mAb and DST and found no evidence for T cell elimination. We have repeatedly found that 
alloreactive T cells persist after treatment with anti-CD154 monotherapy, produce IFN-γ in 
response to polyclonal stimulation and alloantigens, and are functionally capable of rejecting 
allografts upon TLR ligation or secondary transfer (Figures 4-9 and 4-10; Nicolls, 2002; 
Wang, 2013). Other groups using anti-CD154 mAb report similar observations regarding the 
abortive expansion of donor-reactive T cells yet full differentiation of the few responding T 
cells (Ferrer et al., 2011; Ferrer et al., 2012; Chai et al., 2015). Thus we conclude that active 
restraint rather than peripheral clonal deletion or anergy of alloreactive T cells appears to be 
part of the mechanism contributing to tolerance in recipients treated with anti-CD154 therapy. 
We found requirements for early PD-1 signaling and preexisting host FoxP3+ T cells, 
both of which are associated with mechanisms of peripheral tolerance. Although functional 
Teff cells can transiently express inhibitory receptors during activation, prolonged and/or 
high expression of multiple inhibitory receptors, including PD-1, is a key feature of the 
exhaustion of CD8+ and CD4+ T cells (Virgin et al., 2009; Wherry, 2011). Exhausted CD8+ 
T cells could represent a distinct lineage fate for T cells generated during costimulation 
blockade-mediated tolerance induction. Although we did not find evidence for this among 
intragraft T cells in tolerant animals (Figure 4-12B), anti-CD154 blockade could facilitate 
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tolerance induction through cell intrinsic control mechanisms by promoting the expression of 
coinhibitory receptors. 
In several transplantation models, Treg cells have been important to the induction and 
maintenance of tolerance to donor antigens, as their removal results in prompt graft rejection 
(Taylor et al., 2001; Quezada et al., 2005; Kendal et al., 2011). The requirement for early 
peri-transplant Treg cells surprised us, however, as we expected that such cells would be 
necessary for the later establishment and maintenance of tolerance rather than during the 
immediate induction period. In future studies, we would be interested to know whether 
preexisting Treg cells are required to initially restrain Teff cells, or if early therapy-mediated 
restraint is sufficient to block Teff cell responses. 
Overall, our data do not support the “switch” model presented in Figure 4-1 as the 
mechanism for how anti-CD154 mAb promotes transplant tolerance. Instead of switching or 
diverting T cell fates toward alternative phenotypes, our evidence predominantly suggests 
that tolerance-promoting therapies diminish the magnitude of antigen-specific Th1 and Tc1 
responses. Instead of directing T cells toward clonal deletion or anergy, we find that donor-
reactive T cells persist after initial antigen exposure and treatment with anti-CD154 therapy. 
Moreover, we find that tolerance is susceptible to disruption for at least three weeks after 
transplantation (that is nine days after the untreated median time to rejection). We interpret 
this as evidence that anti-CD154 mAb does not immediately create conditions for tolerance. 
Finally, an early conversion of conventional naïve T cells toward a regulatory phenotype is 
not required for tolerance induction. Given that the “switch” model fails to account for our 
observations, we suggest that an alternative model is needed for explaining the mechanisms 
of tolerance induction. We developed and present such a model in Chapter VI. 
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Figure 4-1. The “switch” model: Deviating T cell fates. 
(A) When a naïve alloreactive T cell encounters presented donor antigen after islet cell 
transplantation, its “default” differentiation pathway is to become a pathogenic IFN-γ-
producing Th1 or Tc1 effector cell that targets and kills the graft. (B) In the presence of 
costimulation blockade therapies (e.g. anti-CD154 mAb), T cell fate is deviated, or switched, 
toward inactivation by clonal deletion or anergy, or toward an induced regulatory lineage, 
such as FoxP3, Tr1, or other suppressor phenotypes. The “switch” model implies that the 
therapeutic intervention can generate tolerance in one step as an immediate result of 


















Figure 4-2. Immune-modulating therapies that target T cell-surface molecules can 
promote host tolerance to islet allografts. 
Eight-to-twelve week-old male B6 mice were rendered diabetic with SZ and transplanted 
with BALB/c islets on day 0. (A) Graft survival in untreated recipients (n=8) compared with 
recipients that were treated with anti-CD154 mAb on the indicated days (d) at increasing 
induction doses of 250 µg (n=10), 500 µg (n=6), or 1 mg (n=6). Graft survival was not 
significantly different between the three regimens of anti-CD154 treatment. (B) Graft 
survival in untreated recipients (n=8) compared with recipients treated with anti-CD154 mAb 
(250 µg on days -1, 2, 7, 9, n=19) or anti-LFA-1 mAb (200 µg on days 0, 1, 7, 14, n=5). 
Graft survival with anti-LFA-1 therapy was not significantly different from anti-CD154 
treatment. Results of untreated recipients in (A) and (B) are data duplicated from Figure 3-1B. 
**p<.01, ***p<.001, ****p<.0001, Kaplan-Meier method with log-rank test and Cox 





















































Figure 4-3. Alloreactive T cell responses are reduced but not completely abrogated after 
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Figure 4-3. Alloreactive T cell responses are reduced but not completely abrogated after 
treatment with tolerance-promoting therapy. 
 (A) Scheme for assessing acute T cell responses to alloantigen in an antigen-draining lymph 
node via a footpad assay. Polyclonal B6-GFP cells were labeled with eFluor670 proliferation 
dye and 20 x 106 cells were intravenously adoptively transferred into eight-to-twelve week-
old male B6 hosts. Two days later, the hosts were subcutaneously injected in the footpad 
with 2 x 106 BALB/c cells or HBSS, and were otherwise untreated or treated with anti-
CD154 or anti-LFA-1 mAb therapy. Five days after footpad injection, the draining popliteal 
lymph nodes (popLN) were isolated and T cells assessed for markers of activation and 
differentiation. (B) Total number of live lymphocytes in popLN. (C) Numbers of CD4+ 
GFP+ T cells in popLN. (D) Numbers of CD8+ GFP+ T cells in popLN. (E) Representative 
FACS plots showing frequency of TNFα- and IFN-γ-cytokine producing cells among CD4+ 
GFP+ (top) or CD8+ GFP+ (bottom) T cells following 4 hr polyclonal stimulation with 
phorbol 12-myristate 13-acetate and ionomycin (PMA-I) in the presence of brefeldin A. Data 
in (A-C) are pooled from two to four independent experiments. *p<.05, **p<.01, ***p<.001, 
one-way ANOVA with Tukey’s multiple comparisons test, with a single pooled variance, 
where the mean of each group was compared with the mean of every other group. 
 68 
 
Figure 4-4. Purification of GFP- (FoxP3-) cells by depleting or sorting out GFP+ 
(FoxP3+) cells from transgenic DEREG or FoxP3-GFP mice. 
(A) Representative FACS plots of GFP+ blood lymphocytes from FoxP3-GFP-DTR-
expressing DEREG mice two days after injection with 1 µg, 0.5 µg, or 0.25 µg diphtheria 
toxin (DT). A control DEREG mouse was injected with vehicle PBS. The B6 mouse is a 
transgene-negative littermate of DEREG mice. (B) Representative FACS plots of GFP+ 
splenic lymphocytes from a FoxP3-GFP-expressing mouse before and after sorting out GFP+ 
cells. (C) Frequency of GFP+ lymphocytes before and after purification by DT-depletion or 
sorting. Data are pooled from four independent depletion experiments using 1 µg DT, and 
four independent sorting experiments. Each symbol indicates the data from a single mouse. 
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Figure 4-5. Anti-CD154 mAb is not sufficient to convert GFP- (FoxP3-) precursors to 
GFP+ (FoxP3+) cells. 
GFP- cells were purified as described in Figure 4-4, labeled with proliferation dye, and 
cultured for five days in the presence or absence of gamma-irradiated BALB/c splenocytes, 
recombinant human TGFβ and IL-2 (5 ng/ml and 20 ng/ml, respectively), and anti-CD154 
mAb (50 µg, 25 µg, or 5 µg per ml). (A) Representative FACS plots showing the percentage 
of GFP+ CD4+ cells among live CD45+ cells. (B) Frequencies of induced GFP+ CD4+ cells 
among live CD45+ cells. Data are pooled from four independent experiments using GFP- 
precursors purified from DT-depleted DEREG mice or sorted from FoxP3-GFP mice. Bars 
represent mean ± SD. *p<.05, one-way ANOVA with Dunnett’s multiple comparisons test, 
with a single pooled variance, where the mean of each group was compared with the mean of 
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Figure 4-6. Anti-CD154 mAb does not convert GFP- (FoxP3-) precursors to GFP+ 
(FoxP3+) cells during in vivo alloantigen challenge. 
A footpad assay was performed according to the timeline described in Figure 4-3A. GFP- 
cells were purified as described in Figure 4-4, labeled with proliferation dye, and 1-2 x 107 
cells were adoptively transferred into CD45 congenic B6 hosts. Hosts were challenged 
subcutaneously in the footpad with 1 x 106 BALB/c cells or with vehicle HBSS, and left 
untreated or treated with anti-CD154 mAb. (A) Total number of live lymphocytes in popLNs 
(n=4-5 mice each condition). (B) Representative FACS plots showing the percentage of 
induced GFP+ CD4+ cells among live transferred CD45+ cells in the popliteal lymph node 
from one unchallenged host, one BALB/c challenged host, and one BALB/c challenged and 
anti-CD154-treated host. (C) Frequencies of induced GFP+ CD4+ cells among live 
transferred CD45+ cells in popliteal lymph nodes (n=4-5 mice each condition). (D) 
Representative FACS plot showing splenic detection of GFP+ cells that were sorted and 
adoptively transferred into a B6 host to create a positive control for gating. Data in (A) and 
(C) are pooled from four independent experiments. Bars represent mean ± SD. **p<0.01, 
***p<.001, one-way ANOVA with Tukey’s multiple comparisons test, with a single pooled 
variance, where the mean of each group was compared with the mean of every other group. 























































































Figure 4-7. GFP- (FoxP3-) precursors do not convert to GFP+ (FoxP3+) cells after islet 
transplantation and anti-CD154 treatment. 
GFP- cells were purified from CD45.1/CD4.2 DEREG mice by DT-depletion, labeled with 
proliferation dye, and 3 x 107 cells were adoptively transferred into CD45.2 B6 hosts. Hosts 
were left unmanipulated, or were rendered diabetic, transplanted with BALB/c islets, and left 
untreated or treated with anti-CD154 therapy. Transplant recipients were analyzed at the time 
of rejection or >100 days after transplantation if tolerant. FACS plots showing the percentage 
of induced GFP+ CD4+ cells among transferred cells from the spleens of one unmanipulated 
host (nothing), one transplanted and untreated host (rejected post-operative day 15), and two 
transplanted and anti-CD154-treated hosts (tolerant >100 days). Data are from one 
experiment.  
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Table 4-1. Early TLR3 stimulation blocks tolerance induction. 
Group Treatment (d2) Graft survival (d) P value 
1 PBS 20, ≥100 (x5) -- 
2 PolyI:C (50-100 µg) 15, 15, 16, 19, 34, ≥100 (x2) <.05 





Figure 4-8. Adjuvant blocks tolerance generated independently of CD154/CD40 axis. 
Eight-to-twelve week-old male B6 mice were rendered diabetic with SZ, treated with anti-
LFA-1 mAb (200 µg on days 0, 1, 7, 14), and transplanted with BALB/c islets. Graft survival 
in recipients stimulated on post-operative day 2 with polyI:C plus agonistic anti-CD40 
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Figure 4-9. Time-dependent vulnerability of induced allograft rejection. 
Eight-to-twelve week-old male B6 mice were rendered diabetic with SZ, treated with anti-
CD154 mAb (250 µg on days -1, 2, 7, 9), and transplanted with BALB/c islets. (A) Graft 
survival in recipients stimulated on post-operative day 0 or 2 with polyI:C plus anti-CD40 
(adjuvant) (n=10) compared with control PBS (n=11). (B) Graft survival in recipients 
stimulated on post-operative day 21 with adjuvant (n=7) compared with control PBS (n=4). 
(C) Graft survival in recipients stimulated on post-operative day 60 with adjuvant (n=5). 
*p<.05, ***p<.001, Kaplan-Meier method with log-rank test and Cox regression model. 
 
 
Table 4-2. Adaptive immunity is required for adjuvant-induced destruction of islets. 
Group Treatment Graft survival (d) P value 
1 None ≥100 (x3) -- 
2 Adjuvant (d2) ≥100 (x4) NSa 
3 Adjuvant (d21) ≥100 (x3) NSb 
Diabetic B6 Rag1-/- mice received 450 BALB/c islets. 
aGroup 1 versus Group 2. bGroup 1 versus Group 3.  
NS, not statistically significant. 
 
































































Figure 4-10. Tolerance-disrupting stimulus reverses therapy-mediated T cell restraint. 
A footpad assay was performed as described in Figure 4-3 with adjuvant (day 2) given to 
BALB/c-challenged mice treated with anti-CD154 mAb (n=2) or anti-LFA-1 mAb (n=2); 
some data were previously shown in Figure 4-3. (A) Total numbers of lymphocytes. (B) 
Proliferation of transferred GFP+ cells. (C) Representative FACS plots showing frequency of 
CD4+ GFP+ (top) or CD8+ GFP+ (bottom) T cells producing IFN-γ and TNFα. Data are 
pooled from two to four independent experiments. *p<.05, **p<.01, ***p<.001, one-way 
ANOVA with Dunnett’s multiple comparisons test, with a single pooled variance, where the 
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Figure 4-11. Tolerance-disrupting stimulus rapidly releases primed T cells into graft. 
FACS plots showing the percentage of CD44+ Ki-67+ (activated and proliferating) intragraft 
CD8+ (top) and CD4+ (bottom) T cells from anti-CD154-treated transplant recipients 
analyzed on post-operative day 24. One normoglycemic (tolerant) mouse is compared with 
one hyperglycemic (rejecting) mouse that was administered tolerance-disrupting adjuvant on 
the post-operative day 21. Data are from one experiment.  


















Figure 4-12. Early PD-1 blockade disrupts tolerance induction. 
Eight-to-twelve week-old male B6 mice were rendered diabetic with SZ, treated with anti-
CD154 mAb (250 µg on days -1, 2, 7, 9), and transplanted with BALB/c islets. (A) Graft 
survival in recipients treated with anti-CD154 mAb alone (n=8) compared with recipients 
treated with anti-CD154 and anti-PD-1 mAb (500 µg on day 0, 250 µg on days 2, 4, 6, 8, 10; 
n=11). (B) FACS plots showing the percentage of PD-1+ Ki-67+ intragraft CD8+ (top) and 
CD4+ (bottom) T cells from transplant recipients treated with CD154-specific antibodies and 
analyzed on post-operative day 24. One normoglycemic (tolerant) mouse is compared with 
one hyperglycemic (rejecting) mouse that was administered tolerance-disrupting adjuvant on 
post-operative day 21. Data are from one experiment. *p<.05, Kaplan-Meier method with 
log-rank test and Cox regression model.  
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Figure 4-13. Early FoxP3+ cell depletion blocks tolerance induction. 
Eight-to-twelve week-old male DEREG mice and transgene-negative littermates (B6) were 
rendered diabetic with SZ, transplanted with BALB/c islets on day 0, and treated with 
CD154-specific monoclonal antibodies. DT [1 µg (A) or 0.5 µg (B)] or control PBS was 
intraperitoneally injected on post-operative day 1. (A) Survival of BALB/c islets transplanted 
into FoxP3-depleted DEREG mice (n=3) compared with non-depleted DEREG recipients 
(n=3) and non-depleted/DT-injected B6 recipients (n=7) (no significant difference). (B) 
Survival of BALB/c islets transplanted into FoxP3-depleted DEREG mice (n=2) compared 
with non-depleted/DT-injected B6 recipients (n=3). (C) Graft survival in all FoxP3-depleted 
DEREG recipients (n=5) compared with all non-depleted/DT-injected B6 recipients (n=10), 
and non-depleted DEREG recipients (n=3). Data in (C) were pooled from experiments in (A) 
and (B). NS, not statistically significant. NS≥0.05, *p<.05, **p<.01, Kaplan-Meier method 
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CHAPTER V 
DISRUPTION OF TRANSPLANT TOLERANCE BY AN “INCOGNITO” FORM OF 




• Hosts can harbor preexisting donor MHC-reactive immunity through cross-reactivity 
(or heterologous immunity) to microbial or autoimmune antigens that can block 
tolerance induction. 
• Hosts can also harbor immune memory to donor-derived non-MHC antigens through 
vaccinations, infections, and autoimmunity. 
• “Linked antigens” of donor-derived MHC and non-MHC antigens on the same cell 
can dramatically block tolerance induction in immune hosts via an “incognito” CD8+ 
T cell-dependent response that does not require initial heterologous immunity. 
• Tolerance blockade is not associated with overt or early T cell alloreactivity, 
suggesting that “incognito” memory might disrupt an as yet unknown tolerance-
promoting checkpoint rather than immediately licensing naïve alloreactive T cells. 
Introduction 
Clinical applications of tolerance-inducing therapeutics developed in preclinical 
transplantation models remain challenging to translate into clinical practice (Lechler et al., 
2005; Kang et al., 2007; Morelli and Thomson, 2007; Ford and Larsen, 2009; Li et al., 2009; 
Ferrer et al., 2014). Intrinsic genetic resistance, pathogen exposure, nonspecific immune 
stimulation, and preexisting immune memory each can impede the tolerance process 
(Markees et al., 1999; Pearson et al., 2003a; Pearson et al., 2003b; Gordon et al., 2005) 
(Welsh et al., 2000; Forman et al., 2002; Chen et al., 2006; Thornley et al., 2006), 
(Valujskikh et al., 2002; Adams et al., 2003b). Alloreactive T cell memory can block 
transplant tolerance in part because prior autoimmunity or exposure to pathogens or vaccines 
can generate populations of memory cells that cross-react to any given unrelated MHC allele 
(Pantenburg et al., 2002; Adams et al., 2003b; Urbani et al., 2005; Amir et al., 2010; 
Danziger-Isakov et al., 2010; D'Orsogna et al., 2011; Su et al., 2013). Because memory cells 
                                                
1
 Portions of this chapter were previously published in the American Journal of 
Transplantation, 2017, DOI: 10.1111/ajt.14194, and are included with the permission of the 
copyright holder. 
 79 
resist many tolerance-inducing treatments, this burden of donor MHC-reactive “heterologous” 
immunity represents an important clinical dilemma.  
 Here, we explored an alternative pathway for tolerance disruption by immune 
memory reactive to donor-derived non-MHC antigens. In clinical transplantation, donors 
often harbor latent infections with any number of different pathogens, such as Epstein-Barr 
virus (EBV) and cytomegalovirus (CMV) (Gala-Lopez et al., 2011; Martin and Danziger-
Isakov, 2011; Zamora, 2011; Jr et al., 2014). Recipients can have corresponding immune 
memory to these nonself antigens, either through microbial exposure or via immunization. 
Alternatively, a subset of transplant recipients have underlying autoimmune diseases that 
generate immune memory to non-MHC antigens expressed in donor tissues. The 
consequence of such preexisting host immunity in allograft outcomes often is unclear. 
Specifically, it is not clear whether this form of immune memory is sufficient to disrupt 
tolerance induction. 
We hypothesized that antigen-specific immune memory to donor-derived antigens 
could be sufficient to impair tolerance independent of anti-donor MHC reactivity or host 
inflammation. To address this issue, we developed a generic model system in which immune 
memory was generated to a model nonself antigen, ovalbumin (OVA), and tested for 
potential impact on tolerance induction. Results demonstrate that anti-OVA memory could 
disrupt tolerance when OVA antigens were presented in association with donor cells. 
Importantly, tolerance disruption was CD8+ T cell-dependent, required linked presentation of 
alloantigens and the memory-directed antigen (OVA), and could occur independently of anti-
donor MHC alloreactivity within the memory CD8+ T cell pool. As such, this unapparent, or 
“incognito,” immune memory represents an unanticipated and alternate form of host 
immunity capable of disrupting transplant tolerance. 
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Results 
Vaccination generates robust OVA-reactive cellular and humoral immunity 
We generated preexisting host immunity to a model xenogeneic antigen in transplant 
recipients by vaccinating B6 mice with ovalbumin plus an adjuvant of anti-CD40 and 
polyinosinic-polycytidylic acid (Ahonen et al., 2004b). Control B6 mice were immunized 
with the adjuvant alone. OVA/adjuvant-primed (OVA/Adj’) mice and control adjuvant-
primed (Adj’) mice were analyzed ranging from 4 to 19 weeks postvaccination for OVA-
specific cellular and humoral immunity (Figure 5-1). Compared with Adj’ mice, OVA/Adj’ 
mice showed pronounced generation of OVA257–264/Kb-tetramer–specific CD8+ T cells that 
expressed markers of central memory (Figure 5-1A-D). OVA/Adj’ mice also developed 
tenfold higher titers of serum OVA- specific total Ig than did Adj’ mice (Figure 5-1E). Thus, 
OVA-vaccinated mice generated robust anti-OVA cellular and humoral immunity.  
OVA-vaccinated B6 mice develop limited cross-reactivity to donor BALB/c MHC and 
are amenable to allograft tolerance induction 
Previous reports indicated that vaccinations or pathogen infections can generate 
heterologous immunity toward donor MHC (Pantenburg et al., 2002; Mehta et al., 2005; 
Amir et al., 2010; Danziger-Isakov et al., 2010; D'Orsogna et al., 2011) that can impair 
tolerance induction in preclinical transplant models (Adams et al., 2003b; Selin et al., 2004; 
Taylor et al., 2004). We therefore assessed whether the OVA immunization in B6 mice 
generated elevated pre-transplant heterologous immunity to the intended allograft donor 
strain, BALB/c. While purified splenic T cells from OVA/Adj’ mice made a vigorous and 
rapid IFN-γ response to transgenic B6 cells that constitutively express OVA as a 
transmembrane protein (B6-OVA), they did not show elevated reactivity to allogeneic 
BALB/c cells relative to responses by splenic T cells from control Adj’ mice (Figure 5-2A). 
Given the potential importance of preexisting alloantibody in transplantation (Burns 
et al., 2009; Burns and Chong, 2011), we also determined whether the OVA vaccination 
generated detectable anti-BALB/c antibodies. Relative to sera from control Adj’ mice, sera 
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from OVA/Adj’ mice did not significantly bind BALB/c target cells, despite high reactivity 
to B6-OVA target cells (Figure 5-2B). As a positive control, sera from B6 mice intentionally 
immunized with BALB/c cells showed strong staining of BALB/c target cells (Figure 5-2B). 
Taken together, pre-transplant evaluations showed limited detectable preexisting anti-donor 
immunity in OVA-vaccinated mice. 
We next determined whether anti-OVA memory affected acute rejection or tolerance 
induction to BALB/c islet allografts. Acute allograft rejection was comparable between 
untreated OVA/Adj’ mice and control Adj’ mice (Figure 5-2C). Conversely, OVA 
vaccination did not prevent allograft tolerance induction, as BALB/c graft survival was not 
significantly different between OVA/Adj’ mice and Adj’ mice treated with CD154-specific 
monoclonal antibodies (Figure 5-2D). In stark contrast, allosensitized BALB/c’ recipients 
demonstrated accelerated acute allograft rejection (Figure 5-2C) and complete disruption of 
allograft prolongation after anti-CD154 treatment (Figure 5-2D). Taken together, the data 
indicate that robust vaccine-induced anti-OVA immunity that is largely devoid of preexisting 
anti-donor immunity can be innocuous for acute allograft rejection and tolerance.  
Peri-transplant bystander reactivation of OVA-specific memory does not impair 
allograft tolerance 
Considering that a variety of peri-transplant events, including de novo microbial 
infections and reactivation of latent infections, can stimulate antigen-specific immunity and 
impair allograft survival and tolerance (Welsh et al., 2000; Williams et al., 2001; Forman et 
al., 2002; Williams et al., 2002; Wang et al., 2010), we explored whether bystander peri-
transplant reactivation of memory could affect tolerance induction. OVA/Adj’ mice were 
challenged with B6-OVA cells 7 days before receiving BALB/c islet transplants and 
tolerance-promoting anti-CD154 mAb (Figure 5-3A). The B6-OVA cell challenge expanded 
CD8+ CD44hi tetramer+ T cells even in the presence of anti-CD154 mAb treatment (Figure 
5-3B). Despite pronounced bystander reactivation and expansion of OVA-specific memory 
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CD8+ T cells, recipients could nevertheless be tolerized to BALB/c islet allografts (Figure 5-
3C). 
“Linked” presentation of donor antigens and vaccine-directed antigens disrupts 
tolerance induction 
In contrast to tolerance disruption by alloreactive memory (Heeger et al., 1999; 
Adams et al., 2003a; Taylor et al., 2004; Augustine et al., 2005), at this point it would appear 
that OVA-specific immune memory is essentially irrelevant to allograft immunity and 
tolerance. However, donors can often express non-MHC antigens, such as pathogen-derived 
antigens or autoantigens, to which the host is immune. Host reactivity to donor-associated 
non-MHC antigens could be innocuous or could represent an alternate means through which 
immune memory can impair tolerance. Therefore, using our vaccination model, we explored 
conditions whereby donor-derived cells expressing memory-directed antigens might block 
tolerance induction in immune recipients without apparent preexisting immunity to donor 
MHC. 
 For proof-of-principle studies, we used a standard tolerization protocol (Parker et al., 
1995; Markees et al., 1998) in which recipients were treated pre-transplant with anti-CD154 
therapy plus varied forms of donor specific transfusion (DST) (Figure 5-4A). After treatment 
with anti-CD154 therapy and BALB/c DST cells that did not express OVA antigens, OVA-
vaccinated mice and control-vaccinated mice showed similar survival of transplanted 
BALB/c allografts (Figure 5-4B). Next, to model the scenario of recipient exposure to donor-
derived cells that also express non-MHC memory-directed antigens, OVA-immune mice 
were treated with BALB/c DST cells that transgenically express OVA (BALB/c-OVA). 
When treated with BALB/c-OVA DST plus anti-CD154, control Adj’ recipients still 
accepted transplanted BALB/c islets. In striking contrast, OVA-vaccinated mice displayed a 
profound disruption of allograft prolongation, with 14 of 16 animals showing acute allograft 
rejection (Figure 5-4C).  
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 We hypothesized that tolerance disruption required “linkage” of donor MHC and 
memory-directed antigens on the same donor-derived cells. “Linked” recognition is a well-
known property in which T cells can affect either activation (Tucker and Bretscher, 1982; 
Creusot et al., 2003) or inhibition (Qin et al., 1993; Davies et al., 1996; Wise et al., 1998; 
Honey et al., 1999) of other T cells interacting with the same antigen-presenting cell (APC). 
To address this issue, we determined the impact of delivering BALB/c and OVA antigens on 
separate sets of DST cells as a form of “unlinked” antigen presentation. After sequential 
treatment with B6-OVA then BALB/c DST plus anti-CD154 therapy, OVA/Adj’ mice and 
control Adj’ mice predominantly accepted BALB/c allografts (Figure 5-4D). These results 
indicate that tolerance disruption requires physical linkage of donor and memory-directed 
antigens on the same donor cells.  
Alloreactivity develops gradually following transplantation rather than DST treatment 
The BALB/c-OVA DST resulted in tolerance blockade in the absence of the memory-
directed antigen (OVA) on the islet transplant itself, implying that the recognition of OVA on 
the DST was inciting a response to the linked BALB/c alloantigens despite anti-CD154 
treatment. We posited that OVA-specific memory T cells interacted with host APCs that 
copresented alloantigens during the initial phase of tolerance induction. Therefore, we next 
determined the degree and timing of donor-specific alloreactivity potentially triggered by 
anti-OVA immunity. While one might expect that anti-OVA memory would rapidly license 
anti-donor reactivity in response to BALB/c-OVA DST, this was not the case.  
ELISPOT analysis for splenic anti-donor IFN-γ production indicated that BALB/c-
OVA DST alone (without anti-CD154) triggered robust alloimmunity within 7 days after 
DST (day 0 of transplantation) in both OVA/Adj’ and Adj’ mice (Figure 5-5A). In contrast, 
treatment with BALB/c-OVA DST plus anti-CD154 strongly inhibited initial peri-transplant 
alloimmunity in both OVA/Adj’ and Adj’ animals during the same time period (Figure 5-5A). 
After islet transplantation, host splenic anti-donor reactivity continued to be restrained in 
OVA/Adj’ recipients relative to Adj’ mice at 7 days post-transplant (Figure 5-5B). However, 
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a clear demarcation emerged between Adj’ and OVA/Adj’ animals as the latter group 
progressed toward allograft rejection. Graft rejection in OVA/Adj’ animals (during a period 
of 8-47 days) was associated with significant anti-donor IFN-γ production by splenic T cells, 
while paired, nonrejecting Adj’ control animals showed continued restraint of anti- donor 
reactivity (Figure 5-5C). Interestingly, a concomitant production of alloreactive antibodies 
did not occur in either vaccination group after treatment with DST plus anti-CD154 and 
transplantation (Figure 5-5D). Thus, OVA-specific memory did not trigger an immediate 
allogeneic T cell response after BALB/c-OVA DST and anti-CD154 therapy. Instead, this 
response developed more slowly and was correlated with eventual graft rejection.  
Hematopoietic-derived “linked” antigens from the graft also block tolerance induction 
 To illustrate that DST treatment is not an essential component for this model, we 
conducted ancillary studies using heart allografts from bone marrow chimeras in which 
BALB/c donors harbored OVA-expressing hematopoietic cells (denoted as BALB/c-OVA-
BALB/c chimeras; Figure 5-6A). We found that BALB/c-OVA-BALB/c chimeric heart 
allografts readily disrupted anti-CD154-specific prolongation of graft survival in OVA-
vaccinated animals but not in control-vaccinated recipients (Figure 5-6B). These results 
demonstrate that the donor graft itself is capable of introducing tolerance-disrupting antigens 
without a requirement for DST. 
CD8-dependent “incognito” memory blocks tolerance induction 
Taken together, we find that when donor cells express memory-directed antigens, it is 
possible for host preexisting immunity to incite alloreactivity and markedly disrupt allograft 
tolerance induction. We refer to this kind of immune memory as “incognito” memory, 
because conventional assays for detecting initial anti-donor reactivity would fail to identify 
this potential barrier for transplantation, yet it can covertly and unexpectedly disrupt 




Because OVA-vaccinated recipients harbor both OVA-specific cellular and humoral 
immunity, we next determined whether vaccine-induced memory T cells, antibodies, or both 
were necessary for “incognito” memory to block tolerance induction. To this end, we 
selectively prevented the initial development of CD4- or CD8-dependent immune memory 
by depleting either CD4+ T cells or CD8+ T cells during initial vaccination (Figure 5-7A). 
Four weeks after T cell depletion and vaccination, T cell populations in CD4-depleted mice, 
but not CD8-depleted mice, had reconstituted to nearly normal levels (Figure 5-7B). 
Consistent with previous results indicating that our vaccination protocol generates antigen-
specific memory CD8+ T cells without CD4+ T cell help (Edwards et al., 2013), CD4- 
depleted OVA/Adj’ mice developed splenic CD8+ CD44hi tetramer+ T cells that rapidly 
produced IFN-γ in response to B6-OVA cells (Figure 5-7C). Moreover, CD4-depleted OVA-
vaccinated mice did not develop detectable OVA-specific antibodies (Figure 5-7D). 
Conversely, CD8-depleted OVA/Adj’ mice generated high titers of OVA-specific antibodies 
without developing memory CD8+ T cells (Figure 5-7C and D). Thus, vaccinated recipients 
developed selective CD8+ cellular memory or humoral immune memory in CD4- or CD8-
depleted mice, respectively.  
Mice with selective CD4- or CD8-dependent anti-OVA memory were then tested for 
their respective propensity for allograft tolerance induction after treatment with BALB/c-
OVA DST/anti-CD154 therapy. Vaccine-induced memory generated in the absence of CD4+ 
T cells still markedly disrupted tolerance in seven of seven OVA/Adj’ animals despite the 
absence of detectable anti-OVA antibodies (Figure 5-7E). Conversely, memory generated in 
the absence of CD8+ T cells failed to disrupt tolerance (Figure 5-7F), despite both the 
presence of high-titer anti-OVA antibodies and the ability of these mice to acutely reject 
BALB/c islets when not treated with a tolerance-promoting therapy (Figure 5-7G). Therefore, 
CD8-dependent, and not CD4-dependent, components of vaccine-induced immunity were 
essential for “incognito” memory to disrupt tolerance. 
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OVA-specific T cells are not enriched in rejected BALB/c grafts 
  In OVA/Adj’ mice, linked antigens from the BALB/c-OVA DST might generate a 
cohort of pathogenic cross-reactive (heterologous) CD8+ T cells from the original memory 
pool of OVA-tetramer+ cells that cross-react to BALB/c MHC antigens and directly mediate 
allograft rejection. To investigate this possibility in OVA/Adj’ mice actively rejecting 
BALB/c islet transplants, we assessed intragraft CD8+ T cells for OVA-specificity by 
tetramer binding and compared that frequency to splenic CD8+ T cells in the same individual 
to determine relative enrichment of tetramer+ cells at the graft site. In mice treated with 
BALB/c-OVA DST and anti-CD154 mAb, we found that OVA-specific CD8+ T cells had 
trafficked to the graft site (despite the islets not expressing OVA antigen). However, on 
average, tetramer+ CD8+ T cells were not more enriched in a rejecting graft than in the 
recipient’s spleen (Figure 5-8A). We then compared whether transplanted but untreated 
recipients (which did not receive BALB/c-OVA DST) demonstrated similar trafficking to the 
graft site and found no relative enrichment in intragraft tetramer+ cells (Figure 5-8B). 
Although not definitive, these data suggest that OVA-specific memory cells do not develop 
heterologous immunity against donor MHC during the process of tolerance disruption. 
“Incognito” memory CD8+ T cells do not require heterologous immunity to block 
tolerance 
We next determined whether memory CD8+ T cells that definitively lacked the 
capacity for anti-donor heterologous immunity could be sufficient to disrupt allograft 
tolerance. To achieve this goal, we used OT-I Rag1-/- T cell receptor transgenic (Tg) mice, 
which generate OVA257-264-specific CD8+ T cells that are not cross-reactive to BALB/c 
targets since they do not reject BALB/c skin allografts in vivo (Chapter III, Figure 3-2B). 
Antigen-experienced OT-I Rag1-/- cells were adoptively transferred into naive B6 recipients 
to generate mice with OVA-reactive memory CD8+ T cells lacking donor cross-reactivity 
(Figure 5-9A). Memory OT-1 cells engrafted into host B6 mice at similar or somewhat lower 
frequencies compared with endogenous CD8+ tetramer+ T cells detected in the blood of 
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OVA/Adj’ mice (Figure 5-9B) and had similar phenotypic profiles as vaccine-induced 
memory cells (Figure 5-9C).  
Animals bearing transferred memory OT-I cells (denoted as OTIM mice) were treated 
with either control BALB/c DST or BALB/c-OVA DST plus anti-CD154 mAb and 
subsequently transplanted with BALB/c islets. Transferred memory OT-I cells did not affect 
BALB/c allograft survival when recipients were treated with BALB/c DST plus anti-CD154 
therapy (Figure 5-9D). However, when recipients were treated with BALB/c-OVA DST plus 
anti-CD154 therapy, memory OT-I cells disrupted long-term allograft survival in nine of nine 
OTIM mice (Figure 5-9D). Memory OT-I cells were required for these results because B6 
mice accepted the majority of their grafts when they were not adoptively transferred with 
OT-I cells but were treated with BALB/c-OVA DST plus anti-CD154 therapy and 
transplanted with BALB/c islets (Figure 5-9D). Taken together, these data demonstrate that 
memory CD8+ T cells incapable of heterologous donor reactivity are nevertheless sufficient 
to block tolerance induction in this model system. 
Discussion 
Conventional screening assays test for cellular and humoral host reactivity to donor 
MHC molecules but may not predict host immune responses to donor-associated non-MHC 
antigens, such as microbe-derived antigens or autoantigens. In this study, we determined the 
impact of immunity to donor-derived non-MHC antigens on tolerance induction. Specifically, 
we tested the hypothesis that host immunity to non-MHC antigens can disrupt allograft 
tolerance independently of donor MHC-reactive heterologous immunity. It was essential that 
our study design distinguish between antigen-specific reactivity and non-specific host 
inflammation in attenuating allograft tolerance. While peri-transplant host immune 
stimulation by either pathogens (Welsh et al., 2000; Forman et al., 2002) or toll-like receptor 
agonists (Chapter IV, Table 4-1 and Figure 4-9)(Chen et al., 2006; Thornley et al., 2006) can 
prevent tolerance, the ability of preexisting immune memory itself to impair tolerance may 
be more variable and less apparent. Therefore, we studied the impact of memory on tolerance 
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induction independently of tolerance-disrupting pathogen-associated stimuli. We modeled a 
common clinical scenario in which donor cells harbor non-MHC antigens to which the 
recipient is immune. By linking a model xenogeneic antigen (ovalbumin, OVA) to donor 
cells, we found that host anti-OVA T cell immunity impaired tolerance and incited the 
activation of alloreactive T cells despite tolerance-inducing treatments. This type of 
unapparent, or “incognito,” antigen-specific immune memory was sufficient to dramatically 
disrupt allograft tolerance.  
The observed capacity for host anti-OVA immunity to disrupt allograft tolerance had 
a number of specific properties. First, the vaccination that generated anti-OVA immunity did 
not generate detectable donor-specific heterologous immunity and had no discernable impact 
on either immunity or tolerance to an allograft. Even secondary exposure to OVA-expressing 
cells during the peri-transplant period was insufficient to disrupt tolerance induction by anti-
CD154 therapy. These results illustrate the potentially innocuous impact of antigen-specific 
immune memory on tolerance induction, because even a simultaneous bystander response to 
OVA-bearing cells was insufficient to impair allograft tolerance provided that OVA antigens 
were not expressed on donor cells. 
Second, seemingly benign immune memory can have severe consequences on 
tolerance induction if tolerance-inducing donor cells harbor the memory-directed antigen. 
This inhibition of tolerance required “linked” expression of donor MHC and the immunizing 
antigen on the same DST inoculums. While other transplant tolerance studies indicate a role 
for linked suppression of differing antigens on the same APC for promoting tolerance 
(Davies et al., 1996; Honey et al., 1999; Graca et al., 2004), the current results illustrate the 
key converse property of linked immune activation (Mitchison, 1983; Creusot et al., 2003; 
Desch et al., 2014). Importantly, the activating property of the memory cell population 
appears dominant to the tolerizing property of CD154-specific therapy toward the linked, 
unrelated alloantigens. Thus, we propose that preexisting immunity to OVA results in the 
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dominant disruption of tolerance to other linked antigens in the microenvironment during 
initial alloantigen encounter.  
Third, an essential feature of our model involved the expression of the test antigen 
(OVA) on the initial tolerogen (DST) but not on the subsequent islet transplant. If the donor 
graft expressed OVA, then tolerance disruption could be the result of tolerance-resistant 
memory cells directly contributing to allograft rejection. The DST model demonstrated the 
principle that OVA immunity could incite gradual immunity to unrelated alloantigens akin to 
epitope spreading (Vanderlugt et al., 1998). Ancillary studies using heart allografts from 
bone marrow chimeric donors showed that the expression of OVA antigens by donor 
hematopoietic cells could incite tolerance disruption in OVA/Adj’ animals. Thus, a donor 
graft itself can introduce tolerance-disrupting antigens without a requirement for DST.  
Surprisingly, CD8+ T cells and not CD4+ T cells or antibodies were necessary for this 
particular form of tolerance blockade. Prior studies showed that alloreactive memory CD4+ T 
cells could confer tolerance resistance (Valujskikh et al., 2002; Chen et al., 2004). Moreover, 
in animal models using a similar costimulation blockade approach, memory B cells and anti-
donor MHC antibodies can block cardiac allograft tolerance (Burns et al., 2009; Burns and 
Chong, 2011). In those studies, humoral immunity was directed toward donor MHC 
molecules. Importantly, Burns et al. (2011) demonstrated that anti-donor MHC antibodies 
could disrupt tolerance via linked recognition with other alloantigens, similar to the process 
we observed in the current study. In contrast, we found that tolerance could be induced 
despite high anti-OVA antibody titers. The difference in the specificity of memory T cells 
and preformed antibodies for donor non-MHC antigens versus MHC antigens could be an 
important distinction between these differing studies. Moreover, CD8+ T cell-dependent 
memory may not be a universal feature of how donor non-MHC-directed immunity can 
impair tolerance. The mechanisms through which donor expression of microbial antigens or 
autoantigens activate specific humoral or cellular immunity in the host might dictate which 
immune memory pathways dominate in disrupting tolerance.  
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A key question centers on how this type of immune memory results in tolerance 
blockade. Developing or expanding cross-reactive cells from populations of memory CD8+ T 
cells was not required to prevent tolerance, because OVA-specific OT-I Rag1-/- CD8+ 
memory T cells that do not exhibit detectable donor reactivity were sufficient to confer 
tolerance resistance in naïve B6 hosts. Given that memory OT-I cells could not react to the 
donor MHC to directly mediate graft rejection, the ability of this type of “incognito” immune 
memory to prevent tolerance is best explained by classic linked recognition, in which 
memory cells respond to APCs that simultaneously present OVA antigens and donor antigens 
(Figure 5-10). Analogous to APC licensing during CD4+ T cell help for CD8+ T cells, we 
propose that memory cells alter initial alloantigen presentation and subsequently trigger the 
activation of donor-reactive T cells that are pathogenic to the graft. We envision that memory 
blockade interferes with an as-yet-unidentified checkpoint during fate decision toward 
tolerance. “Incognito” memory does not immediately license the activation of donor-reactive 
T cells after DST in the presence of anti-CD154 treatment (Figure 5-5C) or result in 
accelerated allograft rejection (Figure 5-4C). Instead, the licensing of donor reactivity occurs 
more gradually, indicating a change in ongoing T cell fate decision from tolerance to 
immunity (Figure 5-10). We must emphasize that “incognito” memory is not a new 
phenotype or subset of memory T cells. We use the term “incognito” simply to connote the 
pathway and consequences of memory cell responses to donor non-MHC antigens that can be 
unapparent pre-transplant yet still disrupt transplant tolerance induction.  
Although we intentionally developed a generic model to illustrate a principle of 
tolerance disruption by memory cells, the results raise an important dilemma for the prospect 
of inducing allograft tolerance in most settings of conventional transplantation. The donor 
will likely harbor a number of metagenome-encoded antigens (Virgin et al., 2009) to which 
the recipient may have preexisting immunity that could be deleterious to future tolerance-
promoting regimens. Of course, the tissue distribution of pathogen-associated antigens could 
influence whether immune memory disrupts tolerance induction. 
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In the current study, we modeled one scenario in which the nonself antigen was 
restricted to hematopoietic cells, as would occur in EBV infection (Zamora, 2011). In another 
example, recipients may be intentionally vaccinated against donor-derived pathogens, such as 
CMV, and then transplanted with pathogen-infected donor organs (Streblow et al., 2015). An 
inadvertent consequence of eliciting protective CMV-reactive immune memory is that 
“linked antigen” reactivity could incite graft rejection in the immune host. It would be 
intriguing in future studies to determine if hematopoietic versus parenchymal distributions of 
donor nonself antigens have differing effects on tolerance induction in the immune host. 
Finally, in the setting of autoimmunity, preexisting memory to non-MHC autoantigens might 
also invoke tolerance disruption and trigger the development of alloimmunity due to 
copresented alloantigens and autoantigens. This process could partly explain the severe 
resistance of autoimmune recipients to allografts. Taken together, “incognito” memory 
represents an additional and potentially significant barrier to transplantation tolerance that is 



















































































































Figure 5-1. Vaccination generates robust OVA-specific immunity. 
Male B6 mice were intraperitoneally vaccinated with ovalbumin (200 µg) and adjuvant (50 
µg anti-CD40 and 50 µg polyinosinic:polycytidylic acid) (ovalbumin/adjuvant-primed, 
OVA/Adj’), or for controls, with the adjuvant alone (adjuvant-primed, Adj’). (A) 
Representative FACS plots showing the percentage of OVA257-264/Kb-tetramer-specific 
CD44hi cells among splenic CD8+ T cells from one OVA/Adj’ mouse compared with one 
Adj’ mouse 55 days after vaccination. Frequencies (B) and absolute numbers (C) of OVA257-
264-specific T cells among CD8+ CD44hi spleen cells from OVA/Adj’ mice (n=12) and Adj’ 
mice (n=7). (D) FACS plots showing relative surface expression of CD44, CD62L, CD122, 
and CD11α (LFA-1) by splenic OVA257-264-tetramer specific CD8+ T cells (black 
histograms) compared with tetramer-negative CD8+ T cells (gray histograms) analyzed from 
the same OVA/Adj’ mouse. (E) Serum titers of OVA-specific antibodies (total Ig) from 
OVA/Adj’ mice (n=7) compared with Adj’ mice (n=5) as determined by ELISA. Data in (A-
C) were pooled from twelve independent experiments. Data in (D) are representative of four 
independent experiments. Each symbol in (B), (C), and (D) indicates the data from a single 
mouse. End-point titers in (E) were measured relative to a baseline normal value taken as the 
mean ± 3 SD of sera pooled from 6 non-vaccinated B6 mice. Bars represent mean ± SD. 
***p<0.001, unpaired two-tailed t statistical test.  
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Figure 5-2. OVA-vaccinated B6 mice harbor limited detectable cross-reactivity to 
BALB/c and do not resist CD154-specific antibody-induced allograft tolerance. 
(A) Frequencies of IFN-γ producing OVA-specific or donor-specific T cells from vaccinated 
mice were detected by ELISPOT after stimulating for 18 hr with OVA-expressing B6 cells 
(B6-OVA) or allogeneic BALB/c cells. Bars represent mean ± SD of quadruplicate 
measurements from one OVA/Adj’ mouse and one Adj’ mouse. These results are 
representative of five independent experiments, each with similar results. (B) Detection of 
OVA-specific and donor-specific antibodies by FACS analysis for percent of B6-OVA and 
BALB/c target cells staining positive with FITC-conjugated goat anti-mouse IgG secondary 
antibody that was added after incubating target cells with serum from vaccinated mice. 
Results from OVA/Adj’ mice (n=6) are compared with results from Adj’ mice (n=5) and 
mice that were intentionally pre-sensitized to BALB/c (BALB/c’, n=3). Bars represent mean 
± SD. (C) Untreated survival of BALB/c islets transplanted into OVA/Adj’ recipients (n=7) 
compared with Adj’ recipients (n=7) (no significant difference), and BALB/c’ recipients 
(n=7). (D) CD154-specific monoclonal antibody-induced survival of BALB/c islets 
transplanted into OVA-vaccinated mice (n=16) compared with control-vaccinated recipients 
(n=9) (no significant difference), and BALB/c’ recipients (n=7). Each symbol represents an 
individual mouse. ***p<0.001, 2-way ANOVA statistical test with multiple unpaired t 
statistical posttests and Sidak correction (A, B), Kaplan-Meier method with log-rank test and 
Cox regression model (C, D). 































































































Figure 5-3. Bystander reactivation of vaccine-induced immunity does not block 
tolerance induction. 
(A) Scheme for rechallenging OVA-vaccinated mice using an intraperitoneal injection of 107 
OVA-expressing B6 cells (B6-OVA) 7 days before transplanting BALB/c islets and inducing 
tolerance with CD154-specific monoclonal antibody treatment. (B) FACS plots showing the 
percentages of splenic OVA-specific CD8+ T cells from OVA-vaccinated mice 7 days after 
rechallenge with B6-OVA cells and treatment or no treatment with CD154-specific 
antibodies as described in (A), compared with unmanipulated OVA-vaccinated mice. Results 
are representative of 3 independent experiments. (C) Survival of BALB/c islets transplanted 
into OVA-vaccinated mice (n=10) that were rechallenged with B6-OVA cells and treated 
with CD154-specific antibodies as described in (A), compared with allograft survival data 
previously shown in Figure 2D of OVA/Adj’ mice (n=16) treated with CD154-specific 
antibodies and not re-challenged with B6-OVA (no significant difference). Kaplan-Meier 
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Figure 5-4. “Linked” presentation of BALB/c antigens with vaccine-directed OVA 
antigens results in tolerance disruption in OVA-vaccinated mice. 
(A) Scheme for inducing tolerance to transplanted BALB/c islets in vaccinated mice using 
CD154-specific monoclonal antibodies and an intravascular injection of 107 donor-derived 
spleen cells for donor-specific transfusion (DST) treatment. (B) Survival of BALB/c islets 
transplanted into OVA/Adj’ mice (n=9) compared with Adj’ mice (n=8) that were treated as 
described in (A) with BALB/c DST (no significant difference). (C) Survival of BALB/c islets 
transplanted into OVA/Adj’ mice (n=16) compared with Adj’ mice (n=18) that were treated 
as described in (A) with OVA-expressing BALB/c DST (BALB/c-OVA) to expose recipients 
to the “linked antigens” of donor BALB/c MHC and vaccine-directed OVA antigens 
expressed on the same cells. (D) Survival of BALB/c islets transplanted into OVA/Adj’ mice 
(n=7) compared with Adj’ mice (n=7) that were treated as described in (A) with OVA-
expressing B6 (B6-OVA) cells plus BALB/c DST to expose recipients to the “unlinked 
antigens” of donor BALB/c MHC and vaccine-directed OVA antigens on different cells (no 
significant difference). ***p<0.001, Kaplan-Meier method with the log-rank test and Cox 
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Figure 5-5. Linked presentation of BALB/c antigens with vaccine-directed OVA 
antigens results in a gradual difference in alloreactivity. 
Vaccinated mice were treated with BALB/c-OVA DST with anti-CD154 mAb and 
transplanted with BALB/c islets as described in Figure 5-4C. (A-C) Frequencies of IFN-γ 
producing donor-specific (anti-BALB/c) splenic T cells from OVA-vaccinated mice were 
detected by ELISPOT at (A) 7 days following treatment, (B) 7 days after transplantation with 
BALB/c islets, or (C) the time of allograft rejection by OVA/Adj’ mice (control paired Adj’ 
mice were non-rejectors). (D) Detection of donor-specific antibodies by FACS analysis for 
percent of BALB/c target cells staining positive with FITC-conjugated goat anti-mouse IgG 
secondary antibody that was added after incubating target cells with serum from vaccinated 
mice. Results from OVA/Adj’ mice (n=11) are compared with results from Adj’ mice (n=12). 
Data were pooled from 3-9 independent experiments. Bars in (A-C) represent mean ± SEM 
of quadruplicate measurements from OVA/Adj’ mice (n=3-9 per treatment) and Adj’ mice 
(n=3-9 per treatment). Bars in (D) represent mean ± SD. NS, not statistically significant, 
NS>0.05, *p<0.05, ****p<0.0001, multiple unpaired t statistical tests for individual 
treatments and time points (A-C), 2-way ANOVA statistical test with multiple unpaired t 































































































































































Figure 5-6. Expression of “linked” antigens by donor hematopoietic cells in heart 
allografts results in tolerance disruption in OVA-vaccinated mice. 
(A) FACS analysis of OVA-expression by CD45
+
 cells in blood 6 weeks following BALB/c 
or BALB/c-OVA bone marrow injection into irradiated BALB/c recipients. Results show that 
bone marrow reconstitution in BALB/c-OVA-BALB/c chimeras (n=7) generates OVA-
expressing CD45
+
 cells at levels comparable to intact BALB/c-OVA mice (n=4). (B) OVA-
specific memory blocks tolerance induction by anti-CD154 monotherapy following 
transplantation of heart allografts from OVA-expressing BALB/c bone marrow chimeras 
(BALB/c-OVA-BALB/c) (n=5). Results are compared with OVA-vaccinated recipients of 
control BALB/c-BALB/c bone marrow chimeric heart allografts (n=7). *p<0.05, Kaplan-






























































































Figure 5-7. Host OVA-specific memory CD8+ T cells block tolerance induction in 
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Figure 5-7. Host OVA-specific memory CD8+ T cells block tolerance induction in 
response to linked antigens. 
(A) Scheme for depleting CD8+ or CD4+ T cells near the day of vaccination and then 
approximately 60 days later, treating the vaccinated mice with BALB/c-OVA DST and 
CD154-specific antibodies to induce tolerance to transplanted BALB/c islets. (B) FACS 





 T cells. Results are from n=3 mice per treatment group from three independent 
experiments. (C) FACS plots showing the percentages of IFN-γ producing, CD44hi OVA-
specific T cells among CD8+ spleen cells detected by intracellular cytokine staining after 4 hr 
stimulation with B6-OVA cells. Results are compared with one non-depleted OVA-
vaccinated mouse, one CD4-depleted control-vaccinated mouse, and one CD8-depleted 
control-vaccinated mouse. These results are representative of 3 independent experiments. (D) 
Serum titers of OVA-specific antibodies (total Ig) from CD4- or CD8-depleted vaccinated 
mice as determined by ELISA and compared with non-depleted OVA-vaccinated mice. Each 
symbol indicates ELISA analysis data from a single mouse and these results contain 5 to 6 
mice per group. Bars represent mean ± SD. (E) Survival of BALB/c islets transplanted into 
OVA/Adj’ mice (n=7) compared with Adj’ mice (n=6) that were CD4-depleted before the 
day of vaccination and treated as described in (A) with BALB/c-OVA DST and CD154-
specific antibodies. (F) Survival of BALB/c islets transplanted into OVA/Adj’ mice (n=6) 
compared with Adj’ mice (n=6) that were CD8-depleted near the day of vaccination and 
treated as described in (A) (no significant difference). (G) Survival of BALB/c islets 
transplanted into untreated OVA/Adj’ mice (n=6) compared with Adj’ mice (n=3) that were 
CD8-depleted near the day of vaccination (no significant difference). *p<0.5, **p<0.01, 
unpaired two-tailed t statistical test with Welch’s correction (D), Kaplan-Meier method with 
the log-rank test and Cox regression model (E-G).  
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Figure 5-8. OVA-specific T cells are not consistently enriched in rejecting transplants. 
(A) Frequencies of OVA257-264/Kb-tetramer-specific T cells among splenic and intragraft 
CD8+ T cells from OVA-vaccinated recipients that are rejecting BALB/c islet transplants 
following treatment with anti-CD154 mAb and BALB/c-OVA DST. (B) Frequencies of 
OVA257-264/Kb-tetramer-specific T cells among splenic and intragraft CD8+ T cells from 
OVA-vaccinated recipients that are rejecting BALB/c islet transplants following no treatment 
(untreated; n=3) or treatment (anti-CD154 mAb and BALB/c-OVA DST; n=8). Each symbol 
indicates the data from a single mouse, and lines in (A) show matched pairs where the spleen 
and graft are from the same mouse. Bars represent mean ± SD. NS, not statistically 
significant, NS>0.05, paired two-tailed t statistical test (A), 2-way ANOVA statistical test 








































Figure 5-9. Memory CD8+ T cells without donor-reactivity block tolerance. 
(A) Scheme for generating recipients with OVA-specific memory CD8+ T cells devoid of 
BALB/c-reactivity by adoptively transferring 2-4 x10
6
 antigen-experienced OT-I Rag1-/- 
cells into B6 mice (OT1M), then treating them 40 days later with DST and CD154-specific 
antibodies to induce tolerance to transplanted BALB/c islets. (B) Composite data showing 
percentages of engrafted adoptively transferred OVA257-264-specific OT-I cells among CD8+ 
CD44hi cells in the blood of OTIM mice (n=11), compared with frequencies of vaccine-
induced OVA257-264-specific T cells in the blood of OVA/Adj’ mice (n=8) and control Adj’ 
mice (n=8) (no significant difference). Each symbol represents an individual mouse, and bars 
represent mean ± SD of data pooled from 4 independent experiments. (C) FACS plots 
showing relative surface expression of CD44, CD62L, CD122, and CD11α (LFA-1) on 
splenic OVA257-264-tetramer-specific CD8
+
 T cells from an OVA/Adj’ mouse or a B6 host 
adoptively transferred with primed OT-I cells (OTIM). Results are representative of 4 
independent experiments. (D) Survival of BALB/c islets transplanted into OT1M mice treated 
with CD154-specific antibodies and BALB/c-OVA DST (n=9) compared with control OT1M 
mice treated with BALB/c DST (n=9) and control naïve B6 mice treated with BALB/c-OVA 
DST (n=9). **p<0.01, unpaired t statistical test with Welch’s correction (B), Kaplan-Meier 
method with the log-rank test and Cox regression model (D).  
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Figure 5-10. Proposed model for how “incognito” memory T cells interfere with 
tolerance induction via linked antigen recognition. 
Donor-associated linked antigens (Ag), A and B (such as OVA and BALB/c, respectively), 
are acquired by host APCs and presented on host MHC. (A) During normal tolerance 
induction, naïve donor-reactive T cells are controlled by anti-CD154 therapy, which 
influences fate decision toward tolerance. (B) During “incognito” memory blockade, memory 
T cells interact with APCs that copresent the memory-directed antigen and alloantigens and 
alter the microenvironment of early donor antigen presentation. This disrupts tolerance-
promoting processes and alters the fate of naïve donor-reactive T cells from tolerance to 
immunity.  




























• The successful induction of transplant tolerance could achieve the goal of “one 
transplant for life.”  
• Our “evolution” model proposes biphasic time-dependent requirements for inducing 
tolerance where effector cells must first be restrained and host-dependent regulation 
must then be generated. 
• The design of next-line tolerance-promoting agents and strategies should increase 
focus on protecting host mechanisms of peripheral tolerance. 
Project Rationale and Summary 
We in the transplant community strive to reach the ideal goal of “one transplant for 
life.” We aim to implant grafts into patients who are ill with disease or injury and see the life-
saving and life-enhancing organs, tissues, and cells survive the lifetime of the recipients. The 
induction of durable, donor-specific transplant tolerance promises to mitigate the numbers of 
transplants lost to immune-mediated rejection. Unfortunately, tolerance induction remains an 
elusive goal in clinical transplantation. We do not yet know the immunological mechanism(s) 
by which tolerance can be generated and maintained. We also do not yet fully understand the 
mechanisms by which multiple barriers derail the process. The objective of my dissertation 
research was to provide new knowledge regarding the nature of immune pathways that either 
protect or harm the graft. Closing this gap in our knowledge about the requirements for 
developing tolerance should aid the design and development of improved strategies that can 
intentionally promote tolerance. 
My research delves into the mechanisms by which host immunity targets pancreatic 
islet allografts. I find that T lymphocytes can use at least three distinct pathways of 
alloantigen recognition against islet allografts, such that direct CD8+, direct CD4+, and 
indirect CD4+ T cells are all individually sufficient to reject donor islet cells. Surprisingly, 
indirect CD4+ T cells vigorously reject islet allografts via an IFN-γ-independent mechanism. 
This mechanism needs further characterization both to determine what other immune cells 
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might contribute to rejection and to determine whether the process can be therapeutically 
blocked to prevent rejection. My work further reveals a new mechanism by which preexisting 
host immune memory disrupts tolerance induction without requiring heterologous immunity 
(i.e. cross-reactivity) to donor MHC molecules. CD8-dependent memory T cell responses can 
mediate rejection through linked recognition of donor-derived antigens and vaccine-
associated antigens on the same cell, which raises potential implications for donor and 
recipient matching during cases with donor latent viral infections or autoimmunity in the 
recipient. Many questions remain to be answered regarding the covert process through which 
memory disrupts tolerance and drives immunity against unrelated donor antigens. We are 
especially interested to know whether this form of memory disrupts an as yet unidentified 
tolerance checkpoint. 
My research further explores mechanisms by which tolerance develops from 
therapeutic targeting of T cell surface molecules. Overall, I find that tolerance-promoting 
therapies exert a partially suppressive effect on early alloreactive T cell responses without 
entirely preventing T cell activation. The small numbers of responding CD4+ and CD8+ T 
cells proliferate and differentiate into IFN-γ-producing Th1 and Tc1 phenotypes. Data in this 
dissertation and from others demonstrate that the proximal effect of a tolerance-promoting 
therapy does not include peripheral clonal deletion or hyporesponsiveness to alloantigens. 
Our results are also not consistent with the concept that tolerance-promoting therapies alter 
naïve antigen-specific T cells into an initial tolerant phenotype during their primary 
encounter with antigen. On the contrary, we demonstrate that the proximal impact of therapy 
is restraint in the magnitude of naïve T cell immunity, rather than “induction” of an alternate 
immune response, whether by deletion, anergy, or deviation into non-graft-destructive 
regulatory phenotypes. 
Although my experimental model in this dissertation used islet cell transplantation, 
my findings may have broader applications to other types of allografts. The following section 
will consider many implications from my different studies and synthesize a mechanism for 
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transplant tolerance induction. This model suggests a general approach that might be useful 
in guiding more effective development of next-line tolerance-promoting agents. 
Model 
A major conclusion drawn by the studies in this dissertation and especially from 
Chapter IV is that the initial restraint of antigen-specific reactivity may be necessary but not 
sufficient for developing the tolerant state. As described in Chapter IV, effector T (Teff) cells 
are restrained but not immediately tolerant after treatment with tolerance-promoting therapies. 
T cell responses are unstable for a protracted period after transplantation, since adverse 
inflammation like TLR ligation/CD40 antibodies can reverse therapy-mediated restraint of 
Teff cells up to three weeks post-transplant, resulting in rapid graft destruction. A meta-
analysis of all islet allograft survival data presented in this dissertation revealed a recurring 
pattern during tolerance induction: The majority of graft rejections occurred within 30 days 
post-transplant, regardless of whether the recipient was intentionally exposed to potential 
tolerance-disrupting stimuli or not (Figure 6-1). This analysis thus makes it clear that an early 
vulnerable period exists during tolerance induction before tolerance stabilizes over time. We 
refer to this early vulnerable phase as the metastable period. 
Given that our data are inconsistent with the “switch” model and its proposed 
mechanism of rapid deviation in T cell fate with immediate tolerance induction, we generated 
a new model to account for our observations. In this model, we propose that the restraint of 
effector cells, generation of host-dependent regulation, and time are all necessary conditions 
to achieve tolerance. We propose in this so-called “evolution” model (Figure 6-2) that 
effectors must first be restrained from attacking the donor graft, and regulation must then be 
generated to continue restraining effectors in the long-term absence of immune modulating 
therapies. We predict that these events are interdependent but separable, such that tolerance-
promoting therapies dampen initial effector functions against the graft, and the resulting 
tolerance-permissive milieu then allows natural mechanisms of peripheral tolerance to 
establish. Thus, the host (not the therapy) is responsible for developing long-term regulation. 
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Tolerance develops during a time-dependent process by passing through a metastable state 
that is initially vulnerable to disruption before strengthening and entering a stable state that 
can resist potentially disruptive events. 
In Chapter III, we described that the allograft appears to define the type of rejection 
(acute versus chronic) as well as the T cell subset (CD4+ or CD8+) that attacks it during 
effector immune responses (Table 1-4)(Chalasani et al., 2004). We propose that the allograft 
similarly determines the development of host transplant tolerance, because the graft can act 
as a long-term tolerogen in a quiescent state, providing donor antigens that reinforce recipient 
peripheral tolerance (Miller et al., 2015). This hypothesis is based on prior studies involving 
donor APC-depleted allogeneic tissues (Lafferty et al., 1983). The allogeneic “cultured graft,” 
which is depleted of immunogenic passenger leukocytes before transplantation, fails to 
provoke initial rejection in naïve untreated recipients. Such non-immunogenic allografts are 
sufficient to gradually induce spontaneous allograft tolerance over time (Bowen and Lafferty, 
1980; Coulombe and Gill, 1994; Coulombe et al., 1999). Recipients progressed from an 
initial state of immune “ignorance” to a state of active tolerance induction (Coulombe and 
Gill, 1994; Coulombe et al., 1999), despite the lack of any adjunct tolerance-promoting 
therapy. Similarly, by reducing the magnitude of initial graft-destructive T cell responses, 
tolerance-promoting therapies may simply result in initial passive allograft survival that later 
evolves into an active tolerant state, possibly driven by the allograft itself. 
Future Directions: Potential Next-Line Tolerance Promoting Agents 
The list is seemingly endless for possible future directions related to this dissertation 
project. Many directions that are specifically relevant to the scope of the studies from an 
individual chapter were mentioned within the chapter-specific discussion section and will not 
be further summarized here. Rather than cover additional directions that would further 
elucidate details about basic scientific processes, I want to instead apply the implications 
from the “evolution” model to the problem of designing clinical strategies that specifically 
induce transplant tolerance in humans. 
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The two-step “evolution” model requiring both initial T cell restraint and separate 
generation of active regulation may account for why many tolerance-promoting agents do not 
readily induce tolerance in large-animal models or in clinical use. If a transplant requires a 
quiescent host environment to enhance or develop active tolerance, then simply restraining 
initial T cell reactivity may not be sufficient to result in long-term allograft survival. Unlike 
the protected, specific pathogen-free environments used to house small animals, human 
recipients face many issues of noxious immune stimuli, such as infection and preexisting 
immune memory, which likely abrogate conditions needed for the progressive development 
of allograft tolerance. Thus, as the metastable period in tolerance became evident in my 
studies, it will likely become relevant in future efforts to induce clinical transplant tolerance. 
Therefore next-line tolerance-promoting strategies might necessitate aggressive protection of 
human recipients from inappropriate stimuli during the early post-transplant phase. While we 
cannot feasibly avoid all exposure to TLR stimulation or all combinations of potential linked 
antigens harbored by the donor, areas for future research might identify the key tolerance-
disruptive signals (e.g. inflammatory cytokines like IL-12 and IFNα/β) that can be targeted. 
Improved organ allocation strategies when matching donors with potential recipients might 
also avoid certain combinations of known linked antigens and known host immunity (e.g. 
CMV+ donors into CMV+ recipients) to limit the potential effects of “incognito” immunity 
thereby leading to more favorable outcomes. 
Absolute abrogation of T cell signaling is unlikely to lead to tolerance. We propose 
that tolerance is an active immune response, so some low level of activation is required. Thus, 
immune suppressive drugs that completely block T cell responses (e.g. the calcineurin 
inhibitors, cyclosporine A and tacrolimus) do not promote tolerance and should be avoided in 
clinical tolerance-promoting regimens. Newly developed TCR inhibitors might prove useful 
as next-line antirejection agents in modulating T cell activation during transplantation. For 
example, a first-in-class, small molecule, selective inhibitor of TCR-triggered T cell 
activation blocked the development of autoimmune diseases in mice without preventing the 
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generation of protective immunity against a pathogen (Borroto et al., 2016). These findings 
suggest that the compound can dampen certain T cell responses without exerting global 
immunosuppression. This might mean that TCR inhibitors could be suitable candidates for 
promoting donor-specific immune tolerance. 
Complete clonal deletion of alloreactive T cells does not appear to be necessary for 
tolerance. It has been repeatedly shown that tolerant hosts retain immunity to the donor. Even 
in the first report of acquired immunologic tolerance, the authors concluded, “The antigenic 
properties of [an allograft] are not altered by residence in a tolerant host, and the host itself 
retains the power to give effect to a passively acquired immunity directed against [an 
allograft] which has until then been tolerated by it” (Billingham et al., 1953). 
Besides blocking the CD154/CD40 axis to induce tolerance, there is potential clinical 
utility for treating patients with CD154-specific mAbs to block the formation of donor-
specific antibodies (DSA). As shown in Chapter V, treatment with anti-CD154 mAb 
completely blocked de novo production of alloantibodies, even in recipients that were 
actively rejecting transplants (Figure 5-5D; Bishop et al., 2017). Further research might 
determine whether this reduction in DSA can improve allograft acceptance during cases of 
retransplantation by removing the tolerance disrupting immune barrier presented by 
preexisting alloantibodies (Burns et al., 2009; Burns and Chong, 2011). This blockade in 
DSA formation might also be beneficial for reducing the incidence of antibody-mediated 
chronic rejection in transplanted recipients (Lin et al., 2016). Moreover, besides blocking 
humoral immunity, it would be interesting to investigate whether treatment with anti-CD154 
mAb retains an advantage in reducing barriers associated with sensitized cellular immunity to 
more easily induce tolerance during cases of retransplantation. For example, should tolerance 
induction to an initial transplant fail, then perhaps the previous treatment with anti-CD154 
mAb will at least have sufficiently reduced allosensitization in the recipient such that a 
second graft can survive the next tolerance-induction process. 
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In other future directions, the two-step “evolution” model implies that a number of 
proposed clinical strategies for inducing tolerance might fail if the dual requirements for 
restraint and generation of regulation are not met. For example, strategies that solely prevent 
the activation of Teff cells without concurrently promoting the development of Treg cells do 
not translate to tolerance. This is evidenced by the failure of current immunosuppressive 
therapies (e.g. calcineurin inhibitors and IL-2 receptor inhibitors) to induce tolerance. 
The requirement for host preexisting FoxP3+ Treg cells found in Chapter IV denotes 
the possible necessity that clinical tolerance-promoting strategies must restrain Teff cells 
while preserving regulatory T cell survival and activity. An important area for research is to 
achieve better precision targeting of effector populations while leaving regulatory cells 
unharmed. Interestingly, inhibitors of mammalian target of rapamycin (mTOR) (i.e. sirolimus 
and everolimus) block T cell reactivity while preserving underlying Treg activities (Battaglia 
et al., 2006; Lu et al., 2010). Thus, although mTOR inhibitors impair wound healing, 
balancing their earlier post-transplant use in conjunction with other tolerance-promoting 
agents might help achieve clinical transplant tolerance (Gagliani et al., 2011). 
Besides protecting the development of regulation, it will also be crucial that we 
understand the pathways that disarm Treg cells. Certain stimuli (e.g. IL-6 and IFNβ derived 
from post-transplant pathogen infections) have been shown to block the maintenance state of 
tolerance when an initial tolerant graft was lost during host stimulation, yet the host retained 
intact tolerance mechanisms that protected a second transplant from the same donor after 
resolution of the initial infection (Wang et al., 2010; Miller et al., 2015; Young et al., 2017). 
These studies highlight that the risk for graft loss can persist even in recipients with durable 
immune tolerance. 
Among intriguing currently tested clinical approaches, host-dependent regulation 
might be amplified through ex vivo expansion and reinfusion of the patient’s own Treg cells. 
Alternatively, host-dependent regulation might be artificially generated via adoptive cell 
transfer of “designer” antigen-specific Treg cells made to express donor-specific T cell 
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receptors. In clinical testing, if this strategy relies on Treg cells alone to promote tolerance, 
then the “evolution” model predicts low success because the initial (and separable) 
requirement for inhibiting effector cells for a protracted time post-transplant would not be 
met. In fact, this exact result was demonstrated in an animal model of islet transplantation. 
Large infusions of directly donor-reactive CD4+ Treg cells (4C TCR Tg cells) failed to 
prolong islet allograft survival, thereby “suggesting that Treg [cells] were insufficient to 
protect allograft rejection as a stand-alone therapy” (Lee et al., 2014). Lee et al. (2014) 
further described that preconditioning the recipient by reducing 70-80% of donor-reactive T 
cells prior to administering Treg therapy was essential for long-term graft protection. Thus 
restraining effector cells and promoting regulation were both essential for inducing tolerance. 
While we focused predominantly on anti-CD154 mAb as a tolerance-promoting 
therapy in our studies, we do not think that the interruption of CD154/CD40 signaling is 
required to develop tolerance. This pathway remains an important potential target for clinical 
transplantation but it is certainly not the only pathway toward tolerance. In fact, the shear 
number of different induction therapies that target alloreactivity and that all lead to tolerance 
induction through varying approaches indicates that the initial mechanism through which a 
tolerance-promoting therapy acts is inconsequential to long-term tolerance, so long as the 
therapy adequately restrains Teff cells without inhibiting the natural development of host-
dependent peripheral tolerance. 
In conclusion, during the course of the past seven decades, we have learned much 
about the nature of host immune reactivity to allogeneic cells. We gained valuable insight 
into the development of donor-specific immunity and tolerance. Greater recognition that the 
pathways that govern allograft rejection are not necessarily the only pathways that need to be 
addressed during transplantation has resulted in greater attention being given to guiding 
alternate pathways important for promoting tolerance. Our data indicate that transplant 
tolerance is unlikely to develop rapidly in the recipient. Host vulnerability to tolerance 
disruption suggests that the recipient must generate a variety of regulatory mechanisms to 
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establish and reinforce long-term graft acceptance. Appreciating the requirement for time and 
the evolution of tolerance is a significant step toward designing improved therapies because 
non-antigen-specific events can alter the course of tolerance-promoting events. This 
vulnerability reveals an important remaining gap in our knowledge, which is that tolerance 
passes through critical checkpoints that are still poorly understood. These should be 
identified in future studies in order to more precisely protect and successfully guide the 
tolerance induction process.  
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Figure 6-1. Meta-analysis shows metastable period during the evolution of tolerance. 
Data are from results previously shown in Figures 3-5B; 3-6A and B; 3-7B; 4-2A; 4-9A, B, 
and C; 4-12A; 4-13A and B; 5-2D; 5-3C; 5-4B, C, and D; 5-7E and F; 5-9D; and Table 4-1. 
BALB/c islet allografts were transplanted into SZ-induced diabetic B6 recipients treated with 
the tolerance-promoting therapies, anti-CD154 monotherapy or anti-CD154 mAb combined 
with donor specific transfusion. Additional treatments (e.g. vaccinations, antigenic challenge, 
linked antigens, etc.) were administered to some recipients. Recipients were monitored for 
graft survival. Groups with ≥50% of transplants surviving at the study endpoint (≥100 days) 
were plotted in (A). Groups with <50% of transplants surviving at the study endpoint were 
plotted in (B). Each symbol indicates the graft survival data from a single mouse; the 
connecting lines were removed from group survival curves to simplify visualization of 
clusters related to time to rejection. Regardless of additional treatments received and 
regardless of whether hosts were ≥50% tolerant or <50% tolerant, the overlayed survival 
curves demonstrate that the majority of graft rejection during tolerance induction to islet 
allografts occurs within the first 30 days post-transplant (gray shading). We refer to this 








































Figure 6-2. The “evolution” model: Tolerance develops from time-dependent, biphasic 
T cell responses. 
We propose that transplant tolerance evolves over time and requires at least two distinct 
phases: (1) Inhibition of pathogenic effector T cells (depicted in red), and (2) Host generation 
of regulation (depicted in green). These phases are separable and may occur at different time 
points after transplantation. The degree of overlap of the two phases is unknown, so the 
drawing above is merely a representation of the concept and is not necessarily drawn to scale. 
As tolerance develops over time, it progresses through a metastable state (depicted in gray 
and described in Figure 6-1) wherein the host is vulnerable to disruptive conditions. 
Disruption can occur through innate immune stimulation from vaccinations, loss of 
protective PD-1 signaling or preexisting FoxP3+ cells, or “incognito” memory responding to 
linked antigens. These disruptive events indicate critical checkpoints through which tolerance 
must pass to develop appropriately. In a tolerance-permissive milieu, tolerance continues to 
evolve and stabilize over time. Importantly, the host -- rather than the therapy itself -- must 
actively generate peripheral regulatory mechanisms that control graft-reactive T cells in the 
long-term absence of immune-modulating therapies. We propose that the graft itself is an 
important tolerogen that promotes and reinforces self-regulation. In summary, transplant 
tolerance is an immune response. It is the alternate outcome of an antigen-specific host 
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CLINICAL TRANSLATIONAL SCIENCE CERTIFICATE 
Introduction 
I first learned about the Clinical Translational Science certificate program during my 
recruitment to the University of Colorado Biomedical Sciences Program. As an 
undergraduate, I knew that I wanted a translational science aspect to my research. The TL1 
program thus seemed to be the perfect “fit” for providing me with unique and insightful 
clinical experiences that paralleled my graduate work in the laboratory. By regularly 
shadowing physicians and meeting sick transplant recipients, I came to understand some of 
their real-life challenges, including their health issues related to chronic immune suppression 
and transplant rejection. My clinical shadowing experiences also shaped my research 
directions because I had clear examples of actual clinical scenarios that I could model in my 
basic science research. Most surprisingly, however, I found during the course of my time in 
graduate school and my involvement in the TL1 program that I developed a strong interest in 
pursuing a physician-scientist career. I applied to medical schools, was accepted, and will 
matriculate into the Mayo Clinic School of Medicine this summer. I look forward to 
combining my medical training with my research training, and I hope to make great future 
contributions to translational and clinical science. 
Summary of Research for TL1 Fellowship 
Despite intensive insulin therapy, people with type 1 diabetes mellitus often cannot 
adequately control their blood glucose. Exquisite blood glucose homeostasis can be achieved 
through transplantation of pancreatic islets but the grafts would die by immune rejection if 
left untreated. Recipients thus require chronic treatment with immune suppressive drugs that 
are unfortunately associated with substantial toxicity and poor graft survival. A preferable 
alternative to long-term immune suppression is the use of transient therapies that can result in 
immune tolerance to the graft. While tolerance can be readily induced in small animal 
research models, clinical translation of such tolerance-promoting regimens to humans is 
 134 
inhibited, at least in part, by microbial infections. Infections may impair tolerance induction 
through two major immune pathways: (1) generation of pathogen-specific memory T cells 
that cross-react with the transplant and that are refractory to many forms of tolerance 
induction, and/or (2) stimulation of non-specific innate responses and consequential 
inflammation that alters the fate of immune cells undergoing tolerance. Understanding how 
pathogen-associated disruptive processes occur will be essential for advancing clinically 
useful strategies for tolerance induction in transplant patients. During my TL1 fellowship, we 
determined whether innate immunity or vaccine-reactive immunity represents a greater 
blockade to islet graft tolerance, and through what mechanism disruption occurs. 
 We modeled pathogen exposure in mouse recipients through host immunization with 
both an innate immune stimulant (adjuvant) that induces inflammation similar to viral 
infections, and chicken ovalbumin (OVA) as a model of a strong antigen stimulus. Recipients 
harboring T-cell memory to ovalbumin were rendered diabetic, treated with a short course of 
tolerance-promoting therapy, and transplanted with pancreatic islets from unrelated 
(allogeneic) donors. Without host treatment, allografts were acutely rejected in about 12 days. 
Parallel groups of allograft recipients were given the tolerance-promoting therapy and 
immunized with adjuvant to determine the sole contribution of innate immunity to the 
disruption of allograft tolerance. We analyzed islet allograft survival and graft-specific T-cell 
reactivity among recipients with immune memory and recipients given the innate stimulant. 
 We found no difference in the frequency of allograft tolerance between naïve 
recipients versus those previously immunized with OVA (50% versus 55%, p=0.85). 
However, early non-specific innate stimulation with an adjuvant (0 to 3 days after grafting) 
disrupted tolerance and triggered rapid islet allograft rejection nearly as quickly as untreated 
recipients (15 days versus 11.5 days median graft survival, respectively). Importantly, 
adjuvant-induced tolerance disruption was time-dependent: Early (0 to 3 days) but not late 
(day 60) adjuvant treatment inhibited tolerance (10% versus 100% graft survival, p=0.003). 
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Through the use of T-cell bioassays, we found that the adjuvant blocked the therapeutic 
agent’s initial restraint of graft-reactive T cells. 
 Pre-existing specific immune memory to a model antigen by itself thus failed to 
prevent tolerance induction in transplanted recipients. However, early non-specific innate 
immune stimulation impaired the restraint of graft-reactive T cells and resulted in overt graft 
rejection. Therefore, our findings suggest that the successful generation of transplantation 
tolerance requires reinforcing early T-cell inhibition and minimizing non-specific 
inflammation induced by innate immune stimulation. 
 In follow-up experiments, we determined whether host immunity that does not harbor 
reactivity to donor major histocompatibility complexes (MHC) could nevertheless block 
tolerance under certain conditions. Although we previously found that anti-OVA immunity 
by itself did not represent a barrier to tolerance induction, we reasoned that vaccinated 
recipients might respond to donors that express vaccine-directed (OVA) antigens and 
subsequently block tolerance. Mice that were vaccinated with OVA had strong T-cell OVA-
specific immunity and limited cross-reactivity to donor-derived MHC. OVA-immune mice 
were transplanted with donor grafts and treated with tolerance-promoting therapy and donor-
specific transfusion (DST). As before, relative to controls, the OVA vaccination did not 
inhibit allograft tolerance. However, when vaccinated mice were exposed to DST that 
simultaneously expressed vaccine-associated OVA and donor MHC, tolerance was disrupted 
in 15/16 OVA-immune mice (p<0.001 versus controls). We found altered fates of graft-
reactive T cells in vivo: The tolerance promoting therapy normally restrained the primary 
response to DST, but in response to linked OVA and donor antigens, pre-existing OVA 
memory disrupted this inhibition and naïve donor-reactive T cells were activated. 
 Overall, we find that benign (“incognito”) vaccine-induced memory that is not 
directed against donor MHC can unexpectedly disrupt tolerance and drive donor-reactive T 
cell immunity. Therefore, this indicates that pre-transplant evaluation of anti-donor MHC 
reactivity may not always predict whether pre-existing immunity will interfere with tolerance. 
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Vaccinated recipients who have limited donor cross-reactivity may still be at substantial risk 
for graft rejection if they are exposed to donor cells that express vaccine-associated antigens. 
Clinical Experiences 
My clinical mentor in the TL1 program who also joined my dissertation committee 
was Dr. Martin Zamora, Medical Director of the Lung Transplant Program at the University 
of Colorado Hospital (UCH). As I shadowed Dr. Zamora and met more physicians at UCH, I 
also observed Drs. Trevor Nydam, Michael Wachs, Igal Kam, and Dennis Lyu. In shadowing 
multiple transplant surgeons and physicians nearly monthly, I observed them and their 
patients in operating rooms, intensive care units, inpatient floors, and outpatient clinics. I 
watched laparoscopic and open recoveries of living donors’ kidneys and partial livers, and 
implantation of livers, lungs, pancreas, and en bloc pediatric and adult kidneys into recipients. 
I saw patients in critical condition with graft dysfunction, immune rejection, steroid-induced 
diabetes, and donor-derived reactivated latent viral infections. I met liver transplant 
candidates with jaundice and abdominal ascites, prospective living donors undergoing 
evaluation, and healthy recipients at checkups celebrating their transplant anniversaries. 
 I initially pursued diverse clinical observations in order to understand how my 
graduate research in transplant immunology might benefit patients. For five years, I followed 
my clinical mentors and encountered over 100 patients. I listened to case presentations and 
discussions about diagnoses, treatment plans, medications, and expected patient outcomes. 
My observations eventually became influential beyond understanding the applications of my 
science when these experiences showed me my true vocation lies in a physician-scientist 
career. As I observed my clinical mentors’ compassionate care, professional conduct, 
leadership, and cooperation on interdisciplinary teams, I realized that I, too, could do well in 
that environment. I delved deeper into the medical profession by attending weekly Grand 
Rounds, morbidity and mortality conferences, research-in-progress seminars, clinical 
meetings, and more. With funds awarded from the Broadening Experiences in Scientific 
Training (BEST) program, I traveled to Toronto, Ontario, Canada and spent six weeks 
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learning about surgery, research, and entrepreneurialism by shadowing an accomplished 
thoracic surgeon-scientist, Dr. Shaf Keshavjee. Every shadowing experience affirmed for me 
that a physician-scientist career fits my interests, goals, skills, and personality. 
 In addition to clinical shadowing, I pursued other opportunities that helped me grow 
as a scientist and contribute to my community. In 2012, 120,000 people were on the national 
transplant waiting list but only 28,000 candidates received life-saving transplants. I was a 
second year graduate student, and in facing this gap of unmet need, I wanted to help beyond 
my research in transplant immunology and connect with the transplant community in a 
personal way. When I learned about the local organ procurement organization (OPO)’s 
central role in clinical transplantation, I immediately sought volunteer opportunities with 
them. Our OPO is Donor Alliance, which is the federally designated, non-profit organization 
that facilitates recovery and donation of transplantable organs and tissues in Colorado and 
Wyoming. 
 As an “Advocate for Life,” I volunteered alongside donors’ families, transplant 
recipients, transplant candidates, and others. Together, we reached out to the public to 
educate and raise awareness about the importance of registering as organ and tissue donors. I 
provided resources at major events, hospitals and libraries. I answered questions, listened to 
stories, cheered on participants at the Donor Dash 5K run/walk, and guided the “Gift of Life” 
balloon in Denver’s Parade of Lights. Through encouraging public support for donation, my 
volunteerism helped increase the number of registered donors and annual organ transplants. 
Our community events brought me together with transplant candidates and families of donors 
who shared intense personal stories about their challenges and losses. From those 
experiences, I learned about difficult topics like end-of-life care, death, organ allocation 
decisions, and transplant ethics. 
 In addition to volunteering, I worked for Donor Alliance as a Transplantation Science 
Educator. I taught 6th-12th graders about organ, eye, and tissue donation and transplantation. 
This hands-on program utilized preserved human organs and corneas, anatomical models, 
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and health sciences curriculum. It was always my goal during every presentation to engage 
youth in exploring their scientific curiosities and to encourage them to think critically and 
separate facts from myths about donation. In total, since 2013, I taught approximately 1000 
students in 42 classes in 20 schools and at a museum. At the other educators’ request, I also 
taught an interactive “Immunology 101” lecture that clarified many of their questions about 
the science behind transplantation and immune recognition of grafts. Finally, I helped 
develop a new curriculum for the program that further challenged students’ thinking about 
ethical, medical, and scientific issues surrounding donation and transplantation worldwide. 
Conclusion 
My graduate training and my experiences in the Clinical Translational Science 
certificate program gave me the foundational skills I need to be a successful scientist and 
future physician. I can ask focused questions and address gaps in knowledge by reviewing 
literature, observing and reasoning, or collecting, interpreting, and utilizing data. I know how 
to teach complex biological processes, and I can recognize misunderstanding and adapt my 
communication style to improve others’ comprehension. My leadership service for campus-
wide groups and my community placed me among people with diverse backgrounds and 
perspectives, which enhanced my social development and preparedness for a dynamic, 
interdisciplinary workforce. I am a resilient, creative, and dedicated professional. With this 
platform of skills, I am prepared to pursue new challenges, life-long learning, and discovery 
as a physician-scientist. I look forward to asking and answering important, clinically relevant 
questions. 
